Drivers of redox status & protein glycation by Vlassopoulos, Antonios
Glasgow Theses Service 
http://theses.gla.ac.uk/ 
theses@gla.ac.uk 
 
 
 
 
 
Vlassopoulos, Antonios (2014) Drivers of redox status & protein 
glycation. PhD thesis. 
 
 
 
http://theses.gla.ac.uk/5607/ 
 
 
 
Copyright and moral rights for this thesis are retained by the author 
 
A copy can be downloaded for personal non-commercial research or 
study, without prior permission or charge 
 
This thesis cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the Author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the Author 
 
When referring to this work, full bibliographic details including the 
author, title, awarding institution and date of the thesis must be given 
 
 DRIVERS OF REDOX STATUS & PROTEIN GLYCATION 
 
 
Antonios Vlassopoulos 
BSc, MSc 
 
 
 
A thesis submitted for the degree of Doctor of Philosophy 
to 
The University of Glasgow 
April, 2014 
 
 
From research conducted at the  
School of Medicine, Human Nutrition  
University of Glasgow 
Glasgow, Scotland 
 
 
© A. Vlassopoulos 2014 
  
ii 
 
 
 
 
 
 
 
 
To my aunt who showed me the way 
  
iii 
 
Abstract 
 
Background: In the past 60 years, the median age of the entire world population has increased and 
ageing and chronic diseases are now the main medical concerns in the developed world.  The 
identification of early signs of disease pathogenesis is vital for prevention and targeting populations 
at risk in order to reduce morbidity and mortality. Glycation is well-established as an index of 
control, or otherwise, and a predictor of end-organ damage, for people with type 2 diabetes. At the 
beginning of the work for this thesis (2010), evidence was beginning to be raised to suggest that 
since glycation levels vary considerably, in normoglycaemic, non-diabetic individuals, glycation 
cannot be solely related to glucose levels and early reports allowed for speculations about a 
relationship between early glycation and oxidative stress. The aim of this thesis was to establish the 
relationship between early glycation and oxidative stress in normoglycaemia using techniques from 
the full breadth of Human Nutrition Research. 
Methods: In study 1, existing epidemiological data were used to identify relationships between 
proxies for redox status and early glycation in non-diabetic individuals. One-way ANOVA, Chi-
squared and multivariate linear regressions, adjusted for all known confounders were used to 
explore associations of HbA1c with self-reported smoking status and fruit & vegetables 
consumptions in the Scottish Health Surveys 2003-2010, among individuals without known diabetes 
and HbA1c<6.5%. 
In studies 2 and 3, the associations from epidemiology were explored in mechanistic laboratory 
studies with high physiological relevance (using physiological concentrations and conditions) to 
better characterise the effect of oxidative stress and antioxidants on early glycation. In study 2, 
bovine serum albumin (BSA), reduced BSA (mercaptalbumin) (both 40g/L), and human plasma were 
incubated with glucose concentrations 0-30 mM for 4 weeks at 37oC. All were tested pre-oxidized for 
8 hours prior to glycation with 10nM H202, or continuously exposed to 10nM H2O2 throughout the 
incubation period. Fructosamine was measured (nitroblue tetrazolium method) at two and four 
weeks. In study 3, Bovine Serum Albumin (BSA) was pre-treated prior to in vitro glycation: either no 
treatment (native), pre-oxidised (incubated with 10nM H2O2, for 8 hours) or incubated with a 
mixture of phenolic acids at physiologically relevant concentrations, for 8 hours). In-vitro glycation 
was carried out in presence of i) glucose only (0, 5 or 10mM), ii) glucose (0, 5 or 10mM) plus H2O2 
(10nM), or iii) glucose (0, 5 or 10mM) plus phenolic acids (10-160nM). Fructosamine was again 
measured using the nitroblue tetrazolium method. Prior to the experimental study we carried out a 
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systematic literature review of dietary interventions reporting plasma concentrations polyphenol 
metabolites, to inform the design of a physiologically relevant in-vitro study. 
In study 4, clinical trial data and biological samples were analysed from a randomised controlled 
dietary advice trial in obese pregnant women, a group at risk from higher glycation and oxidative 
stress. Samples and data from the UPBEAT study trial (n=117) were analysed. Plasma fructosamine, 
plasma sRAGE, urinary Ferric Reducing Ability of Plasma (FRAP), urinary Total Phenol (TP) and urinary 
Advanced Oxidised Protein Products (AOPPs) were measured at 16-18+6 and 27-28+6 weeks gestation. 
Dietary recalls were used to calculate fruit and vegetable and polyphenol intake at the same 
timepoints. Data were analysed to identify associations between dietary variables and biochemical 
markers, as well as their relationships with diagnosis of complications. Associations between 
maternal variables and neonatal anthropometry were also investigated. 
Results: In study 1, HbA1c was higher in smokers by 0.25 SDs (0.08%), and 0.38 SDs higher (0.14%) in 
heavy smokers (>20cigarettes/day) than non-smokers (p<0.001 both). Smokers were twice as likely 
to have HbA1c in the ‘pre-diabetic’ range (5.7-6.4%) (p<0.001, adj.model). Pre-diabetes and low 
grade inflammation did not affect the associations. For every extra 80g vegetable portion consumed, 
HbA1c was 0.03 SDs (0.01%) lower (p=0.02), but fruit consumption did not impact on HbA1c, within 
the low range of consumptions in this population. 
In study 2, oxidized BSA (both pre-oxidised and continuously exposed to H2O2) was more readily 
glycated than native BSA at all glucose concentrations (p=0.03). Moreover, only oxidized BSA was 
glycated at physiological glucose concentration (5mM) compared to glucose-free control (glycation 
increased by 35% compared to native albumin p<0.05). Both 5mM and 10mM glucose led to higher 
glycation when mercaptalbumin was oxidised than un-oxidised (p<0.05). Fructosamine 
concentration in human plasma was also significantly higher when oxidized and exposed to 5mM 
glucose, compared to non-oxidised plasma (p=0.03). The interaction between glucose concentration 
and oxidation was found to be significant in all protein models (p<0.05). 
In study 3, the presence of six phenolic acids with BSA during in-vitro glycation did not lower 
fructosamine formation. However, when BSA was pre-incubated with phenolic acids, significantly 
lower concentration of fructosamine was detected under glycoxidative conditions (glucose 5 or 
10mM plus H2O2 10nM) (p<0.001 vs. native BSA). 
In study 4, women in the lowest quartile of total polyphenol intake had 8% greater fructosamine 
levels compared to those in the top quartile. Total polyphenol intake was negatively correlated with 
sRAGE levels. Diagnosis of severe preeclampsia was associated with elevated AOPPs. Maternal 
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polyphenol intake was positively correlated with birth weight, while maternal glycoxidation showed 
the opposite relationship. 
 
Conclusions:  
Study 1 added evidence to relate smoking (an oxidative stress proxy) to protein glycation in 
normoglycaemic subjects. This association has implications for individuals exposed to ROS and for 
epidemiological interpretation of HbA1c and its clinical usefulness. 
Study 2 offered a mechanistic background to the previously shown epidemiological association. This 
study demonstrated for the first time albumin glycation in-vitro, using physiological concentrations 
of albumin, glucose and hydrogen peroxide. These results identified low-grade oxidative stress as a 
key element early in the glycation process, especially in glucose concentrations relative to 
normoglycaemia. Furthering those findings, study 3 showed that protein-phenolic acid interactions 
are important regulators of protein glycation.  Together those studies highlighted that protein pre-
treatment, either with oxidants or phenolic acids, is an important regulator of subsequent glycation 
in a physiologically relevant system. An important outcome of those studies is that high quality in-
vitro studies under conditions closer to physiology are feasible and should be employed more 
frequently. 
Finally, study 4 demonstrated an association between polyphenol intake and glycation during 
pregnancy, with an impact on neonatal outcome measures. Maternal glycoxidation is a promising 
marker of pre-eclampsia and neonatal anthropometry and could be modulated by maternal lifestyle 
and dietary habits. 
Overall, the results of this thesis implicate that drivers of redox status have the capacity to modulate 
protein glycation in normoglycaemia. These results challenge the assumption that glycation levels 
are solely dependent on circulating glucose levels and suggest a useful application of glycation 
outside the field of diabetes. 
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1.1 General Introduction 
 
In the modern world non-communicable diseases (NCD) are the greatest public health concern. In 
2008, 63% of global deaths, 36 million deaths in numbers, were caused by one of the four major 
NCDs; diabetes, cardiovascular disease, cancer and chronic respiratory diseases (WHO, 2011). 
Even though at the moment in most places in the world, NCD mortality is higher than that of 
maternal, neonatal, perinatal, communicable and nutritional condition mortality combined, it is 
far from reaching a plateau. It is estimated that by 2020, NCD deaths will have increased globally 
by 15%, with low-to-middle income countries seeing the greatest increase (over 20%) and the 
European region remaining generally unaffected (WHO, 2010). 
The burden of NCD deaths is disproportionately affecting different parts of the world. The 
majority (80%) of NCD deaths caused by diabetes or cardiovascular disease occur in low-to-middle 
income countries, while at the same time 29% of total NCD deaths in those countries are likely to 
happen before the age of 60 (WHO, 2011). In developed countries, on the other hand, more and 
more people are living daily with NCD risk factors, as the population group of over 60 is the 
fastest growing population group in the developed world and early NCD deaths are only 13% of 
the total (WHO, 2014). 
NCDs have been causally linked to four major risk factors: alcohol overuse, tobacco smoking, 
unhealthy diet and inactivity. These behaviours lead to four common (metabolic) conditions: high 
blood pressure, overweight/obesity, hyperglycaemia and raised cholesterol, all identified as 
common underlying causes of NCDs. Raised blood pressure has been attributed 13% of global 
deaths, while tobacco smoke and overweight/obesity are responsible for 9% and 5% of global 
deaths, respectively. As far as unhealthy diet is concerned 1.7 million deaths worldwide (~3%) are 
attributable to low fruit and vegetable consumption (WHO, 2011). Data from the European 
Investigation in Cancer and Nutrition (EPIC) showed that consuming ≥5 portions of fruit and 
vegetable per day was associated with a nearly 10% lower risk of diabetes (Cooper et al., 2012). 
Similarly an investigation into three of the largest US prospective studies the Nurse’s Health 
Study, Nurse’s Health Study II and the Health Professional’s Follow-up study showed that every 3-
portion increment in the consumption of blueberries, grapes and apples was associated with 26%, 
12% and 7% lower diabetes hazard ratio respectively (Muraki et al., 2013). Other prospective 
studies have also shown apples to be associated with a 28% reduction in the risk of diabetes from 
consumptions as little as 1-apple a day (Song et al., 2005). More interestingly a recent report 
calculated, using existing data, that consuming one apple daily is associated with lower vascular 
mortality of those aged over 50 years, with a net gain of 8500 lives annually (Briggs et al., 2013). 
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Interventions aiming to reduce the prevalence of NCD risk factors and the development of 
screening to identify people at risk of NCDs early in the lifecourse have been proposed by the 
WHO as cost-effective solutions to a growing public concern (WHO, 2011). 
Inflammation is a common trait for all the NCD risk factors. Large scale cross-sectional 
investigations, like the MONICA (Multinational MONItoring of trends and determinants 
in CArdiovascular disease) Survey have showed a significant positive correlation between smoking 
and inflammation markers like C-Reactive Protein (CRP), white blood cell count and fibrinogen in 
men (Fröhlich et al., 2003). Increased levels of CRP, smoking and features of metabolic syndrome 
have all been independently associated with increased risk of hypertension (Niskanen et al., 2004) 
and having IL-6 in the highest tertile was associated with a 60% increase in the risk of developing 
diabetes as a non-smoker compared to those in the lowest tertile (Duncan et al., 2003). Similarly 
obesity and especially central adiposity, both NCDs risk factors, have been strongly associated 
with CRP levels (Festa et al., 2001, Forouhi et al., 2001, Yudkin et al., 1999). Visceral and 
subcutaneous adipose tissue as measured with tomography were also significantly associated 
with CRP and IL-6 levels in the Framingham study, which indicated a positive correlation with 
oxidative stress as well (Pou et al., 2007). Other groups have also found a positive correlation 
between oxidative stress levels and NCDs risk factors like smoking, obesity and low fruit and 
vegetable intake, showcasing its importance as another potential common trait in NCDs 
pathogenesis (Isik et al., 2007, Marangon et al., 1998, Keaney et al., 2003, Holt et al., 2009, Block 
et al., 2002, Mayne, 2003, Sies et al., 2005). 
Oxidative stress has been identified as a unifying mechanism leading to disease pathogenesis. In 
the healthy state, Reactive Oxygen Species (ROS) are formed constantly through cell respiration, 
immune mechanisms and metabolic pathways, but their levels are tightly control by endogenous 
antioxidant systems, like glutathione peroxidase (Rizzo et al., 2010). In the process, though, of 
disease pathogenesis there is increased production of ROS which overwhelms the endogenous 
antioxidant systems (Juranek and Bezek, 2005). The imbalance between antioxidant defences and 
ROS production is called oxidative stress. Inflammation, obesity, tissue hypoxia and lifestyle 
parameters like smoking and low physical activity have all been associated with higher oxidative 
stress (Hulsmans and Holvoet, 2010, Bondia-Pons et al., 2012, Peng et al., 2003, Lavie, 2009, 
Wood et al., 2009). At the stage where endogenous antioxidant systems are overwhelmed dietary 
intake of antioxidant compounds, like vitamins, minerals and (poly)phenols may be of importance 
in maintaining a better regulated redox status (Pham-Huy et al., 2008, Rodrigo et al., 2011, 
Serafini and Del Rio, 2004, Sies et al., 2005).  
As most NCDs are diseases related with the ageing process, glycation and the Maillard reactions 
have attracted a fair amount of attention as a pathogenic mechanism of NCDs (Lyons, 1993, 
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Geroldi et al., 2005, Zieman et al., 2007). Glycation is a process central to ageing and strongly 
related with oxidative stress and inflammation (Wolff et al., 1991, Ramasamy et al., 2005). 
Biopsies from liver, fat and muscle tissues have shown accumulation of glycation products in 
obesity and during weight gain (Gaens et al., 2012, de la Maza et al., 2008). Also experimental 
data on adipocytes, suggest that glycation products are deposed intra-cellularly as part of the 
adipogenesis process and this deposition is associated with increased oxidative stress and 
inflammation (Gaens et al., 2013, Chen et al., 2012). Early reports also suggest that smoking is 
associated with higher levels of glycation and that diet may also be playing a role in the levels of 
circulating glycation products (Nicholl and Bucala, 1998, Harding et al., 2004, Sebekova et al., 
2001). Western type diets, high in fried and processed foods, are a good source of Advanced 
Glycation Endproducts (AGEs) produced during heat-treatment of food items (Uribarri et al., 
2010, Goldberg et al., 2004). These dietary/exogenous AGEs contribute towards the circulating 
AGEs pool and have been shown to increase systemic inflammation and oxidative stress (Uribarri 
et al., 2005, Šebeková and Somoza, 2007), but there insufficient evidence so far to support any 
health benefit following a low-AGE diet (Kellow and Savige, 2013). 
 
1.2 The glycation reaction - historical background 
 
Glycation, also called non-enzymatic browning or the Maillard reactions, has attracted scientific 
interest for nearly a century. Initiated by the non-enzymatic condensation of a reducing sugar 
(like glucose) with a protein, glycation is one of the most important forms of protein damage, 
relevant to both medicine and food science. Not be confused with enzymatic glycosylation, a 
tightly regulated process that attaches carbohydrates to specific sites on the protein molecule 
(Darnell et al., 2000, Moharir et al., 2013, Spiro, 2002), glycation is a form of protein damage 
reducing functionality (Hunter et al., 2003) while glycosylation is an essential post-translational 
modification required for the molecule to function (Darnell et al., 2000, Moharir et al., 2013, 
Spiro, 2002).  
Named after the pioneer in the field, the Maillard reactions were described in 1912 (Maillard, 
1912). The exact chemical transformations taking place as part of the Maillard reactions are 
complex and, despite years of research, still poorly understood. The early work of Louis Camille 
Maillard described the theoretical background for the reactions, which attracted interest from 
food scientists, as relevant to aroma and flavour development during cooking, as well as a cause 
of protein loss during storage and cooking. The reactions were not properly described until John 
E. Hodge proposed a mechanism of action in three stages: 1) the carbonyl group of a sugar reacts 
with the amino group of a protein/amino acid to produce an unstable Schiff base, 2) the Schiff 
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base undergoes Amadori rearrangements to produce the first stable product, a ketoamine 
(Amadori, 1931, Hodge, 1955) and 3) the ketoamine, undergoes further rearrangements, 
polymerization and condensations leading to the production of a broad range of compounds , 
collectively termed AGEs (Hodge, 1953). In the same step, AGEs undergo further degradation, 
polymerisation and oxidation to produce high molecular weight polymers called melanoidins, 
which are still poorly characterised and understood (Ledl and Schleicher, 1990, Wang et al., 2011) 
(Figure 1.1).  
The concept of in-vivo protein glycation was later discovered in 1977, when HbA1c, a fraction of 
haemoglobin shown to migrate slower during electrophoresis, was identified as a ketoamine, 
specifically a fructosamine (Koenig et al., 1977). Upon its discovery, HbA1c was proposed as a 
useful biomarker for diabetes monitoring (Koenig et al., 1976a, Koenig et al., 1976b), and 
endogenously produced AGEs attracted further scientific attention, beyond food chemistry, from 
fields including medical biochemistry and pathology. At this point it is important to highlight that 
there are two sources of AGEs: the endogenously produced AGEs, a product of the reaction 
between proteins and sugars in the circulation, and exogenous AGEs, produced during cooking 
and absorbed in the small intestine (~10% bioavailability).  
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Figure 1.1. Brief overview of the Maillard reactions 
 
The figure describes the main pathways of glycoxidative AGEs production. In pathway 1, a sugar 
reacts with the amino group of a protein to form a Schiff base, which will then undergo Amadori 
rearrangement to produce the first stable product, a ketoamine (in the case of glucose being the 
reducing, a fructoseamine). This represents stages 1 and 2 in the model proposed by Hodge 
(1953). In pathway 2, the ketoamine undergoes oxidative fragmentation and forms the two main 
AGEs, carboxymethyllysine and Pentosidine. Then the AGEs enter another final step of reactions 
to produce a class of poorly understood compounds, melanoidins. Pathway 2 and the melanoidin 
production step represent the third stage of the Maillard reactions according to Hodge. Pathway 
3, depicts the glucose autoxidation or Wolff pathway(Wolff and Dean, 1987). In that, glucose is 
autoxidised in the presence of free radical to produce a-oxoaldehydes. These a-oxoaldehydes can 
then react further with proteins to produce AGEs. a-oxoaldehydes can also be produced from 
ketoamine degradation and lipid peroxidation (not shown in the figure). 
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1.3 The importance of glycation for health 
 
1.3.1 Glycation and the AGE-RAGE axis 
 
The study of the role played by glycation in disease pathogenesis originally relied on measuring 
fructosamine levels in biological fluids combined with the characterisation of endogenous AGEs in 
the circulation and tissues (Schmidt et al., 1994, Sell and Monnier, 1989a). The discovery that 
AGEs can bind on cellular receptors and alter intracellular events was a breakthrough (Schmidt et 
al., 1992), linking glycation to signalling. These receptors include AGE-R1, AGE-R2, AGE-R3, MSRII, 
CD36, LOX-1 and the Receptor for AGEs (RAGE), the most characterised receptor (Vlassara et al., 
1995, Maillard-Lefebvre et al., 2009). RAGE is a multi-ligand cell-surface immunoglobulin, with the 
ability to initiate injury-like intracellular events, mainly expression of genes related with 
inflammation and oxidative stress (Schmidt et al., 1995, Hofmann et al., 1999, Kislinger et al., 
1999). Together, accumulation of AGEs in tissues and their interaction with cell surface receptors 
are the main mechanisms that explain glycation-related pathophysiology to date.  
These discoveries were accompanied by the study of systems in place to reduce glycation-related 
damage, further contributing to the understanding of pathophysiological mechanisms. One such 
system is the glyoxalase system that neutralises α-oxoaldehydes, oxidatively produced AGEs 
precursors, and inhibits oxidative stress related glycation (Thornalley, 2003b). Similarly, 
fructosamine-3-kinase, which removes ketoamine moieties from proteins, is able to reverse the 
second stage of the Maillard reactions (Delpierre et al., 2000). Finally, sRAGE, the soluble form of 
RAGE, can bind on AGEs and may act as a decoy, preventing AGEs from interacting with RAGE 
(Raucci et al., 2008, Lindsey et al., 2009, Koyama et al., 2007, Maillard-Lefebvre et al., 2009, Selvin 
et al., 2013). 
Accumulation of AGEs in tissues and AGE-RAGE interactions are the two main pathways of 
glycation involvement in disease pathogenesis. These two pathways are often acting 
simultaneously and their individual effects are hard to distinguish; hence they are commonly 
presented in the same context when discussing glycation related pathophysiology (Takeuchi and 
Yamagishi, 2008, Munch et al., 2012, Brownlee et al., 1988, Zhang et al., 2009, Stitt, 2001, Creager 
et al., 2003).  
In hyperglycaemia (post-prandially or in non-controlled diabetes) and to a lesser extent in 
normoglycaemia, both circulatory proteins and proteins of the endothelium are exposed to 
(excess) glucose, leading to the slow formation of AGEs (Monami et al., 2006, Landgraf, 2004, 
Ahmed et al., 2005, Beisswenger et al., 2001). Long-lived proteins, such as collagen and elastin, 
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are the molecules most affected by glycation. In the presence of glucose, glycation adducts are 
created on the collagen molecule, as a function of glucose levels. Those adducts promote 
excessive cross-linking among collagen molecules, inhibiting the formation of an ordered and 
functional polymeric complex. These changes lead to the formation of a thick vascular wall with i) 
reduced elasticity (or increased intermolecular pore size of the basement membrane in kidneys) 
and ii) a high affinity of collagen for other circulating proteins like IgG, albumin and lipoproteins 
like Low Density Lipoprotein (LDL) (Brownlee et al., 1988, Lepape et al., 1981, Sensi et al., 1986, 
Vlassara, 1996, Sell and Monnier, 1989b, Monnier, 1989, Bobbink et al., 1997, Kent et al., 1985, 
Tanaka et al., 1988, Sensi et al., 1989). The immobilisation of proteins onto the vascular wall 
creates a vicious cycle where these proteins are becoming more susceptible to glycation (reduced 
removal by enzymes-increased half-life) and to further crosslinking. Once glycated, these proteins 
act as chemo-attractors for macrophages and monocytes, promoting inflammation and ‘foam’ cell 
formation in the endothelium (Klein et al., 1995, Iwashima et al., 2000, Basta et al., 2004). 
Glycated molecules like LDL and insulin also display lower affinity to their receptor, with a 
reduced ability to initiate receptor mediated events, like glucose uptake (Abdel-Wahab et al., 
1997, Monnier, 1989, Berrou et al., 2009, Duran-Jimenez et al., 2009). 
RAGE mediated events are also central to the role of glycation in pathophysiology. Upon 
activation of RAGE, intracellular ROS levels are increased through the NAD(P)H oxidase. This in 
turns leads to the activation of the Ras-MAP kinase pathway, ultimately upregulating NFκB and 
the production of inflammatory molecules (including TNF-α, VCAM-1, I-CAM1 and IL-1β). The 
upregulation of NFκB also initiates a positive feedback loop that sensitises the cell (and hence the 
tissue) to AGEs by promoting RAGE production (Basta et al., 2004).  
1.3.2 Glycation and health throughout the lifecycle 
 
Glycation is relevant to all stages in the lifecycle, including conception and early gestation. The 
reproductive tract is a known target of AGEs accumulation both in men (Mallidis et al., 2009) and 
women (Diamanti-Kandarakis et al., 2007). AGEs accumulation is followed by changes in the 
distribution of RAGE in reproductive tissues (Mallidis et al., 2007), and sRAGE in seminal/follicular 
fluid (Karimi et al., 2012, Bonetti et al., 2013), which may lead to lower sperm quality (Karimi et 
al., 2012), lower likelihood of success following assisted reproduction (Malickova et al., 2010, 
Jinno et al., 2011) and reduced embryonal quality and development (Jinno et al., 2011, Bonetti et 
al., 2013, Hao et al., 2008). During the course of pregnancy, activation of the AGE-RAGE axis may 
be involved in the pathogenesis of preeclampsia (Oliver et al., 2011, Naruse et al., 2012, Cooke et 
al., 2003). 
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So far evidence on the involvement of AGEs and/or RAGE in fetal development are limited and 
based on animal studies. For example a study on transgenic mice showed that overexpression of 
RAGE was associated with impairements of alveolar morphogenesis. The degree of RAGE 
overexpression was related to the magnitude of the abnormality with homozygous mice having 
histological changes similar to human bronchopulmonary dysplasia. The study also found that this 
early life changes could lead to increased risk of ‘destructive’ emphysema (Fineschi et al., 2013). 
In humans the leading hypothesis is linking glucose/fructose related damage during diabetic 
pregnancies with diabetic embryopathy. In this hypothesis, glycation of proteins, lipids and DNA 
of the developing offspring could be one potential mechanism linking the high prevalence of 
malformations in babies of diabetic mothers to the high maternal blood glucose levels (Chugh et 
al., 2003, Vlassara and Palace, 2002).  
While the role of glycation in human fetal development still needs to be documented, the child is 
exposed to external sources of AGEs early in life. Dietary AGEs have the potential to act as 
allergens or increase the immune response to known allergens. In particular, the glycated form of 
casein, peanut proteins and ovalbumin have been shown to increase the immunological and 
inflammatory responses involved in allergies (Ilchmann et al., 2010, Deo et al., 2009, Mueller et 
al., 2013). Glycation is a feature of juvenile idiopathic arthritis (JIA), a disease occurring in 
adolescence. Increased glycation, AGE accumulation through the lifecycle, and its relationship 
with arthritis and the disease activity, may be potentiated by early activation of RAGE in younger 
patients suffering from JIA (Myles et al., 2011).  
Glycation has been proposed as a mechanism of ageing (Gul et al., 2009, Gkogkolou and Bohm, 
2012). Evidence from animal models suggest that a diet low in AGEs (50% reduction in AGEs 
intake) was associated with amelioration of insulin resistance, lower AGEs accumulation (both 
indications of the ageing process) and ultimately increased lifespan compared to the controls (Cai 
et al., 2007). Similarly, mice on caloric restriction, a popular model of lifespan expansion in animal 
models, have lower levels of collagen cross-linking and lower levels of lens cataract, suggesting 
lower AGEs accumulation in the vitreous and the extracellular matrix (Taylor et al., 1995, Reiser, 
1994) as well as in the brain (Mouton et al., 2009). In fact, mice fed high AGEs diets while on 
caloric restriction did not show any increase in their lifespan and the authors of the report 
suggested that lower AGEs intake may be one of the mechanisms behind the caloric restriction 
model (Cai et al., 2008, Cai et al., 2007). These findings seem to be universal among species and 
have been replicate in non-human primates, highlighting the central role of glycation in the ageing 
process at least in mammals (Sell et al., 2003).  
Within the concept that ageing and apoptosis are timed by ‘a master biological clock’, AGEs 
accumulation has been proposed as the mechanism that sensitises this ‘clock’ and programmes 
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ageing and cellular death (Severin et al., 2013). On a cellular level, longevity is associated with 
decreased oxidative stress, more effective signal transaction, improved insulin sensitisation and 
decreased level of mutations (Sinclair, 2005). AGEs through their receptor RAGE, have the 
capacity to regulate NFκB activation (Nedic et al., 2013). Upregulation of NFκB has a pro-oxidant 
effect as it increases ROS production. It also increases the production of TNF-α, IL-6, IL-1β and 
there is evidence to suggest that this pathway is responsible for vascular ageing (Wautier and 
Schmidt, 2004, Sousa et al., 2000, Schmidt et al., 2001). DNA glycation has been shown to take 
place intracellularly and leads to increased number of mutations (Baynes, 2002). Finally, the 
glycation of intracellular proteins, like insulin, has the capacity to substantially reduce signal 
transaction and in this case also reduce insulin sensitivity (Abdel-Wahab et al., 1997, O'Harte et 
al., 1996, Oliveira et al., 2011, Hunter et al., 2003). An interesting observation linking the effect of 
AGEs in ageing and as early in life as in conception comes from a study showing the active 
involvement of AGEs accumulation in ovarian ageing and ovarian function in human subjects 
(Stensen et al., 2014). 
1.3.3 HbA1c and risk of chronic diseases 
 
Even though the exact mechanisms of disease pathogenesis remain elusive, extensive evidence is 
available to associate glycation with disease risk. Glycation has a particular relevance for age-
related diseases, including Alzheimer’s disease (Smith et al., 1995, Srikanth et al., 2011), skin 
ageing (Gkogkolou and Bohm, 2012) and cataract (Gul et al., 2009). These conditions are 
characterised by increased, possibly lifelong, deposition of AGEs in the affected tissue (Vitek et al., 
1994, Bailey et al., 1993, Nicholl et al., 1998). The AGEs are mainly produced locally and often 
increased concentrations in tissue are not reflected in increased plasma levels, like in the case of 
Alzheimer’s disease (Thome et al., 1996). Similar deposition of AGEs in the cartilage and/or 
increased circulating levels of AGEs is also found in rheumatoid arthritis and osteoarthritis 
(DeGroot, 2004, Matsumoto et al., 2007, Vos et al., 2010); collagen glycation has been proposed 
to be a contributor to stiffening of the micro and macro-vasculature, with implications for chronic 
kidney disease (Nakamura et al., 2009) and loss of kidney function in both diabetic and non-
diabetic nephropathy (Tanji et al., 2000).  
As in-vivo glycation is believed to be mainly driven by plasma glucose concentrations, the most 
established relationship is between glycation and diabetes. HbA1c is the gold standard method 
for diabetes diagnosis and monitoring (American Diabetes et al., 2007). According to the 
American Diabetes Association, individuals with HbA1c levels between 5.7-6.5 % are considered at 
high risk of developing diabetes. Those with HbA1c>6.5% are classified as having diabetes 
(American Diabetes, 2011). Among patients with diabetes, higher HbA1c levels are associated 
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with increased risk of retinopathy (Porta et al., 2001, Klein et al., 1994, Klein et al., 1998, 1995, 
McCarter et al., 2004), neuropathy (El-Salem et al., 2007) and nephropathy (McCarter et al., 
2004). These associations led to an expert position statement describing the benefits of glycaemic 
control, measured as HbA1c levels, in reducing the risk for micro and macrovascular diabetic 
complications (Skyler et al., 2009). Similar results were reported by the UKPDS documented a 21% 
reduction in the risk of any diabetes related endpoint for every 1% reduction in mean HbA1c 
(Stratton et al., 2000). Even though HbA1c levels are traditionally associated with disease 
pathogenesis in diabetes, glycation has recently attracted attention as a risk factor for 
normoglycaemic individuals.  
For the purpose of this thesis, we conducted a systematic literature search to identify studies 
documenting the association between glycation and the risk of non-communicable chronic 
diseases in normoglycaemic subjects. We identified 15 reports from 8 studies (European 
Prospective Investigation into Cancer and Nutrition-EPIC (Khaw et al., 2004a, Khaw et al., 2004b), 
Atherosclerosis Risk in Communities study-ARIC (Selvin et al., 2010, Selvin et al., 2005, Matsushita 
et al., 2010, Selvin et al., 2014), Australian Diabetes, Obesity and Lifestlyle study-AusDiab (Barr et 
al., 2009), the Hoorn Study (de Vegt et al., 1999, van't Riet et al., 2012), Framingham Offspring 
(Meigs et al., 2002), Rancho Bernardo (Park et al., 1996), Women’s Health Study-WHS (Pradhan et 
al., 2007, Lin et al., 2006, Blake et al., 2004) and National Survey of Cardiovascular Disorders 1990-
NIPPON DATA90 (Sakurai et al., 2013)) analysing data from a total of over 63,000 participants, 
followed-up for 4-15 years. The outcomes of interest were diabetes risk, cardiovascular disease 
(CVD), ischemic heart disease, stroke, coronary heart disease (CHD) and all-cause and CVD 
mortality. Two reports focused on the association between glycation and cancer risk, especially 
colorectal (Khaw et al., 2004b) and breast cancer (Lin et al., 2006). 
Data from the ARIC and EPIC studies suggested a positive association between HbA1c levels and 
CVD. Higher HbA1c levels (by 1%) were associated with a nearly 40% higher risk of heart failure 
(Matsushita et al., 2010). Similarly there was almost a 23% higher risk for stroke between 
individuals in the highest HbA1c tertile compared to those in the lowest tertile in non-diabetic 
subjects (Selvin et al., 2005, Selvin et al., 2010). In the total population of the ARIC study, each 1% 
increase in HbA1c was associated with a 55% higher risk of stroke (Selvin et al., 2010). Although 
increased HbA1c is quite consistently shown to be related with higher risk for all-cause mortality 
the relationship is not necessarily linear as proposed by the analysis of the EPIC-Norfolk data 
(Khaw et al., 2004a). An analysis of the ARIC study data showed that having HbA1c levels lower 
than 5% may also be related to increased all-cause mortality suggesting a J-shaped relationship 
(Selvin et al., 2010). Overall the EPIC, ARIC and AusDiab studies suggested a 18-26% higher all-
cause mortality among for every 1% higher HbA1c levels (Barr et al., 2009, Khaw et al., 2004a, 
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Selvin et al., 2010) while HbA1c levels higher by 1% were associated with 32-50% higher risk CVD 
death in the AusDiab and NIPPON90 investigations (Barr et al., 2009, Sakurai et al., 2013). On the 
contrary, the Hoorn study in elderly individuals did not show any association between HbA1c and 
all-cause mortality or CVD mortality, but reported a positive association between HbA1c and non-
fatal CVD risk (de Vegt et al., 1999, van't Riet et al., 2012). Both reports and the results from WHS 
suggested that HbA1c is associated with increased risk of CVD/all-cause mortality in non-diabetic 
women and older participants, but this association is largely explained by the correlation between 
HbA1c and traditional CVD risk factors (Blake et al., 2004, de Vegt et al., 1999, Pradhan et al., 
2007, van't Riet et al., 2012). Selvin et al (Selvin et al., 2010) found that the increase in CHD and 
all-cause mortality associated with higher HbA1c levels was not related to fasting glucose levels 
(Selvin et al., 2010). 
As far as cancer incidence is concerned the results are still inconclusive. Data from the EPIC cohort 
suggest a 33% higher incidence of colorectal cancer per every 1% higher HbA1c (Khaw et al., 
2004b), but an analysis of the WHS data did not find any association between HbA1c and breast 
cancer risk (Lin et al., 2006). As the two cancer types differ significantly in aetiology, colorectal 
cancer has a strong dietary link (Edwards et al., 2010) while breast cancer is mainly of genetic 
aetiology (McPherson et al., 2000); more research is needed before any conclusion is reached. It is 
important at this stage to highlight that the epidemiological associations between HbA1c levels 
and morbidity/mortality in both diabetics and non-diabetics may be pointing towards a direct 
mechanism of action, but it could also be the case that HbA1c serves a proxy marker for poorer 
general health. 
 
1.4 Oxidative stress and glycation 
 
As observed by Selvin et al (2010), fasting glucose may fail to explain the positive relationship 
between HbA1c and CVD and/or mortality. Correction for classical risk factors (including smoking, 
dyslipidaemia, inflammation) explain the relationship better (van't Riet et al., 2012, de Vegt et al., 
1999, Pradhan et al., 2007, Blake et al., 2004), suggesting that a shared mechanism may drive the 
increase in HbA1c levels.  
In the glycation pathway, oxidative stress can increase glycation in two ways, by promoting 
glucose autoxidation or by fructosamine oxidation leading to increased AGEs production (mainly 
CML). The first mechanism, the Wolff pathway, suggests that in the presence of oxidative stress, 
especially transition metal ions, glucose can get ‘autoxidised’ and produce a-oxoaldehydes (like 
methylglyoxal). The oxoaldehyde can react with the protein and contribute to AGEs formation; 
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the hydroxyl radicals can induce further oxidative damage to both the protein and the sugar 
molecule (Wolff et al., 1991, Harding and Beswick, 1988, Wolff and Dean, 1987, Thornalley et al., 
1984, Hunt and Wolff, 1991). The second pathway is not completely independent from the first, 
as in this, the Amadori product (fructosamine) reacts with oxidative agents, like hydroxyl radicals, 
and undergoes modifications that lead to the formation of carboxymethyllysine (CML), one of the 
main AGEs (Ahmed et al., 1986, Booth et al., 1997, Thorpe and Baynes, 2003). The hydroxyl 
radicals can be produced either by transition metal-catalysed oxidation or by glucose autoxidation 
(Hunt and Wolff, 1991). This close interaction between glycation and oxidation leads to the 
development of the term glycoxidation, which describes the fact that AGEs are produced mostly 
from the interaction of these two processes (Baynes, 1991) (Figure 1.1). 
Although indications and potential mechanisms are in place to suggest an active involvement of 
oxidative stress in protein glycation in normoglycaemia and hence the increase in the risk of 
chronic diseases, so far little evidence is available to support such a hypothesis. 
 
1.5 Antiglycative capacity of antioxidants and polyphenols 
 
In the search for compounds that can inhibit or slow the glycation reaction, antioxidants have 
attracted attention. The first AGE blocker identified is aminoguanidine (Brownlee et al., 1986); a 
dicarbonyl scavenging agent that reduces AGE production by removing the oxidatively produced 
precursors, like α-oxoaldehydes (Ahmed and Thornalley, 2002, Thornalley, 2003c). 
Aminoguanidine, like other glycation inhibiting compounds aspirin and ibuprofen, has the capacity 
to scavenge free radicals and improve redox status, which may contribute to their antiglycative 
capacity (Urios et al., 2007, Menzel and Reihsner, 1996, Thornalley, 2003c).  
Lifestyle and diet can have a significant impact on glycation levels in normoglycaemia. Higher 
intake of vitamins C and E, and higher vegetable intake, have all been associated with lower levels 
of HbA1c in normoglycaemic subjects (Bates et al., 2004, Samaha et al., 2003, Sargeant et al., 
2000, Vlassopoulos et al., 2013a, Boeing et al., 2000). Similarly polyphenol supplementation may 
lead to a reduction in HbA1c levels but the evidence is still inconclusive. Conversely, higher 
saturated fat intake and smoking have been related with higher HbA1c levels (Harding et al., 
2001, Vlassopoulos et al., 2013a, Clair et al., 2011), while intakes of carbohydrates, protein, fibre 
and lower physical have no effect on glycation levels (Boeing et al., 2000, Sahyoun et al., 2005). 
The antiglycative capacity of antioxidant vitamins and polyphenols has also been investigated, 
with in-vitro studies showing some polyphenols and phenolic acids to be even more effective than 
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aminoguanidine in inhibiting glycation (Wu et al., 2009, Choi et al., 2008, Kiho et al., 2004). Herb 
extracts and commonly consumed herbal preparations have been shown to inhibit glycation of 
albumin in experimental settings. Red wine, green tea, maté tea (Ilex paraguariensis) (Gugliucci et 
al., 2009, Bixby et al., 2005), cinnamon, garlic(Ahmad et al., 2007) and other herbs used to 
prepare hot drinks or added during cooking are rich in a variety of micronutrients with anti-
glycative effects (Xi et al., 2008, Stote and Baer, 2008). A recent review of the literature by Xie et 
al. (2013) analysed results from 19 in-vitro trials and 11 animal studies and concluded that 
antiglycative capacity of polyphenols is linked to ring hydroxylation patterns. In this context, 
molecules with hydroxyl groups in the A and B rings (i.e. apigenin < luteolin, fisetin < quercetin, 
daidzein < genistein) those with multiple hydroxyl groups especially in the ortho- and meta- 
structure (i.e. sieboldin > phloridzin), the proanthocyanidin di/trimmers and the ellagitannins all 
showed increased antiglycative capacity. On the other hand, hydrogenation of the C2-C3 bond 
(i.e. eriodictyol < luteolin), methylation (i.e. diosmetin < luteolin) and the addition of rutinosides 
all decreased the antiglycative capacity (Xie and Chen, 2013).  
The results of in-vitro studies were still heterogeneous and a thorough review of the glycation 
models and assays used would help to understand why translation of the findings to a 
physiological setting has not been forthcoming. Some of the reasons include use of high glucose 
or fructose concentrations, supraphysiological concentrations of polyphenols/phenolic acids and 
variability in the incubation period/temperature. Doses tested in vitro are, most of the times, 
supra-physiological, beyond concentration that could be reached via habitual consumption of 
phenolic-rich foodstuff. Most polyphenols are metabolised extensively by the gut microflora after 
ingestion due to their low bioavailability (Crozier et al., 2009, Del Rio et al., 2010), so studies 
focusing on the systemic effects of the parent compounds are likely to have low translational 
values. Phenolic acids, such as 3-hydroxyphenylacetic acid, 3,4-dihydroxyphenylacetic acid and 
caffeic acid on the other hand have a higher bioavailability than larger polyphenols and are more 
likely to exert systemic effects (Crozier et al., 2009, Del Rio et al., 2010).  
Despite the extensive mechanistic evidence, epidemiological data on polyphenol consumptions 
are scarce. The main reasons include the difficulties and the biases associated with deriving 
polyphenol intake data from dietary records. The process involves the use of databases, such as 
PhenolExplorer (Rothwell et al., 2012) documenting the polyphenol content of foods (Rothwell et 
al., 2012, Bhagwat, 2013) and/or the analysis of Food Frequency Questionnaires (FFQ) to identify 
patterns of higher intake of polyphenol-rich foods. So far, there are no reports addressing the 
relationship between polyphenol intake and glycation levels. The reports associating polyphenol 
intake with diabetes risk have reached contradictory conclusions (Nettleton et al., 2006, Wedick 
et al., 2012, Song et al., 2005). 
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We performed a systematic review of the literature to identify all studies reporting findings 
relating antioxidant intake with protein glycation in normoglycaemia (Table 1). The literature 
research was carried out on PubMed and ISI Web of Knowledge. The search was inclusive of all 
years up to February 2014. The following search terms were used to identify relevant studies: 
phenol*, polyphenol*, elligitan, catechin, flavan*, flavon*, fruit*, vegetable*, spice*, tea*, cocoa 
or juice*, oil*, wine*, coffee, paired with treatment, intervention, consumption or 
supplementation. The wild-card term “*” was used to improve the sensitivity of the search by 
increasing the number of matches. The references of all relevant studies and reviews were hand-
searched for additional studies. The review was limited to studies focusing on non-diabetic 
subjects.  
Human trials with polyphenol rich supplements and foods are also limited and characterised by 
high heterogeneity and small sample sizes. In the past 20 years, only 14 trials used polyphenols as 
a means to reduce glycation in non-diabetic individuals, out of which two did not have any control 
group (Basu et al., 2013, Celec et al., 2013). Taken together, the results of these studies suggest 
that polyphenol supplementation fails to improve glycation markers in non-diabetic individuals. In 
populations with already established IGT, increased intake of polyphenols might be promising in 
reducing protein glycation (Cho et al., 2012, Fukino et al., 2008), but no hard conclusions can be 
made. Sample sizes ranged between 19-95 participants with different prevalence of 
overweight/obesity, hypertension, glucose abnormalities (metabolic syndrome, IGT) and age 
groups (Fukino et al., 2005, Banini et al., 2006, Fukino et al., 2008, Brown et al., 2009, Shiina et al., 
2009, Aoki et al., 2012, Barth et al., 2012, Cho et al., 2012, Evans M., 2012, Vinson et al., 2012, 
Basu et al., 2013, Celec et al., 2013, Dallas et al., 2013, Miyazaki et al., 2013, Ogawa et al., 2013).  
The bioactive molecules tested are also diverse, with flavonoids and catechins being the most 
common, but with dose administered ranging from 500mg to 2g daily. The main glycation marker 
measured is HbA1c but with study duration ranging from 2 to 12 weeks, it is questionable 
whether negative results are due to the limited duration (haemoglobin has a half-life of 12 weeks) 
or the supplement itself. Moreover, for the majority of studies, glycation was a secondary 
outcome and not the primary focus meaning that statistical power could be substantially affected. 
Furthermore, although the working hypothesis is that polyphenols will reduce glycation via 
improvements in the antioxidant capacity, there are no measurements to support that the 
interventions did anything towards improving the antioxidant status (beyond the post-prandial 
period).  
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Table 1.1 Supplementation trials reporting changes in glycation markers using antioxidant 
compounds/ antioxidant rich foods 
Author Study Population Design Treatment Duration Results 
Davie et al. 
(1992) 
Non-diabetics 
(n=12) 
Parallel Vitamin C (100mg) vs 
placebo 
12 wks 1.13% decrease in 
GHb 
33% decrease 
glycated albumin 
16% increase in 
HbA1c with 
electrophoresis 
Weykamp et 
al. (1995) 
Non-diabetic  
(n=30) 
Parallel Vitamin C (0,750, 
1500mg/d) 
12 wks No difference 
Fukino et al. 
(2005) 
Borderline diabetes 
(n=66) 
Parallel GTE capsule (458mg 
catechins; 106 mg 
caffeine) vs control 
8 wks No difference 
Cheng et al. 
(2004) 
Healthy 
 (n=23) 
Parallel 1000ug Cr vs placebo 24 wks No changes reported 
Banini et al. 
(2006) 
Non-diabetic 
(n=23) 
Parallel Muscadine grape 
juice (150mL) vs 
control 
4 wks No effect on HbA1c 
Camargo et 
al. (2006) 
Healthy non 
diabetic (n=28) 
Parallel Vitamin C 1g/d or 
Vitamin E 400mg/d 
vs control 
16 wks No effect on HbA1c 
Fukino et al. 
(2008) 
Borderline diabetes 
(n=64) 
Cross-over GTE beverage 
(456mg catechins) vs 
control 
8 wks Reduction in HbA1c 
Brown et al. 
(2009) 
Overweight/obese 
 (n=88) 
Parallel DGTE capsule (800mg 
EGCG) 
8 wks No effect 
Shiina et al. 
(2009) 
Healthy men 
(n=39) 
Cross-over Flavonoid-rich 
chocolate (550mg/d 
catechin,epicatechin 
and procyanidin) vs 
white chocolate 
2 wks No effect on HbA1c 
Aoki et al. 
(2012) 
Erectile dysfunction 
patients 
 (n=23) 
Parallel 10mg Pycnogenol, 
115 mg L-arginine & 
92mg aspartic acid/d 
vs placebo 
8 wks Moderate decrease in 
HbA1c (data not 
shown) 
Barth et al. 
(2012) 
Obese non diabetic 
(n=68) 
Parallel Cloudy Apple juice vs 
placebo 
750mL/day (803 mg 
total phenol) 
4 wks No changes reported 
Cho et al. 
(2012) 
IGT  
(n=99) 
Parallel Sajabalssuk extract 
3000mg/d vs placebo 
vs 1140mg/d pinitol 
(positive control) 
9 wks HbA1c reduction 
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Evans M. 
(2012) 
Overweight/obese 
(n=19) 
Parallel Diabetinol 
1050mg/d (dried 
fruit and orange 
peel supplement) 
vs placebo 
12 wks No difference 
Vinson et al. 
(2012) 
Hypertensive 
overweight 
(n=18) 
Cross-over 
No wash-out 
6-8 Purple majesty 
potatoes daily vs 
normal potatoes 
4 wks No difference 
Basu et al. 
(2013) 
Healthy 
WC<88/102cm 
(n=9) 
Uncontrolled 
 
POMx capsules 
(1506mg/d 
polyphenols) 
4 wks No reduction 
Celec et al. 
(2013) 
Young healthy 
(n=88) 
Uncontrolled 
 
2g/kg soybeans 
daily 
1 wk No effect on 
fructosamine/AGE 
fluorescence 
Dallas et al. 
(2013) 
Overweight healthy 
(n=95) 
Parallel 900mg citrus fruit 
extract capsules 
(Sinetrol-XPur) vs 
placebo 
12 wks HbA1c increased in 
both groups, 
significantly smaller 
increase in Sinetrol 
group 
Ogawa et al. 
(2013) 
IGT 
(n=34) 
Parallel multi-
centre 
1000mg Acacia 
polyphenol daily vs 
placebo 
8 wks No effect on HbA1c 
Miyazaki et 
al. (2013) 
Older healthy 
(n=52) 
Parallel 631 mg Green Tea 
Catechins vs 
control 88.7 mg 
14 wks No effect on HbA1c 
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1.6 Hypothesis and research questions to be tested in this thesis 
 
This thesis will be focused in studying the interactions of oxidative stress and molecules with 
antioxidant properties, particularly polyphenols and phenolic acids, with protein glycation. It was 
hypothesised that in normoglycaemic conditions, oxidative stress will be an important driver of 
the glycation process and that phenolic acids and polyphenols will exhibit an antiglycative 
capacity, both in an in-vitro physiologically relevant system and in an in-vivo system of increased 
oxidative stress. 
So far experimental evidence support the active involvement of oxidative in the glycation process 
and epidemiological studies hint that glucose levels may not be the only driver of the process. 
When focusing in non-diabetic individuals conditions and lifestyle factors associated with 
increased oxidative stress can explain the variations in Hba1c levels.  
RQ1: Is redox status associated with glycation in normoglycaemic individuals?  
Given that glucose is tightly controlled, both in the fasting and post-prandial state, in individuals 
free of diabetes or impaired glucose tolerance there are still a gap in research to explain what 
drives the formation of fructosamine (HbA1c or glycated protein). Mechanistic studies so far have 
focused on the involvement of oxidative stress in the production of AGEs, either by fructosamine 
degradation or a-oxoaldehyde production. Little is known, though, on the impact of oxidative 
stress in the early step of the Maillard reactions. If so, should oxidative stress and glucose act 
synergistically or can prior oxidation of the protein molecule lead to increased glycation? 
RQ2: Could oxidation promote fructosamine production in the presence of physiological glucose 
concentrations? 
RQ2a: Are oxidised proteins more prone to glycation than the native forms? 
As reviewed above, the plethora of studies employed to study the antiglycative capacity of 
polyphenols and phenolic acids are of low physiological values due to the study design. Even 
though this evidence is providing details on potential mechanisms of action and structures 
required for polyphenols to exhibit glycation protection there is a need to test their relevance in 
conditions simulating physiology. 
RQ3: Can phenolic acids reduce glycation in a physiologically relevant in-vitro system? 
Finally, if the hypothesis is that polyphenols/phenolic acids have the capacity to protect against 
glycation through oxidative stress regulation in-vivo, studies should be designed so to include 
participants with increased oxidative stress. This assumption is based on the fact that in a fairly 
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healthy population, the impact of any dietary intervention on markers of disease is likely to be 
subtle. Hence studies should either be aiming to recruit large samples to ensure statistical power 
for the detection of small effect sizes, or they should aim for high risk populations. When the 
working hypothesis is that polyphenol intake will be negatively correlated to glycation markers, 
through redox status regulation, individuals with increased oxidative stress (obese, pregnant, 
smokers) could be considered in high risk of glycative damage. Recruitment of such a population 
could allow for greater effect sizes between polyphenol intake and glycation markers to be 
detected allowing for a smaller sample size. 
RQ4: Is polyphenol intake negatively correlated to glycation markers in a population at high risk of 
oxidative stress? 
RQ4a: Is polyphenol intake and/or glycation related to maternal health or pregnancy 
complications? 
RQ4b: Is maternal polyphenol intake and/or maternal glycation related to neonatal health? 
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Chapter 2: General Methods 
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This chapter describes the general methodologies chosen, developed and used throughout this 
thesis. The thesis comprises of 4 main experimental studies (chapters 3, 4, 5 and 6). Methods 
specific to each study are described in the relevant chapters. The objective of this thesis is to 
investigate the impact of oxidative stress and antioxidants on protein glycation in 
normoglycaemia. In an attempt to produce evidence of high translational value the thesis was 
designed to follow a mixed methods research designs. 
 
2.1 Mixed methods research design 
 
Mixed methods research is usually referred to research designs that combine qualitative and 
quantitative analysis in an attempt to improve the study design. Mixed methods research has 
been proposed as a superior research design that allows for pluralism and offers the best chance 
to approach a hypothesis from all the possible angles (Johnson and Onwuegbuzie, 2004). The 
combination of research methodologies from different fields is also common when studying the 
exposure to substances and its impact on health. Again in this case the combination of 
methodologies has been proposed as a tool to reach more biologically informative conclusions 
(Howard and Webster, 2013). When testing a new hypothesis, one is attempting to answer a 
currently unresolved issue, by a) generating a hypothesis for a mechanism of action/association 
and b) testing this hypothesis to be true. In order to generate valid hypotheses analysis of 
epidemiological data is a common first step. Following that the set-up of experimental studies 
could allow for these hypotheses to be tested and potential answers to be generated. The 
combination of epidemiology and experimentation in this case allows researchers to bring 
together data from various settings and analyse the recurrent patterns to reach biologically 
relevant and true conclusions (Schwarze et al., 2006). 
In nutrition, discussing the totality of evidence available from epidemiology, in-vitro studies, 
animal studies and intervention trials when describing food-health interactions is not a new 
concept. This combined approach has been used in order to identify food patterns and food-
borne agents that have the potential to modulate health, especially in the field of cancer (Wynder 
et al., 1994, Yun, 2003, Wolff et al., 1996, Hashim et al., 2005). In fact, the World Cancer Research 
Fund (WCRF) uses a similar approach when reviewing the evidence linking diet and cancer. 
Evidence from epidemiological studies, human interventions, animal studies and in-vitro studies 
are all reviewed together. The latter two studies are of particular importance as they provide with 
the evidence of ‘plausible biological mechanisms’, explaining the association proposed by the 
human trials and the epidemiology. Lack of investigations focusing on identifying those biological 
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mechanisms is considered a substantial drawback and the evidence is unlikely to be characterised 
as being convincing, probable or even suggestive (Wiseman, 2008). 
This thesis follows a design similar to the epidemiological approach in investigating disease 
problems as proposed by the Food and Agriculture Organisation (FAO) (Putt et al., 1987). In this 
model there are 8 stages in each investigation, the diagnostic, the descriptive, the investigative, 
the experimental, the analytical, the intervention, the decision-making and the monitoring phase. 
Once a disease/health problem is confirmed (diagnostic phase), an analysis of the population at 
risk/of interest is performed to generate hypotheses about the determinants (descriptive phase). 
In the investigative phase, these hypotheses are initially tested with a series of field studies which 
describe the exposures and risk factors in more detail. If the hypotheses are promising, then 
experiments are performed to test the capacity of single-agent exposures to explain the 
disease/outcome (analytical stage). By the analysis of the results of the experiments, a set of 
agents capable to modulate the outcome are identified (analytical phase). Following that, 
interventions aiming to manipulate the exposures of interest take place and their effect on 
disease outcome is measured (intervention phase). At this point, the research phase of the 
investigation is nearly complete. The next two phases, the decision-making and monitoring phase, 
see the interventions being applied in the field and monitor their long-term outcomes. 
In this thesis, epidemiological data were used to generate and test hypotheses in a population 
level, followed by a series of in-vitro experiments that investigated the molecular mechanisms in 
place to explain the previous findings. The biological relevance of these mechanisms was then 
tested using samples from a nutritional intervention (randomised controlled trial). 
 
2.2 Epidemiological data 
 
The Scottish Health Survey (SHS) is a population wide investigation aimed to provide with a 
detailed picture of health, health related behaviour and their changes over time in Scottish 
households. The Survey started in 1995 and was repeated in 1998 and 2003. In 2008 the SHS 
design was changed and it is now conducted annually until 2015 (Scottish Government, 2014). 
The SHS aims to estimate the prevalence of health conditions and to identify and monitor related 
disease risk factors over time, making sure that all regions and population subgroups are 
successfully represented in the time of sampling. To achieve that a multi-stage stratified 
probability sampling of eligible households is performed (Scottish Government, 2014). 
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The survey takes place as a two-stage interview process. During the personal interview a trained 
interviewer collects data on health, disability, health service use, cardiovascular and respiratory 
disease, smoking, drinking, common health problems and eating patterns/physical activity. The 
second nurse visit is focused on obtain blood, urine and saliva samples, anthropometrical 
measurements and use of drugs (prescribed) and vitamins. From 1995 to 2003 all the sample was 
offered both visits but from 2008-2011 only a sixth of the sample was offered the nurse visit. The 
SHS has a strong focus on nutrition with fruit and vegetable consumption been measured annually 
as part of the core content, alongside smoking, drinking and physical activity and a more 
elaborate investigation of eating habits taking place biennially (Scottish Government, 2013). As 
such the SHS can be a useful tool in nutritional epidemiological research, allowing the study of 
association between biochemical markers, nutrition and health. 
 
2.3 In-vitro design 
 
The study of the glycation mechanisms has been utilising in-vitro protein model systems. The 
most commonly used proteins are LDL, albumin and collagen (Li et al., 1996, Xi et al., 2008, Vinson 
and Howard, 1996, Harris et al., 2014, Kazeem et al., 2012, Xie and Chen, 2013). Albumin the most 
abundant protein in circulation has a half-life of 14-28 days and is a known glycation target 
(Schultze and Heremans, 1966, Schleicher et al., 1993). In fact measurement of albumin glycation 
as fructosamine has been part of clinical practice, diabetes risk monitoring and it may still be a 
useful marker for individuals with altered red blood cell turnover (Inaba et al., 2007, Takahashi et 
al., 2007, Peacock et al., 2008, Koga and Kasayama, 2010, Selvin et al., 2014). The study of 
glycation promoters and inhibitors has not been yet standardised with different groups employing 
different settings, in terms of duration, protein concentration and sugar concentration (Li et al., 
1996, Xi et al., 2008, Vinson and Howard, 1996, Harris et al., 2014, Kazeem et al., 2012, Xie and 
Chen, 2013, Joglekar et al., 2013). Also although glucose is the most common circulating sugar, 
some reports have used fructose and ribose as glycation drivers (Sompong et al., 2013, 
Kontogianni et al., 2013); others have also used a-oxoaldehydes, like methylglyoxal (Tarwadi and 
Agte, 2011, Li et al., 2008, Gutierrez, 2012).  
Although from a mechanistic point of view these studies may be of importance, their biological 
relevance is limited. Only a small number of studies have attempted to replicate the physiological 
process of glycation in-vitro by using concentrations and duration relevant to physiology. In this 
thesis the in-vitro setting was designed to mimic physiology as much as possible. The glycation 
experiment lasted for 28 days (4 weeks) with measurements of glycation taking place at both 14 
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days (2 weeks) and 28 days (4 weeks). Albumin concentration was chosen to be within the 
physiological 35-50g/L and glucose levels ranged from 5mM to 30mM. The choice of glucose 
levels was such that it would allow for the investigation to focus both in normoglycaemia (5mM 
glucose) and diabetes (10mM glucose) (American Diabetes, 2000). Glucose concentrations of 20 
and 30mM glucose were chosen to test the same hypothesis in glucose concentrations previously 
used in the literature to allow for the results of the experiments to be compared with previous 
reports (Voziyan et al., 2003, Chesne et al., 2006, Bourdon et al., 1999). 
Similarly the concentrations of all the reagents added in the incubation mix to act as promoters or 
inhibitors of glycation were physiologically relevant. Reviews of the literature were performed 
prior to any experimental set-up to inform the choice of the agents of interest, their potential 
synergistic/antagonistic effect and their concentration in human plasma. Details of these reviews 
are presented in the following chapters where appropriate and relevant. 
2.4 Experimental data from randomised controlled trials 
 
As mentioned earlier, the study of the association between redox status and glycation may be 
more sensitive if the population at focus is at high risk of oxidative stress. Epidemiological 
investigations have showed that obesity and smoking are associated with impaired redox status 
(Vargas et al., 2013, Pou et al., 2007, Isik et al., 2007, Marangon et al., 1998). Similarly during 
pregnancy there is a significant increase of oxidative stress and decrease in antioxidant capacity, 
especially during the 3rd trimester (Hung et al., 2010, Toescu et al., 2002). Obesity during 
pregnancy has been associated with increased risk of pre-eclampsia, gestational diabetes and 
other complications (Ramachenderan et al., 2008, Baeten et al., 2001, O'Brien et al., 2003). At the 
same time oxidative stress and changes in the level of AGEs and sRAGE have also been shown to 
carry some predictive value of pregnancy-complications (Raijmakers et al., 2004, Sharma et al., 
2006, Moretti et al., 2004, Harsem et al., 2008, Naruse et al., 2012), giving room to hypothesise 
that obesity during pregnancy may be related with a deregulation of the oxidation and glycation 
pathways.  
All the above suggest that obese pregnant women are likely to serve as a population in high risk of 
oxidative in which antioxidant/polyphenol intake could deliver multiple benefits including 
glycation reduction. Furthermore, with increasing indications for the involvement of glycation in 
pregnancy complications and fetal outcomes, such a study will provide with useful information 
about the potential impact of diet on maternal and neonatal health. 
For the purpose of this thesis we analysed samples and data from the UK Pregnancies Better 
Eating and Activity Trial (UPBEAT) pilot, a multi-centre UK trial with a randomised controlled 
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design. The detailed designed of the trial has been published elsewhere (Poston et al., 2013, 
Briley et al., 2011) and discussed in more detail in the relevant chapter. Participants in the 
UPBEAT trial were offered an 8-week intervention aiming to reduce the dietary glycaemic index 
(GI) and increase physical activity or standard care. The reduction in glycaemic index was to be 
achieved by higher consumption of low glycaemic index foods and replacement of sugar 
sweetened beverages with low GI alternatives. Alongside, GI reduction women in the intervention 
arm were asked to replace saturated fats with mono and polyunsaturated fats (MUFA, PUFA). As 
low glycaemic food products like wholemeal cereal, vegetables and legumes are also high in 
antioxidant compounds (Ludwig, 2002, Slavin, 2003, Hu, 2003, Jenkins et al., 2002) we 
hypothesised that women in the intervention arm could benefit from an improved redox status 
compared to the control.  
 
2.5 Statistical analysis 
 
Detailed presentations of the statistical analysis performed for each experiment is presented in 
relevant chapters. 
Generally, epidemiological data and data from human trials were initially tested for normality 
using the Kolmogorov-Smirnoff test. Data were then presented as mean and standard deviation 
(SD) or median and interquartile range (IQR) as appropriate. No transformation of the data was 
performed to force them in following a normal distribution. Differences in means/medians were 
assessed using the Student’s t-test or ANOVA or the non-parametric equivalents. When post hoc 
comparisons were applied in ANOVA tests, the Tukey post hoc test was applied. In the case of 
epidemiological data all analyses were performed using parametric tests following the central 
limit theorem. The central limit theorem suggests that given a large enough population size 
normality of the data can be assumed and hence parametric tests and regression can be 
performed without prior transformation, as supported by the work of (Lumley et al., 2002). 
Regression analysis (linear and logistic) was employed to investigate potential relationships 
between exposures (oxidative stress, antioxidant intake etc.) and outcomes of interest (e.g. 
glycation levels). All regression analyses were performed initially as a non-adjusted model and 
then as a fully adjusted model. In the fully adjusted model all the known confounders of the 
relationship of interest were added in the model without previous stepwise regression being 
performed. 
In the in-vitro studies all incubations were performed in 5 or 6 replicates to ensure sufficient 
numbers to be entered in the statistical analysis. All data were again assumed to be normally 
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distributed and so Student’s t-test or ANOVA were employed to test for differences among mean 
values. All data were presented as mean values with standard deviation. When post hoc 
comparisons were applied in ANOVA tests, the Tukey post-hoc test was applied, in this case as 
well. In order to test the interaction between two different exposures (i.e. oxidative stress and 
glucose concentration) a two-way ANOVA model was applied to the data, again with Tukey post-
hoc correction, if needed. 
Statistical significance was set at a p-value <0.05 for two-tailed comparisons. All tests were 
performed using the PASW 18 statistical software.  
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Chapter 3: Influence of smoking and diet on glycated haemoglobin and 
‘pre-diabetes’ categorisation: a cross-sectional analysis 
 
This chapter is presented exactly as published in BMC Public Health 
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Abstract 
 
Background: The new HbA1c criteria for diagnosis of pre-diabetes have been criticised for 
misdiagnosis. It is possible that some elevation of HbA1c is not driven by hyperglycaemia. This 
study assesses associations of HbA1c, commonly assumed to relate solely to glucose 
concentration, with (i) smoking, a major source of ROS and (ii) fruit & vegetables consumption 
associated with improved redox status. 
Methods: One-way ANOVA, Chi-squared and multivariate linear regressions, adjusted for all 
known confounders were used to explore associations of HbA1c with self-reported smoking status 
and fruit & vegetables consumptions in the Scottish Health Surveys 2003-2010, among individuals 
without known diabetes and HbA1c<6.5%. 
Results: Compared to non-smokers (n=2831), smokers (n=1457) were younger, consumed less 
fruit & vegetables, had lower physical activity levels, lower BMI, higher HbA1c and CRP (p<0.05). 
HbA1c was higher in smokers by 0.25 SDs (0.08%), and 0.38 SDs higher (0.14%) in heavy smokers 
(>20cigarettes/day) than non-smokers (p<0.001 both). Smokers were twice as likely to have 
HbA1c in the ‘pre-diabetic’ range (5.7 - 6.4%) (p<0.001, adj.model). Pre-diabetes and low grade 
inflammation did not affect the associations. For every extra 80g vegetable portion consumed, 
HbA1c was 0.03 SDs (0.01%) lower (p=0.02), but fruit consumption did not impact on HbA1c, 
within the low range of consumptions in this population. 
Conclusion: This study adds evidence for to relate smoking (an oxidative stress proxy) to protein 
glycation in normoglycaemic subjects, with implications for individuals exposed to ROS and for 
epidemiological interpretation of HbA1c. 
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3.1 Background 
 
Patients with large waists and related, potentially-reversible, metabolic features are at risk of 
developing type 2 diabetes and a range of chronic diseases (Han et al., 2006). Their specific 
pathologies are characterised by pro-inflammatory states and a shift in tissue redox homeostasis 
towards excess free-radical activity (Hermsdorff et al., 2011). Redox status is influenced by diet 
and lifestyle factors, including fruit and vegetable consumption, cigarette smoking and by 
inflammatory disease activity (Alberg, 2002, Moriarty et al., 2003, Lesgards et al., 2002). Smoking 
is a well-established risk factor for diabetes, as shown by a recent meta-analysis (Willi et al., 
2007), contributes to the production of ROS and increases production of inflammatory molecules, 
β-cell dysfunction and end-organ protein damage (Fagard and Nilsson, 2009, Naudi et al., 2012, 
Cerami et al., 1997). On the other hand, low fruit and vegetable consumption is associated with 
impaired redox status in young, healthy populations (Lesgards et al., 2002) and diets rich in fruit 
and vegetable with lower concentrations of oxidative stress markers (Esposito et al., 2011, Dai et 
al., 2008). Individuals exposed to higher levels of oxidative stress experience greater benefits in 
their redox status from fruit and vegetables consumption (Peluso et al., 2012).  
Protein glycation is a common form of protein damage, and approximately 1%-16% of albumin is 
glycated in normoglycaemic blood (Shaklai et al., 1984, Selvin et al., 2011), which has been 
associated with metabolic deterioration. Advanced Glycation Endproducts (AGEs) are involved in 
the aetiology of various chronic disease (Yan et al., 2010), especially diabetes and its vascular 
complications. Protein glycation levels are determined by the concentration of sugars (mainly 
glucose) (Goldstein et al., 2004, Nathan et al., 2008) and dependant on the protein half-life, as 
well as fructosamine removal through the action of fructosamine-3-phosphokinase (Delpierre et 
al., 2002). An individual’s pro-oxidant status, however, has been speculated to be involved in later 
stages of the glycation reaction, leading to the formation of glycoxidation products, like 
pentosidine (Fu et al., 1994, Baynes, 1991). Moreover, glucose autoxidation, associated with 
increased oxidative stress, may play a role in promoting Maillard product formation, in the early 
glycation stages (Chetyrkin et al., 2011). HbA1c is an early glycation product used diagnostically as 
a specific marker for glucose exposure. HbA1c has become established for monitoring of glycaemic 
status in diabetes, as an indicator of glucose levels in the previous 90 days, and more recently its 
diagnosis (ADA, 2011). HbA1c relates strongly to tissue damage in diabetic patients and it has also 
been found to predict coronary heart disease (CHD) and cancer in non-diabetic individuals, even 
within the ‘normal’ non-diabetic range (4.9 - 6.3%) (Brewer et al., 2008). The concentration of 
HbA1c is usually assumed to relate mainly to glucose concentration in populations with similar red 
blood cell turn-over. Since blood glucose fluctuations are minimal within HbA1c levels <5.7%, it 
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seems possible that the relatively large variations on HbA1c concentration might reflect variations 
in redox status, and could indicate wider protein glycation. Supporting this concept, we have 
shown previously, in national survey data, that HbA1c in non-diabetic subjects, correlates with 
CHD risk factors, but that it is inversely correlated with dietary intake of fruits and vegetables, and 
with both dietary intake and plasma concentration of dietary antioxidants (Vitamin C, Vitamin E, 
Vitamin B6) (Bates et al., 2004). 
Since the process of glycation is non-enzymatic, it is relatively slow, so day-to-day variations are 
unlikely to have a major impact. This is an advantage for health surveys and screening. The 
Scottish Health Survey (SHS) comprises representative population-based surveys, in a population 
at high risk of CHD (Government, 2008), conducted every 3-5 years from 1995 until 2003, and 
annually since 2008. We have investigated whether lifestyle drivers of redox status (cigarette 
smoking, fruit and vegetable consumption) are associated with protein glycation, using HbA1c as 
a marker of the process, in sub-samples of non-diabetic adults. 
 
3.2 Methods 
 
This study is a secondary analysis of the anonymised data from the Scottish Health Survey and the 
Health Survey for England. Original ethical approval for the Scottish Health Surveys was granted 
by the Multicentre Research Ethics Committee (Scotland). As the data are in the public domain 
and available through the Economic and Social Data Service (ESDS), this study required no 
additional ethical approval. 
Subjects 
Data from the 2003, 2008, 2009, and 2010 SHSs were compiled in order to create the large 
database used in the current analysis. The SHS is a cross-sectional nationally representative 
survey reporting the health and health-related behaviour of people living in private households in 
Scotland, using a multistage, stratified, clustered probability-sampling design. Full survey 
procedures are described elsewhere (Lynch et al., 1996, Bromley C, Bromley C); a brief summary 
is given here. 
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General methods 
During two household visits, data on demographic, economic, occupational, age, sex, general 
health and health related habits were collected. Weight was measured to the nearest 100g using 
electronic scales. Height was measured to the nearest millimetre using a stadiometer. Body Mass 
Index (BMI) was calculated as weight (kg) divided by height squared (m2). The waist was measured 
at the midpoint between the lowest rib and upper margin of the iliac crest. The measurements 
were recorded to the nearest millimetre with at least two measurements within 5cm combined to 
provide a mean (Lean et al., 1995). 
Dietary measures 
Two different tools were used to assess eating habits in the Scottish Health Surveys. One, a FFQ 
validated against weighed intakes (Lean et al., 2003), was specifically designed to assess fruit and 
vegetable intake. Responders were asked about the total number of portions of vegetables (fresh, 
frozen or canned) and vegetables in composites, salads, pulses, fruit (fresh, frozen or canned), 
dried fruit and fruit in composites consumed in the 24h preceding the interview. From the 
available nutritional information, variables that reported total portions of vegetable, total 
portions of fruit and the two of them combined were selected for the current analysis.  
Smoking habits 
Participants were asked to report if they were currently smoking, ex-occasional or ex-regular 
smokers, or never smoked. Present smoking status was classified as light (under 10 cigarettes a 
day), moderate (10 to under 20 cigarettes a day), heavy (20 or more cigarettes a day) and non-
smoker. 
Physical activity 
Frequency of participation was assessed for various domains of activity, including leisure time 
sports and exercise (for at least 15 minutes per occasion). The total physical activity was then 
categorised to ‘low/medium/high’ according to the metabolic equivalents spent during each 
activity and the total activities reported.  
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Biochemical and other measurements 
Serum CRP was measured by N Latex high sensitivity mono-immunoassay on the Behring 
Nephelometer II analyzer (coefficient of variation <6%, limit of detection 0.17mg/l ) in nmol/L ( 
conversion factor to mg/L= 0.105) and total glycated haemoglobin (HbA1c) analysis was carried 
out in the Biochemistry Department at the RVI using the Tosoh G7 HPLC analyser, which was 
calibrated using Diabetes Control and Complications Trial (DCCT) standards with coefficient of 
variation <2.5%. 
Statistical analysis 
In order to exclude undiagnosed diabetes cases, the cut-off point of HbA1c ≥6.5% (48mmol/mol) 
was employed (ADA, 2011). Participants without diagnosed diabetes and with HbA1c ≤6.5% 
(48mmol/mol) were included in the analysis. Pregnant women were excluded. Individuals with 
HbA1c between 5.7% (39mmol/mol) and 6.4% (46mmol/mol) were classified as being at high risk 
or ‘pre-diabetic’ (ADA, 2011). Body mass index, mean waist circumference, age and CRP levels 
were used as continuous variables. CRP was also used in order to identify and exclude individuals 
with low grade inflammation (CRP >28.5nmol/L or >3mg/L) (Wildman et al., 2008, Grundy et al., 
2004). Data were checked for normality and homoscedasticity using the Kolmogorov-Smirnoff 
test, and for skewness. Parametric tests were used for data with normal and non-normal 
distributions since, according to the Central Limit Theorem (Lumley et al., 2002), parametric tests 
can safely be used with skewed data when the sample size is over 500. The Student’s t-test, one 
way-ANOVA and χ2 test were used to examine the differences among groups of smoking status 
and fruit and vegetables intake in HbA1c levels. General linear models were used to compare 
HbA1c levels among smoking groups that were adjusted for age and sex. Multivariate linear 
regression was used to describe the effect of smoking and fruit and vegetables intake on HbA1c, 
after adjusting for age, sex, ethnic group, socioeconomic group, activity levels, BMI, waist 
circumference, CRP levels, vitamin supplementation and year of survey. Logistic regression was 
performed to investigate the association of smoking status and presence of increased risk for 
diabetes. In the case of fruit and vegetable intake the model was adjusted to include smoking in 
the confounders. All analyses were performed using PASW Statistics (18.0.0) and statistical 
significance was taken as p<0.05. 
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3.3 Results 
 
Glycated haemoglobin levels (HbA1c) were higher in ex-smokers and current smokers compared to 
non-smokers (Table 3.1) and this increasing trend (p<0.001) was seen even when the age-sex 
adjusted means were plotted against smoking status (Figure3.1). The trend remained consistent 
when the ex-smokers were split into those who smoked occasionally and those who smoked 
regularly (Figure 3.1). The same analysis of age-sex adjusted HbA1c levels was conducted among 
groups based on number of cigarettes smoked per day, with similar results (p<0.001) (Figure3.2). 
Figure 3.1 Age-sex adjusted mean (SD) of %HbA1c according to smoking status 
 
 
Figure 3.2 Age-sex adjusted mean (SD) of %HbA1c according to number of cigarettes/day  
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Table 3.1 Descriptive characteristics of the population in total and according to smoking status 
  Smoking status 
 All 
(n=6120) 
Non-smokers 
(n=2831) 
Ex-Smokers 
(n=1832) 
Current Smokers 
(n=1457) 
Age (years) 50.5±16.9 (18.0-95.0) 49.0±17.2 (18-95) 56.2±16.0 (19-94)* 46.1±15.3 (18-91)* 
Sex (% Male) 45.2 42.6 49.0* 45.4* 
Social class (% High
†
) 43.2 50.6 44.2* 27.7* 
Body Mass Index (kg/m
2
) 27.3±4.8 (13.3-62.7) 27.3±4.8 (15.2-53.3) 27.8±4.5 (13.3-54.5)* 26.4±5.1 (15.1-62.7)* 
Waist circumference (mm) 91.6±13.2 (54-152) 90.5±13.2 (54-152) 93.8±13.0 (60-152)* 89.8±13.4 (58.5-147) 
Physical activity (%Low) 30.7 28.1 33.7* 32.1* 
HbA1c (%) 
(mmol/mol) 
5.4±0.4 (2.8-6.4) 
36±4.4 (30.6-46) 
5.3±0.4 (2.8-6.4) 
34±4.4 (30.6-46) 
5.4±0.4 (3.8-6.4)* 
36±4.4 (18-46) 
5.4±0.4 (2.9-6.4)* 
36±4.4 (31.7-46) 
CRP (nmol/L) 33.3±65.7 (1.9-971) 27.6±55.2 (1.9-971) 36.2±75.2 (1.9-95.4)* 40.9±68.6 (1.9-762)* 
Total fruit portions/d 2.0±1.8 (0.0-20.0) 2.3±1.8 (0.0-12.5) 2.2±1.8 (0.0-10.5) 1.3±1.7 (0.0-22.0)* 
Total vegetable portions/d 1.3±1.4 (0.0-22.0) 1.4±1.3 (0.0-20.0) 1.4±1.3 (0.0-15.3) 1.1±1.3 (0.0-17.7)* 
Total fruit & vegetable portions/d 3.4±2.5 (0.0-31.4) 3.7±2.4 (0.0-22.5) 3.6±2.4 (0.0-25.3) 2.5±2.4 (0.0-31.4)* 
Data presented as mean ± SD (range)
 †
High social class: Professional and managerial technical;* compared to non-smokers; p<0.05 
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Current smokers were twice as likely as non-smokers to have HbA1c in the pre-diabetes range 
(Table 3.2). Lighter smokers (<10 cigarettes/day) were almost twice as likely as non-smokers to 
have HbA1c in the pre-diabetes range (OR 1.88), while smoking 10 to 20 cigarettes per day 
increased the risk for HbA1c ≥5.7% (39mmol/mol) more than 2-fold (OR 2.63) (Table3.2). Being an 
ex-occasional or ex-regular smoker was not associated with higher chances of being classified in 
the high risk/pre-diabetes category of HbA1c. 
Body mass index (BMI) differed significantly by smoking status: current smokers had a lower BMI 
than non-smokers when ex-smokers had a significantly higher BMI than non-smokers (Table 3.1). 
Smoking is associated with poorer social circumstances, while ex-smoking status is more frequent 
among those with better social circumstances (% high social class 44.2 vs. 27.7 in ex-smokers and 
current smokers respectively p<0.001) (Table 3.1). Current smokers included younger subjects 
than non-smokers (46.1±15.3 vs. 49.0±17.2 years; p<0.001), whereas ex-smokers included older 
subjects. There was no difference in waist circumference between current smokers and non-
smokers, but ex-smokers had a higher mean waist circumference than non-smokers (p<0.05). 
Current smokers consumed fewer portions of fruit, vegetables, and the two combined, than non-
smokers and a higher proportion were classified as having low physical activity. Although ex-
smokers also included more subjects classified as having low physical activity than non-smokers, 
they were no different for fruit and vegetable consumption. CRP concentrations were greater 
among smokers, both ex-smokers and current smokers having higher values than non-smokers 
(Table 3.1). Ex-smokers and current smokers had CRP levels significantly higher than the 
28.5nmol/L cut-off indicating high risk for metabolic diseases range and low-grade inflammation 
(p<0.001; data not shown). In all following analysis the above mentioned variables were used as 
confounders. 
Consumption of vegetables was associated with having marginally lower chances of having HbA1c 
in the pre-diabetes range. This effect remained after adjustment for various confounders, using 
either smoking status or number of cigarettes per day (Table 3.2). 
Multivariate linear regression showed that current smokers have higher HbA1c than non-smokers, 
by 0.08% (0.9mmol/mol) (equal to 0.25 the SD of this population). Heavy smoking (20 or more 
cigarettes a day) is associated with a larger effect of 0.14% (1.5mmol/mol) (equal to 0.38 the SD 
of this population) greater HbA1c. The regression model explained ≈35% of the variance in HbA1c. 
From all the confounding factors employed in this study only year of survey had a significant 
effect on HbA1c levels in the full factorial model (coefficient 0.13±0.04, p<0.001) (data not 
shown). HbA1c levels were lower by 0.01% (0.1mmol/mol) for each extra portion of vegetable 
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consumed, after controlling for number of cigarettes per day. The same was not found for fruit 
portions per day or fruit & vegetables portion combined (Table 3.3). 
When individuals with HbA1c in the pre-diabetes range were assessed alone, the R2 value of the 
multiple regression model for the narrow range of HbA1c was only 0.06, leaving a large 
proportion of variance unexplained (data not shown). Thus neither vegetable nor fruit 
consumption had an effect on HbA1c (Table 3.3). There was no interaction between smoking 
status and HbA1c level (p=0.20) but there was weak evidence for an association between number 
of cigarettes per day and greater HbA1c levels (p=0.06). 
In order to avoid confounding effects from any mild metabolic disruptions associated with the 
pre-diabetic status or low-grade inflammation, the above analysis was conducted among 
individuals with HbA1c below the 5.7% (39mmol/mol) cut-off, and with a CRP lower than 
28.5nmol/L. Heavy smoking (10-20 cigarettes/day) was still associated with ≈0.1% (1.1mmol/mol) 
(equal to 0.28 the SD for this population) greater HbA1c than non-smoking (Table 3.3). Although 
vegetable consumption was significantly (inversely) associated with HbA1c among the non-
diabetic individuals as a whole, the level of significance dropped for this analysis restricted to 
individuals with HbA1c less than 5.7% (39mmol/mol) (p=0.09). However, individuals with both 
HbA1c <5.7% (39mmol/mol) and also CRP<3mmol/L had significantly lower HbA1c, by 0.01% 
(0.1mmol/mol) (equal to 0.03 the SD of this population) (p=0.02) for every extra portion of 
vegetables consumed (Table 3.3). 
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Table 3.2 Logistic regression for smoking status and fruit & vegetable consumption predicting high 
risk of diabetes 
 OR 95%CI p-value 
Smoking status    
Non-smoker (contrast)    
Ex-occasional 0.88 0.59-1.32 0.54 
Ex-regular 1.11 0.92-1.34 0.26 
Current smoker 2.25 1.84-2.75 <0.001 
# cigarettes/day    
None (contrast)    
Less than 10 1.88 1.31-2.71 <0.001 
10 to less than 20 2.63 2.04-3.39 <0.001 
More than 20 2.06 1.57-2.71 <0.001 
(adjusted for smoking status)    
Vegetable intake 0.94 0.89-1.01 0.08 
Fruit intake 0.99 0.94-1.03 0.56 
Fruit & vegetable intake 0.98 0.95-1.01 0.17 
(adjusted for # cigarettes/day)    
Vegetable intake 0.95 0.89-1.01 0.09 
Fruit intake 0.99 0.94-1.03 0.53 
Fruit & vegetable intake 0.98 0.95-1.01 0.17 
*adjusted for age, sex, ethnic group, social class, physical activity level, CRP, BMI, waist circumference & year of study  
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Table 3.3 Regression analysis summary for smoking status and fruit &vegetable consumption with 
%HbA1c levels 
a) Non-diabetics (HbA1c<6.5%) (n=5425)  Coef* SE p-value 
Smoking status 0.027 0.004 <0.001 
# cigarettes/day 0.047 0.005 <0.001 
Vegetable intake
†
 -0.009 0.004 0.008 
Fruit intake
†
 0.001 0.003 0.754 
Fruit & vegetable intake
†
 -0.002 0.002 0.236 
b) High risk of diabetes (HbA1c 5.7%-6.4) (n=1391)    
Smoking status 0.050 0.004 0.201 
# cigarettes/day 0.010 0.005 0.060 
Vegetable intake
†
 0.001 0.004 0.947 
Fruit intake
†
 0.004 0.003 0.170 
Fruit & vegetable intake
†
 0.002 0.002 0.292 
c) Low risk of diabetes (HbA1c<5.7%) (n=4155)    
Smoking status 0.017 0.003 <0.001 
# cigarettes/day 0.031 0.005 <0.001 
Vegetable intake
†
 -0.005 0.003 0.092 
Fruit intake
†
 0.001 0.002 0.603 
Fruit & vegetable intake
†
 -0.001 0.002 0.605 
c) Low risk of diabetes(HbA1c<5.7%) & CRP<28.5nmol/L (n=3172)    
Smoking status 0.014 0.004 <0.001 
# cigarettes/day 0.029 0.005 <0.001 
Vegetable intake
†
 -0.009 0.004 0.021 
Fruit intake
†
 0.002 0.003 0.546 
Fruit & vegetable intake
†
 -0.001 0.002 0.464 
*adjusted for age, sex, ethnic group, social class, physical activity level, CRP, BMI, waist circumference & year of 
study;
 †
adjusted for #cigarettes/day 
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3.4 Discussion 
HbA1c is commonly regarded mainly as a biomarker for blood glucose levels; however, observing 
the substantial variation in HbA1c among non-diabetic individuals, unlikely to result from 
sustained differences in blood glucose, we postulated that HbA1c may also reflect oxidative stress 
or redox status. In our analysis, we have demonstrated that smoking (a proxy for oxidative stress) 
is positively associated with protein glycation, as measured by HbA1c levels in non-diabetic 
subjects. This finding adds complexity to the evidence that smoking increases the risk of 
developing type 2 diabetes (Alter et al., 2012, Willi et al., 2007). 
Although smoking has been extensively studied as a risk factor for deteriorating diabetic status 
and as promoting end-organ damage in diabetic subjects, evidence on the effect of smoking on 
protein glycation and diabetes progression is not so clear. A large epidemiological study 
conducted in the USA has found similar results with smokers having a relative 7% increase in 
HbA1c levels compared to non-smokers, in a population free of diabetes (Clair et al., 2011). An 
early report of 191 hypertensive and normotensive non-diabetic subjects detected a statistically 
significant difference in HbA1c levels between smokers and non-smokers (Nilsson et al., 1995). 
The same was reported in a sample of 3,240 healthy non-diabetic adults (Simon et al., 1989) and 
in 1,773 middle-aged non-diabetic participants from the Potsdam cohort of EPIC (Boeing et al., 
2000) where smoking was associated with increased HbA1c levels in both sexes. A recent Dutch 
study assessing the role of increased waist circumference (>88cm for women, >102cm for men) 
on protein glycation, measured by skin auto-fluorescence, in non-diabetic individuals identified 
current smoking as an important confounder in the association, which agrees with our data (den 
Engelsen et al., 2012). Among these diverse studies, some can be considered valid, but others 
have low numbers and weaknesses in design. The current study benefits from the large sample 
size and the numerous diabetes related variables available, in order to control for confounding. 
In the current study we have also shown that smoking remains positively correlated with HbA1c in 
a subsample of participants who are not affected by any metabolic derangements from pre-
diabetes (with HbA1c<5.7%, 39mmol/mol) and in a subsample with both HbA1c<5.7% 
(39mmol/mol) and CRP levels <28.5nmol/L to exclude any influence from low-grade 
inflammation. This fractioning of the population was performed on the basis that individuals with 
HbA1c levels within the prediabetic range, would already have some degree of abnormalities in 
glucose metabolism. These abnormalities are most likely to explain the variation in HbA1c levels 
in this population subgroup (Monnier et al., 2003, Bastyr et al., 2000). These results provide 
robust evidence for a true association between oxidative stress and protein glycation. In fact, we 
did not find evidence for the same association with smoking among the individuals with HbA1c in 
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the pre-diabetic range 5.7 - 6.4% (39 - 46mmol/mol), probably because of smaller number of 
participants in this group, with a range of HbA1c too narrow to detect an influence, however the 
main driver protein glycation in this group is likely to be their altered glycaemia and glucose level 
fluctuations. It seems likely that oxidative stress and redox status are more potent drivers of 
protein glycation on a background of normal glucose metabolism, but elevated blood glucose 
concentrations in the fasting and/or post-prandial states would dominate. Unfortunately lack of 
data on blood glucose levels did not allow for this association to be investigated in the present 
study. Measuring both HbA1c and glucose concentrations in large epidemiological studies, 
together with indicators of exposure to oxidative stress and antioxidant/anti-inflammatory 
influences, would be of great value to discriminate these effects. 
There was some evidence in the present study that vegetable consumption (a proxy for 
antioxidant influences on redox status) was inversely associated with HbA1c levels in all non-
diabetic subjects (HbA1c <6.5%, 48mmol/mol) and among individuals with low HbA1c (<5.7%, 
39mmol/mol) and low CRP (<28.5nmol/L), suggesting some benefit from diets high in antioxidant 
rich sources. It is likely that fruit would have the same physiological effect, but the present study, 
in a population notorious for its low fruit consumption (and a narrow range of fruit consumptions 
for statistical analysis) was unable to detect an effect. Our data have shown mean intakes of 
vegetables to be 1.3±1.4 portion per day and fruit 2.0±1.8 portions per day. 
In a large study of older English adults, by Bates et al (Bates et al., 2004), both dietary antioxidant 
consumption and antioxidant plasma levels of non-diabetic individuals were found to have inverse 
associations with HbA1c levels. There was also an inverse correlation between plasma vitamin C 
concentration and HbA1c. A similar inverse relationship has been found for vitamin C and vitamin 
E in a younger population, also suggesting that antioxidant intake and hence antioxidant capacity 
and redox status are playing a role in protein glycation in normoglycaemia (Boeing et al., 2000). A 
link between antioxidant intake and protection against protein glycation is supported by in-vitro 
evidence clearly showing that antioxidants, including vitamin C, flavonoids and tocopherols 
reduce glycation of proteins (Davie et al., 1992, Krone and Ely, 2004), and pro-oxidants, such as 
H2O2 and lipid peroxides, drive glycation of haemoglobin (Selvaraj et al., 2005, Nambiar et al., 
2012). Protein glycation and oxidation processes share common sites on the protein molecules, 
which supports a mechanistic relationship (Rondeau and Bourdon, 2011). Oxidative stress and an 
associated increase in protein glycation is present not only in smokers (Nilsson et al., 1995) but 
also in chronic renal failure (Sabater et al., 1991), and myocardial infarction (Chowdhury and 
Lasker, 1998). Our study adds to an increasing body of evidence from various fields, to strengthen 
our hypothesis that redox status drives protein glycation in non-diabetic individuals.  
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This study inevitably has limitations. A cross-sectional survey design can only ever be hypothesis-
generating, and does not allow for causality to be investigated. We are not claiming that oxidation 
is the only, or the main mechanism behind protein glycation in non-diabetic and pre-diabetic 
subjects, but our data do allow us to make the hypothesis that it is playing a part, and a 
potentially modifiable part. Using proxy measures of oxidative stress and redox status, rather than 
actual levels of oxidative stress markers (like isoprostanes), is an in-built limitation in this type of 
general-population health survey. We established the independence of pro- and anti-oxidant 
environmental factors by including them in the same analytical model. Specific measures could be 
made in future research. The lack of data on average levels of glycaemia, independent of HbA1c 
limits the interpretation of the data. Fasting glucose or 2-hour postprandial glucose levels are 
seldom measured in large epidemiologic studies, and in any case one-off measurements are 
considered relatively unreliable as reflections of ambient blood glucose. We have explored the 
possible of effect of small differences in glycaemia by analyses within narrow HbA1c sub-
categories, and find the same associations with the indicators of redox status. It would be possible 
to define the independence of theses associations from those of fasting and 2-hour blood glucose 
in large diabetes screening datasets which also include measures to reflect redox status, but not 
in the present study. It is also possible that increased fruit and vegetable intake might be 
associated with a decreased intake of heat-processed food, a main contributor of dietary AGEs, 
and an increased consumption of fibre, minerals and other micronutrients. Unfortunately this 
association could not be investigated in this study due to the nature of the nutritional information 
available. 
 
3.5 Conclusion 
This large population-based study suggests that protein glycation, indicated by HbA1c, is 
positively associated with smoking, and inversely correlated with vegetable intake. An 
unfavourable redox status, may thus account for some people having HbA1c in the pre-diabetic 
range, and this mechanism may promote progression to diabetes, as well as promoting tissue 
damage. These results strengthen the case for the balance between antioxidant and pro-oxidant 
status being important in the pathogenesis of chronic diseases.  
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Chapter 4: Role of oxidative stress in physiological albumin glycation: a 
neglected interaction 
 
 
This chapter is presented exactly as published in Free Radical Biology and Medicine  
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Abstract 
 
Background: Protein glycation is a key mechanism involved in chronic diseases development in 
both diabetic and non-diabetic individuals. About 12 - 18% of circulating proteins are glycated in 
vivo in normoglycaemic blood, but in-vitro studies have hitherto failed to demonstrate glucose-
driven glycation below concentration of 30mM. 
 Methods: Bovine Serum Albumin (BSA), reduced BSA (mercaptalbumin), (both 40g/L) and human 
plasma were incubated with glucose concentrations 0 - 30mM for 4 weeks at 37oC. All were 
tested pre-oxidized for 8 hours prior to glycation with 10nM H202, or continuously exposed to 
10nM H2O2 throughout the incubation period. Fructosamine was measured (nitroblue tetrazolium 
method) at two and four weeks. 
Results: Oxidized BSA (both pre-oxidised and continuously exposed to H2O2) was more readily 
glycated than native BSA at all glucose concentrations (p=0.03). Moreover, only oxidized BSA was 
glycated at physiological glucose concentration (5mM) compared to glucose-free control 
(glycation increased by 35% compared to native albumin p<0.05). Both 5 and 10mM glucose led 
to higher glycation when mercaptalbumin was oxidised than un-oxidised (p<0.05). Fructosamine 
concentration in human plasma was also significantly higher when oxidized and exposed to 5 mM 
glucose, compared to non-oxidised plasma (p=0.03). The interaction between glucose 
concentration and oxidation was found to be significant in all protein models (p<0.05).  
Conclusion The current study has for the first time demonstrated albumin glycation in-vitro, using 
physiological concentrations of albumin, glucose and hydrogen peroxide, identifying low-grade 
oxidative stress as a key element early in the glycation process.  
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4.1 Introduction 
 
Protein glycation is the non-enzymatic glycosylation reaction between reducing sugars and amine 
residues in proteins (Turk et al., 2001). It is usually considered to be driven by elevated glucose 
concentrations. Products of this reaction include AGEs which are stable and accumulate in the 
body where they may exert antigenic effects, and contribute to tissue damage such as 
atherogenesis (Anderson et al., 1993, Galkina and Ley, 2006). One early-glycation product is 
glycated hemoglobin (HbA1c), used as a biomarker for the diagnosis of diabetes and monitoring 
of glucose control in diabetic individuals (Roohk and Zaidi, 2008). Monitoring, and minimizing, 
glycative damage in diabetic care is of high importance, as glycated proteins and AGEs are 
implicated in cataract, neuropathy, nephropathy as well as macrovascular diseases (Plutzky, 
2011). 
However, glycation also occurs in non-diabetic people, in whom up to 6 % of hemoglobin and 12-
16% of serum albumin is glycated (Selvin et al., 2011), without exposure to high glucose 
concentrations (fasting plasma glucose <6mmol/L). Protein glycation heralds tissue damage and 
function loss, in the normal aging process and as part of the pathogenesis of various chronic 
diseases. RAGE, found in most tissues, have potent immunomodulatory actions, promoting ROS 
production and inflammation. Elevated HbA1c can serve as a proxy for both pre-diabetes and 
metabolic syndrome, as shown in large longitudinal studies (Veeranna et al., 2011). In both non-
diabetic and diabetic subjects, HbA1c correlates with coronary heart disease (CHD) risk factors 
and predicts future CHD and strokes (Myint et al., 2007). A recent study showed that among non-
diabetic individuals who did not develop diabetes in the next 3.5 years, those with a higher yet 
physiological level of HbA1c had higher risk for CVD, in both men and women and after controlling 
for traditional risk factors (Adams et al., 2009). 
The mechanisms leading to protein glycation in the non-diabetic state are not established. The 
very few in vitro studies which have used physiological concentrations are inconclusive as to 
whether glucose, alone, can successfully promote glycation (Chesne et al., 2006, Bourdon et al., 
1999). In diabetic subjects, protein glycation is assumed to be mainly a mass action effect driven 
by high glucose concentration. However the full process of glycation in diabetes is in fact driven 
by two separate factors - the concentration of sugars in the initiation phase (mainly glucose, due 
to its high concentration in blood), and later the pro-oxidant status during Maillard reactions to 
generate stable AGEs (Fu et al., 1994). We hypothesize that at physiological concentrations of 
glucose, oxidation may have another role in initiating glycation, supporting earlier speculations 
from a cross-sectional study in non-diabetic individuals which showed inverse associations 
between protein glycation and dietary fruit and vegetable consumption, plasma vitamin C and 
45 
 
plasma tocopherol (Bates et al., 2004). Defining an early, preventable oxidative component to the 
overall glycation mechanism could be of importance in the management of pre-diabetes, when 
glucose metabolism is only mildly disrupted and glucose-centred clinical approaches might have 
little effect. 
The current study investigates the effect of introducing a mildly pro-oxidative state (hydrogen 
peroxide at a low physiological concentration of 10nM (Mueller et al., 1997)) on the susceptibility 
of protein (albumin) to glycation, particularly at physiological and near-physiological glucose 
concentrations. Another common glycation driver, methylglyoxal, which causes glycative damage 
in a more oxidative fashion than glucose, was used in physiological concentration both alone and 
in combination with glucose, to explore possible synergistic effects.  
This oxidation-driven glycation hypothesis was also tested on reduced albumin (mercaptalbumin) 
on the assumption that commercially source native albumin would be already partly oxidized. This 
work was also extended to proteins in human plasma to extend the physiological relevance of our 
findings. 
4.2 Material and methods 
 
Impact of constant oxidation & pre-oxidation on BSA glycation 
Chemicals 
Bovine serum albumin (BSA), sodium azide, nitroblue tetrazolium, d-glucose, methylglyoxal, PBS, 
1-deoxy-1-morpholinofructose (DMF), hydrogen peroxide, sulphuric acid, dithiothreitol and 
quinine were purchased from Sigma-Aldrich (Dorset, UK). SnakeSkin Dialysis Tubing, 3.5K MWCO 
was purchased from Thermo Fisher Scientific (Nottinghamshire, UK). 
Glycation of pre-oxidized BSA 
BSA (80g/L) was incubated with H2O2 (10nM) for 8 hours at 37
oC in PBS and was then dialyzed 
against PBS (8:1) for another 8 hours. The dialysate was discarded and replaced with fresh PBS 
three times during dialysis. 
To measure the effect of protein pre-oxidation on the susceptibility of BSA to glycation, both 
native and pre-oxidized albumin (40g/L) were incubated in the presence of glucose (0, 5, 10, 20, 
and 30mM) for 4 weeks. The combination of methylglyoxal (150nM) and glucose (0, 10 or 20mM) 
was also studied in order to replicate glycoxidative conditions of albumin in the circulation. All 
incubations were repeated in 6 replicates. 
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Albumin glycoxidation  
All incubations took place in PBS with sodium azide (0.2g/L) and a final volume of 1.5ml. To 
investigate the effect of continuous exposure to oxidative damage in the progress of the glycation 
reaction (glycoxidation) native BSA was incubated with glucose (0, 5, 10, 20 or 30mM) and 
combinations of methylglyoxal (150nM) plus glucose (0, 10, 20mM) for 4 weeks in the presence of 
H2O2 (10nM). Native BSA was also incubated under the same conditions without H2O2 (10nM) to 
serve as a reference. All incubations were repeated in 6 replicates. 
Comparison of the effect of constant glycation among BSA, mercaptalbumin & human plasma 
To enhance a concern over the oxidation status of the bovine serum albumin sold by Sigma-
Aldrich, the BSA used in the experiments was i) pre-treated with 1.5mM dithiothreitol (DTT) at 
37oC for 15min and then DTT was removed by extensive dialysis against PBS for 10 hours to create 
mercapralbumin and ii) BSA as bought from Sigma-Aldrich. 
In order to investigate the effect of hydrogen peroxide exposure in plasma proteins glycation, 
pooled plasma from 8 healthy, normal weight volunteers was collected in heparin tubes after an 
overnight fast.  
Protein glycoxidation  
All incubations took place in PBS with sodium azide (0.2g/L) and a final volume of 1.5ml. To 
investigate the effect of constant exposure to oxidative damage in the progress of the glycation 
reaction (glycoxidation) native BSA and native mercaptalbumin was incubated with glucose (0, 5, 
10 or 20mM) for 4 weeks in the presence of H2O2 (10nM). Proteins were also incubated under the 
same conditions without H2O2 (10nM) to serve as a reference. 
The glucose concentration of 30mM was not employed as it is a highly supra-physiological 
concentration and the combinations of methylglyoxal plus glucose were also not employed. 
All incubations were repeated in 5 replicates. 
Fructosamine measurement 
The NBT assay was modified in this experiment using a larger amount of sample (25 vs 10µL) 
which resulted in a smaller Coefficient of Variation. 
Fructosamine levels were measured at week 2 and 4 with the NBT assay, performed in 
microplates as described previously (Baker et al., 1993). Briefly, samples (25µL) were added to of 
sodium carbonate buffer (100µL, 100mM, and pH 10.8) with Nitroblue Tetrazolium (0.25mM). 
Microplates were incubated for 15min at 37oC and measured spectrophometrically against 
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controls at 550nm after 10 and 15min of incubation. The difference between the two readings 
was used to calculate concentrations. The fructosamine analog 1-deoxy-1-morpholinofructose 
(DMF) was used as a standard. All fructosamine measurements were performed in duplicate. 
Standards and NBT reagent were made fresh every week and stored at -20oC and 4oC respectively. 
All samples were stored at -20oC. 
Statistical analysis 
All combinations of oxidative damage and glycation drivers were tested as five or six true 
replicates, according to the experiment. The independent sample t-test was used to assess the 
differences in glycation between native BSA and either of the oxidation set-ups. Difference in 
fructosamine production between glucose levels and glycation drivers were tested using a one-
way ANOVA and Tukey’s post-hoc test. Differences between exposure to oxidation and no 
oxidation were studied in each protein system separately using one-way ANOVA and the 
interaction between glucose levels and oxidation was studied using two-way ANOVA. Statistical 
analysis was performed using PASW 18. 
4.3 Results 
 
Effect of constant oxidation on BSA glycation 
Incubation of native BSA (40g/L) with glucose concentrations below 20mM did not lead to 
measurable levels of glycated BSA measured after 2 weeks, with or without 150nM methylglyoxal, 
compared to glucose-free control (Table 4.1). After 4 weeks, incubation with 10mM glucose (with 
or without methylglyoxal) significantly promoted glycation in native BSA compared to glucose-
free control. Exposure to a physiological concentration of hydrogen peroxide (10nM), however, 
led to significantly higher glycated BSA (measured as fructosamine) at the lower glucose 
concentrations of 10mM after 2 weeks, and 5 mM after 4 weeks incubation (both p<0.05 vs. 
glucose free control). 
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Table 4.1 Fructosamine concentration after two weeks incubation of albumin with different 
glucose concentrations, between and within treatments (glucose / MGO exposure and oxidation) 
Week 2 
Glucose levels 
(mM) 
Oxidation status 
 Native 
Mean (SD) 
H2O2 10nM 
Mean(SD) 
p-value  
Native 
Mean (SD) 
Pre-Oxidized 
Mean(SD) 
p-value 
0 0.26(0.04) 0.27(0.02) 0.669  0.26(0.01) 0.26(0.03) 0.807 
5 0.31(0.04) 0.38(0.02) 0.017  0.23(0.02) 0.29(0.05) 0.016 
10 0.35(0.02) 0.53(0.02)* 0.001  0.26(0.04) 0.28(0.03) 0.177 
20 0.51(0.05)* 0.69(0.07)* 0.002  0.57(0.06)* 0.57(0.04)* 0.940 
30 0.82(0.06)* 0.82(0.03)* 0.987  0.79(0.10)* 0.64(0.10)* 0.041 
0+MGO 0.26(0.02) 0.31(0.01) 0.015  0.19(0.02) 0.19(0.03) 0.510 
10+MGO 0.34(0.05) 0.46(0.03)* 0.001  0.62(0.07)* 0.48(0.05)* 0.002 
20+MGO 0.53(0.08)* 0.67(0.01)* 0.008  0.46(0.05)* 0.39(0.07)* 0.048 
Oxidised vs native#    <0.001    0.005 
Week 4 
0 0.37(0.03) 0.39(0.09) 0.767  0.20(0.02) 0.17(0.02) 0.021 
5 0.40(0.09) 0.54(0.06)* 0.015  0.26(0.02) 0.24(0.02)* 0.063 
10 0.55(0.04)* 0.68(0.06)* 0.003  0.31(0.02)* 0.31(0.02)* 0.825 
20 0.78(0.04)* 0.92(0.04)* <0.001  0.56(0.05)* 0.52(0.07)* 0.292 
30 0.95(0.08)* 1.17(0.10)* 0.002  0.62(0.05)* 0.64(0.03)* 0.844 
0+MGO 0.43(0.02) 0.40(0.04) 0.590  0.22(0.02) 0.17(0.01) 0.016 
10+MGO 0.70(0.03)* 0.84(0.09)* 0.010  0.52(0.01)* 0.46(0.03)* 0.028 
20+MGO 0.86(0.07)* 1.05(0.12)* 0.015   0.40(0.02)* 0.33(0.01)* <0.001 
Oxidised vs native#   <0.001    <0.001 
*p<0.05 vs. glucose 0mM, 
# 
two-way ANOVA analysis 
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Using constantly-oxidized BSA generated significantly more fructosamine than native BSA after 2 
weeks of incubation with 5, 10, and 20mM glucose (increased by 23%, 36% and 35% respectively). 
Similar results were observed with methylglyoxal (150nM) alone (19% increase in fructosamine), 
and with a combination of methylglyoxal (150nM) plus glucose at concentrations of 10 and 
20mM, with 35% and 26% increases in fructosamine respectively (Figure 4.1). Significantly greater 
glycation of constantly-oxidized BSA compared to native BSA was also observed after 4 weeks at 
all glucose concentrations, and with combinations of glucose (10 & 20mM) and methylglyoxal 
(150nM) (Figure 4.2). In particular, incubation of BSA with 5mM glucose and 10mM H2O2 led to a 
35% higher fructosamine concentration compared to the non-oxidised control (p=0.04). Although 
incubating BSA in presence of methylglyoxal (150nM) alone did not lead to significantly increased 
glycation after neither 2 nor 4 weeks (Table 4.1), combining methylglyoxal (150nM) and glucose 
(10mM) had a synergistic effect on glycation of constantly-oxidised BSA after 4 weeks (p=0.02 vs. 
glucose alone), as well as some suggestion of an effect on native BSA (p=0.08) (data not shown). 
The individual impacts of glucose concentration and oxidation, as well as their interaction, on 
glycation over periods of 2 and 4 weeks were investigated using a two-way ANOVA. Oxidation had 
a significant effect on glycation at both two and four weeks (p<0.001) There was strong evidence 
for an interaction between continuous-oxidation and glucose concentration in driving glycation 
after 2 weeks of incubation (p<0.001) with a non-significant indication of an effect of this 
interaction on glycation after 4 weeks (p=0.058). While removing data relating to methylglyoxal 
and glucose incubations from the analysis did not change impact on the significance of the effect 
of oxidation on protein glycation (p <0.001 at both two and four weeks), the interaction between 
oxidation and glucose concentration significantly affected glycation after both two and four weeks 
(p=0.001 and p=0.01, respectively).  
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Figure 4.3 Fructosamine concentration (mM DMF equivalent) after two weeks incubation with 
glucose and constant exposure to oxidation from hydrogen peroxide (10nM). 
 
 Two-way ANOVA analysis showed a significant effect of oxidation to promote glycation.*p<0.05 native vs. 
constant oxidation for each given glucose concentration 
Figure 4.4 Fructosamine concentration (mM DMF equivalent) after four weeks incubation with 
glucose and constant exposure to oxidation from hydrogen peroxide (10nM). 
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Effect of pre-oxidation on BSA glycation 
Incubation of native and pre-oxidised BSA with glucose concentrations lower than 20mM for two 
weeks did not lead to significantly more fructosamine being produced than the glucose-free 
control. Nonetheless the pre-oxidation step led to significantly higher glycation, compared to 
native BSA, after two weeks at the lowest glucose concentration (5mM) (p=0.016). 
A 4-week incubation with 5mM glucose alone was sufficient to drive glycation of pre-oxidized BSA 
(p=0.03 vs. glucose-free control), but not native (un-oxidized) BSA which required at least 10mM 
glucose (p=0.001, Table 4.1).  
Comparison of the effect of constant-oxidation on BSA and mercaptalbumin glycation 
Reduction of BSA to mercaptalbumin was employed in order to investigate whether commercially 
available BSA, possibly being oxidised to some extent, would be more or less prone to subtle 
oxidation driven glycation. For this reason, DTT-treated BSA was incubated with glucose (0-
20mM) in presence or absence of 10nM H2O2.  
When mercaptalbumin was incubated with 5 and 10mM glucose under constant oxidation for two 
weeks, significantly higher fructosamine levels were observed compared to non-oxidised 
mercaptalbumin (p=0.03 & p=0.006; respectively). While incubation for two weeks with 5mM 
glucose was sufficient to drive higher glycation in constantly-oxidized mercaptalbumin than 
glucose-free control (p<0.001), non-oxidised mercaptalbumin required incubation with 10mM 
glucose to lead to higher glycation than the glucose-free control (p<0.001). No differences 
between oxidized and non-oxidised mercaptalbumin were observed at week 4 (Figure 4.3). 
Two-way ANOVA, analysing the effect of oxidation at all glucose levels, showed that oxidized 
mercaptalbumin was subject to higher glycation than non-oxidised, at both weeks two and four 
(p=0.003 & p=0.035 respectively). The interaction between glucose and oxidation was not 
significantly affecting glycation in both weeks (p for interaction glucose × oxidation = 0.48 & 0.78 
for week 2 and 4 respectively). 
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Figure 4.5 Fructosamine concentration (mM DMF equivalent) after two and four weeks 
incubation with glucose and constant exposure to oxidation from hydrogen peroxide (10nM) in 
mercaptalbumin. 
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When mercaptalbumin glycation was compared to BSA glycation. Mercaptalbumin was more 
prone to glycation than BSA in both the presence and absence of H2O2. In the absence of H2O2 
mercaptalbumin had higher fructosamine concentration than BSA at 5 and 10mM glucose at two 
weeks (p=0.004 & p=0.002 respectively) and that was significant at week 4 for 5mM glucose 
(p=0.005) and nearly significant for 10mM glucose (p=0.06). In the presence of H2O2 
mercaptalbumin was again more successfully glycated than BSA at 5&10 mM glucose at week 2 
(p<0.001, for both) and nearly significantly more at 20mM (p=0.057). At week 4 mercaptalbumin 
was significantly more glycated than BSA only at 5mM glucose (p=0.04) (data not shown). 
Employing two-way ANOVA showed that mercaptalbumin was more prone to glycation than BSA 
(p<0.001) and there was a significant positive interaction between oxidation and the type of 
protein employed, in favour of mercaptalbumin (p interaction protein-type x oxidation= 0.047) at 
week 2. Although the interaction between the protein type and oxidation was not documented at 
week 4 (p=0.33), glycation was still positively affected by using mercaptalbumin rather than BSA 
(p<0.001) (data not shown). 
Effect of constant-oxidation on human plasma glycation 
Protein glycation in human plasma was studied to explore the reactions studied previously in a 
more complex protein system with antioxidant mechanisms in place and closer to human 
physiology. Plasma exposure to constant hydrogen peroxide (10nM) promoted glycation when 
incubated with 5mM glucose for 2 weeks, compared to non-oxidised plasma (p=0.03). 
Surprisingly, this effect of oxidation was no present after 4 weeks, and actually led to significant 
lower fructosamine concentration for incubations with 10mM glucose compared to non-oxidised 
plasma (p=0.001) (Figure 4.4).  
Two-way ANOVA suggested that oxidation had no impact on glycation in human plasma at week 
two but it had a significant negative impact at week four (p=0.01). The interaction glucose × 
oxidation was also significant (p<0.001) at week four, only.  
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Figure 4.6 Fructosamine concentration (mM DMF equivalent) after two and four weeks 
incubation with glucose and constant exposure to oxidation from hydrogen peroxide (10nM) in 
human plasma. 
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4.4 Discussion 
 
Protein glycation was first described as part of the Maillard reactions cascade, as a cause of food-
spoiling. Although the same reactions have been identified in-vivo, and glycated proteins are 
probably causally associated with the tissue damage that occurs during aging, in diabetes and 
other chronic diseases (Plutzky, 2011), there are still gaps in the understanding of the exact 
mechanisms involved. It is striking that 12-18% of circulating albumin, and up to 6% of 
haemoglobin is glycated in apparently healthy non-diabetic people, amongst whom most heart 
disease occurs (Selvin et al., 2011). 
Perhaps surprisingly, this study is the first to demonstrate in vitro protein glycation at 
physiological glucose concentrations. The clear effect of including an oxidative agent (hydrogen 
peroxide at a low, physiologically relevant concentration (Mueller et al., 1997)), supports the 
concept of oxidative stress as a key mechanism behind in-vivo glycation of albumin in 
normoglycaemic individuals. It is worth stressing that the concentration of hydrogen peroxide 
used was very low. Although the literature is still controversial over the exact concentration of 
hydrogen peroxide in plasma with values up to 35μM being documented (Varma and 
Devamanoharan, 1991), even the supporters of the theory that hydrogen peroxide concentration 
is not important in plasma documented values of 250nM (Frei et al., 1988), which is 25 times 
higher than the concentration equipped in the current study. Several factors might explain why 
previous studies have failed to achieve glycation in vitro under physiological conditions. We used 
a physiological concentration of albumin, while previous studies have used lower (sub-
physiological) concentrations (0.01 -7g/L) (Gugliucci et al., 2009, Tarwadi and Agte, 2011), and/or 
high (supra-physiological) glucose concentrations (30mM - 0.5M) (Harris et al., 2011, Verzelloni et 
al., 2011a). Albumin glycation had previously been achieved in the presence of 15mM glucose 
alone at 5 weeks or 30mM glucose alone at 4 weeks (Barnaby et al., 2011). With physiological 
glucose concentrations, results have varied according to sample treatment and methods used to 
measure glycation. Bourdon et al. (1999) reported that incubation of albumin for 4 weeks with 
5mM glucose did not promote glycation, while later reporting contradictory findings (with, 
however, glycation only implied from qualitative results (Chesne et al., 2006)). 
Similarly, while methylglyoxal is a potent glycative molecule in supra-physiological conditions 
(Tarwadi and Agte, 2011b), it did not show significant glycative activity in physiological 
concentrations. Our data suggest it might act synergistically with glucose to promote glycation at 
lower glucose concentrations (10mM), but we demonstrated that both glucose and methylglyoxal 
at physiological concentrations will glycate albumin if it is oxidised. 
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In both the BSA and mercaptalbumin models, glycation of the protein was significantly higher 
than the glucose-free control when exposed to a physiological concentration of hydrogen 
peroxide for two weeks. Although the effect of pre-oxidation and continuous oxidation were very 
similar with a favour towards continuous oxidation, in so low hydrogen peroxide concentrations 
the continuous oxidation model is more likely to be of physiological relevance. Continuous 
exposure to hydrogen peroxide led to higher fructosamine concentrations at all glucose levels and 
oxidation was also shown to act synergistically with glucose, as the interaction between the two 
was found to be significant in our experiments.  
Hydrogen peroxide positively interacts with glucose in promoting glycation reactions. One has to 
keep in mind that the hydrogen peroxide exposure was weak in term of concentration in order to 
resemble physiological condition and hence it is likely to induce important but subtle effects.  
When human plasma was exposed to hydrogen peroxide, glycation was significantly higher with 
5mM glucose after two weeks, compared to the non-oxidized control. The opposite was found 
when oxidised plasma was incubated with 10mM glucose for 4 weeks, but the lower fructosamine 
concentration of the oxidised plasma in that case could be attributed both to increased protein 
instability and/or glycation being driven to the production of AGEs (not detectable by the NBT 
method used) rather than early-glycation products as fructosamine. 
Constant oxidative stress is clearly damaging and relevant to diabetic and obese chronic pro-
oxidant states, however a dynamic balance between pro- and anti-oxidant factors is usually 
present in plasma and other body fluids. The level of oxidative stress fluctuates during the day 
(e.g. higher post-prandially) and a variety of events can trigger short-term production of Reactive 
Oxygen Species. Our results suggest that episodes of relatively unopposed oxidation, e.g. from 
infection or inflammation, or smoking, could damage proteins to promote subsequent glycation, 
as we have demonstrated with the increased susceptibility of pre-oxidized albumin to glycation at 
a physiological glucose concentration. This mechanism could apply in vivo. 
Recognizing that, in physiological systems, protein glycation depends on oxidative damage as well 
as glucose concentration has implications for scientific understanding and potentially for clinical 
practice. The term ‘glycoxidation’, currently restricted to the latter stages of Maillard reactions, 
seems more appropriate than simply ‘glycation’ to describe the overall in vivo protein glycation 
process, and similar protocols to ours would be appropriate to study the phenomenon in vitro. 
The quest for normoglycaemia in diabetes management is important to delay vascular and other 
complications, but potentially hazardous interventions are entirely directed at glucose-lowering: 
using insulin or anti-diabetic drugs intensively to reduce glycation has been associated with 
increased risk of hypoglycemia, and of mortality (Terry et al., 2012). If oxidative stress is also 
involved as a trigger for protein glycation and tissue damage, then approaches aimed solely at 
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glucose handling are insufficient, and reducing oxidative stress might be less hazardous. This is 
not arguing for indiscriminate or high-dose antioxidant treatments. Several trials have suggested 
worse outcomes from antioxidant vitamin supplementation (Virtamo et al., 2003), leading to 
understandable prejudice against their effectiveness and safety, but a recent meta-analysis of 66 
randomised controlled trials indicates benefit from vitamin E supplementation for primary 
prevention (where there is some baseline insufficiency) (Biesalski et al., 2010), and vitamin E also 
contributes to secondary prevention (Stephens et al., 1996), renewing interest in antioxidant 
interventions. Our results support findings from the cross-sectional study of Bates et al. (2004), 
which led to the hypothesis that dietary antioxidants may reduce tissue glycation. Also evidence 
from in-vitro studies suggests that antioxidants are having a protective role in protein glycation 
(Harris et al., 2011, Vinson and Howard, 1996). Exposure to oxygen radicals such as TBH and H2O2 
significantly increased haemoglobin glycation in-vitro and pre-treatment with vitamin E blocked 
that effect (Jain and Palmer, 1997). Replenishment of the antioxidant defences of GSH-deficient 
red blood cells, on the other hand, protected them against increased haemoglobin glycation (Jain, 
1998), both supporting the hypothesis of oxidative stress being involved in protein glycation. 
The present studies suggest some important avenues for future research, as well as changes to 
commonly-used experimental models. It is important to question accepted patho-physiological 
mechanisms if they cannot be demonstrated in vivo at physiological concentrations. Our evidence 
that mild oxidation plays an early role in AGE production is novel and explains a gap in the 
literature. Prior reduction of BSA might indeed increase the oxidation potential of the protein and 
hence strengthen the effect of oxidation on glycation, as shown by the two-way ANOVA analysis. 
While being designed to replicate physiological conditions and employing a large number of 
replicates (6 instead of the usual 3) to reduce random errors under physiological conditions, the 
current study does have limitations. Hydrogen peroxide’s stability in the incubation media was 
not tested, which allows for the possibility of the molecule having a shorter half-life than the 
experimental duration. Nonetheless the effects of exposure to hydrogen peroxide, no matter how 
long, are carried over the 4-week experimental period. In circulation hydrogen peroxide would be 
continuously produced and removed leading to fluctuations and a continuous exposure of the 
protein to oxidative damage, likely to amplify the effects seen in this experimental study. 
Albumin, although the major circulating protein, may not be representative of other glycation-
prone proteins, and the results cannot provide an exact mechanism linking oxidative damage to 
glycation. Using human plasma led to slightly different results than BSA and mercaptalbumin. No 
effect on glycation was seen from oxidation at glucose levels above 10mM after two weeks of 
incubation; that could be attributed to the fact that plasma from healthy volunteers involves 
different proteins with different degrees of pre-oxidation and glycation and also a much more 
competent antioxidant system which would be expected to rapidly scavenge ROS. Glycated 
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proteins already present in plasma could also affect the speed and general kinetics of the 
reaction. Finally, multiple testing could have resulted in chance findings of ‘significance’ but since 
for every condition there were no more than 7 tests ran, p-values lower than 0.007 should be 
considered as true findings. Possible mechanisms involve protein damage by hydrogen peroxide 
and/or increased glucose autoxidation in the presence of hydrogen peroxide, both likely to 
increase the affinity of the molecules for the non-enzymatic sugar linkage. There may be selective 
oxidation of amino acids: i.e., tryptophan, a main site for protein glycation, is an oxidation site for 
human albumin (Rondeau and Bourdon, 2011, Guerin-Dubourg et al., 2012), suggesting that 
oxidized amino acids maybe more susceptible to further glycative damage.  
4.5 Conclusion 
 
Oxidative damage, although known to be important for the late stages of protein glycation, has 
not previously been linked with the early stage of the Maillard reaction. Our data suggest that 
oxidative damage, induced by a very low (physiological) concentration of hydrogen peroxide, 
plays a critical early role in fructosamine production. Importantly, the effect is seen at 
physiological glucose concentrations, potentially opening an avenue for new preventive 
treatments. Our experiments highlight the importance of oxidative stress on protein glycation, as 
a promoter and even a necessary condition to achieve glycation in physiological glucose 
concentrations.  
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Chapter 5: Inhibition of protein glycation by phenolic acids: physiological 
relevance and implication of protein-phenolic interactions 
 
 
This chapter is presented exactly as published in Food & Function 
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Abstract 
 
Background: While antiglycative capacity has been attributed to (poly)phenols, the exact 
mechanism of action remains unclear. Studies so far are often relying on supra-physiological 
concentrations and use of non-bioavailable compounds.  
Methods: To inform the design of a physiologically relevant in-vitro study, we carried out a 
systematic literature review of dietary interventions reporting plasma concentrations polyphenol 
metabolites. Bovine Serum Albumin (BSA) was pre-treated prior to in vitro glycation: either no 
treatment (native), pre-oxidised (incubated with 10nM H2O2, for 8 hours) or incubated with a 
mixture of phenolic acids at physiologically relevant concentrations, for 8 hours). In-vitro glycation 
was carried out in presence of i) glucose only (0, 5 or 10mM), ii) glucose (0, 5 or 10mM) plus H2O2 
(10nM), or iii) glucose (0, 5 or 10mM) plus phenolic acids (10-160nM). Fructosamine was 
measured using the nitroblue tetrazolium method.  
Results: Following (high) dietary polyphenol intake, 3-hydroxyphenylacetic acid is the most 
abundant phenolic acid in peripheral blood (up to 338μM) with concentrations for other phenolic 
acids ranging from 13nM-200μM. Presence of six phenolic acids with BSA during in-vitro glycation 
did not lower fructosamine formation. However, when BSA was pre-incubated with phenolic 
acids, significantly lower concentration of fructosamine was detected under glycoxidative 
conditions (glucose 5 or 10mM plus H2O2 10nM) (p<0.001 vs. native BSA).  
Conclusion: Protein pre-treatment, either with oxidants or phenolic acids, is an important 
regulator of subsequent glycation in a physiologically relevant system. High quality in-vitro studies 
under conditions closer to physiology are feasible and should be employed more frequently.  
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5.1 Introduction 
 
Protein glycation has been implicated in the development of several chronic diseases, particularly 
diabetic micro and macrovascular complications (Sabanayagam et al., 2009, Yan et al., 2003). The 
process of glycation, in diabetes, is mainly driven by the elevated blood glucose concentration 
through non-enzymatic condensation of a sugar molecule on a protein, lipid or DNA molecule 
(Baynes, 2002, Thornalley, 2003a). Measurement of glycated haemoglobin is the standard 
method for monitoring diabetes control (American Diabetes, 2011) and elevated levels are clearly 
related to tissue damage. Glycated albumin levels in plasma can vary widely, between 1% to up to 
16% in normoglyceamic individuals (Shaklai et al., 1984, Selvin et al., 2011) and the reasons for 
this wide range are not fully understood. In individuals free of diabetes for every 1% increase in 
HbA1c levels there is an associated 30-50% in the risk of cardiovascular disease (Selvin et al., 
2010, Barr et al., 2009, Selvin et al., 2005). Although in-vitro studies have been employed to study 
glycation mechanisms, few have used physiologically relevant glucose concentrations. In vitro 
protein glycation does not easily occur with physiological concentrations of glucose, implying that 
another factor was necessary. We recently demonstrated that albumin glycation at physiological 
glucose concentrations (5 and 10mM) was driven by oxidative stress, and that oxidised albumin is 
more susceptible to glycation than the native form of the protein (Vlassopoulos et al., 2013b). We 
have suggested that the reaction might be considered protein glycoxidation, rather than simply 
glycation. The study of early glycation, fructosamine, in in-vitro model is of high importance both 
for translational value (HbA1c  is commonly used in clinical practice) and due to the fact that it is 
the first stable glycation product and so its production rate is influential on AGEs 
production(Venkatraman et al. 2001). 
Antioxidants, and (poly)phenols and their metabolites in particular, have been studied for their in-
vitro antiglycative properties (Xie and Chen, 2013, Kim and Kim, 2003, Hou et al., 2013, Wu et al., 
2009, Sompong et al., 2013). (Poly)phenols may offer protection by scavenging ROS produced 
during the glycation reaction, thereby slowing glycation and inhibiting the formation of AGEs (Wu 
and Yen, 2005, Xie and Chen, 2013). Another possible mechanism involves “physical” protection 
against glycation. This mechanism suggests that (poly)phenols have the capacity to bind on the 
protein molecule, most likely with a non-covalent bond, and in this way make glycation targets on 
the protein molecule (usually amino acids like lysine) inaccessible to take part in the glycation 
reaction (Xiao and Kai, 2012, Verzelloni et al., 2011b). 
While these studies may hold value in food science (for example, reduction of AGEs formation 
during cooking in the presence of polyphenols (Zhang et al., 2014)), their physiological relevance 
to human health is sometimes questionable. (Poly)phenols are subject to extensive metabolism in 
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the lumen (hydrolysis by the enterocytes’ glucosidase system) and after absorption 
(glucuronidation/sulfation in the liver) (Scalbert et al., 2002, Manach et al., 2005). Most high 
molecular weight dietary polyphenols have low bioavailability and even though aglycones may 
reach systemic circulation in small amounts, glycosides do not (Nagasawa et al., 2003, Williamson 
and Manach, 2005, Manach et al., 2005, Crozier et al., 2009). Those which do not get absorbed 
instead accumulate in the colon lumen, where they are subject to bacterial degradation, leading 
to the formation of the phenolic acids. Phenolic acids have a relatively higher bioavailability 
(Scalbert et al., 2002, Scalbert and Williamson, 2000). In plasma, an increase in phenolic acid 
levels is seen 8-10 hours after ingestion, which represents the ‘colonic tide’ of (poly)phenol 
metabolites (Manach et al., 2004, Scalbert et al., 2002, Vitaglione et al., 2007). Studies using 
foodstuff extracts and mixtures containing aglycones and glycosides thus do not replicate 
physiology (Williamson and Manach, 2005, Harris et al., 2014) when (poly)phenols in the 
circulation are mostly phase II metabolites and rarely exceed 1μM concentration (and if so, 
transiently) (Manach et al., 2004, Scalbert and Williamson, 2000). Finally, while single compound 
studies are informative and allow for mechanisms of action to be dissected, polyphenols and their 
metabolites are not found or consumed in isolation (Crozier et al., 2009, Manach et al., 2005); 
they are, also, all consumed within complex food matrices with other nutrients that may modify 
absorption and metabolism (Serafini et al., 2009, Mullen et al., 2008). 
The present paper systematically reviews the literature reporting plasma levels of phenolic acids 
as key polyphenol metabolites, following ingestion of polyphenol rich food products (not under 
“acute” trial settings). The outcomes of this review are then used to test whether phenolic acids 
can inhibit the early stages of glycation under physiologically-relevant experimental conditions, 
using the bench-top design we previously described (Vlassopoulos et al., 2013b).  
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5.2 Material and methods 
 
Systematic literature review 
This review was conducted following the Preferred Reporting Items for Systematic Review and 
Meta-Analysis (PRISMA) guidelines. A literature research was carried out in PubMed® and ISI Web 
of Knowledge® for trials reporting plasma phenolic acid levels after a high polyphenol food/diet 
intake. The search was inclusive of all years up to February 2014. The following search terms were 
used to identify relevant studies: (phenol*, polyphenol*, phenolic acid*, fruit, vegetable, spice, 
cocoa, herb, juice, oil, wine, extract, tea or coffee), paired (bolean AND) with (feeding, trial, 
intervention, consumption OR supplementation). The wild-card term “*” was used to improve the 
sensitivity of the search by increasing the number of matches. The review was limited to studies 
utilising chromatographic techniques to identify (poly)phenolic compounds in serum or plasma. 
Studies on animals were excluded, as well as studies reporting cross-sectional data. Only 
controlled long-term feeding trials were reviewed. Studies were included in the review if absolute 
concentrations of phenolic acids were reported.  
Experimental procedures 
Chemicals 
Bovine serum albumin (BSA), sodium azide, nitroblue tetrazolium, d-glucose, PBS, 1-deoxy-1-
morpholinofructose (DMF), hydrogen peroxide, caffeic acid, p-coumaric acid, vanillic acid, 3-
hydroxyphenylacetic acid, 3,4-dihydroxyphenylacetic acid and protocatechuic acid were 
purchased from Sigma-Aldrich (Dorset, UK). SnakeSkin Dialysis Tubing, 3.5K MWCO was 
purchased from Thermo Fisher Scientific (Nottinghamshire, UK). 
Albumin pre-treatment 
BSA (40g/L) was studied in three different forms: native BSA (BSA), pre-oxidised BSA (ox-BSA), and 
phenolic acid-preincubated BSA (PP-BSA). Ox-BSA was incubated with 10nM hydrogen peroxide 
(H2O2) for 8hrs pre-glucose incubation and PP-BSA was incubated with a phenolic acid mixture for 
8hrs pre-glucose incubation. The phenolic acids used were selected based on the results of the 
literature review aiming to be representative of plasma concentrations of free phenolic acids, 
with a higher degree of physiological relevance. The acids and concentrations used were: caffeic 
acid 10nM, p-coumaric acid 8nM, vanillic acid 21nM, protocatechuic acid 40nM, 3-hydroxyphenyl 
acetic acid 160nM and 3,4-dihydroxyphenyl acetic acid 40nM. Following pre-treatment, ox-BSA 
and PP-BSA were dialysed against PBS for 24 hrs to remove any free H2O2 and/or phenolic acids 
(Figure 5.1).  
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Protein glycation 
All incubations took place in PBS (0.137M Sodium chloride, 0.0027M potassium chloride, and 
0.010M phosphates) with sodium azide (0.2g/L), in a final volume of 1.5ml, for 14 days. BSA, ox-
BSA and PP-BSA (40g/L) were incubated with glucose (0, 5, 10mM) with or without 10nM H2O2 or 
a physiologically relevant phenolic acid mix (as described above). All incubations were replicated 6 
times. 
Figure 5.7 Experimental design for the study of the antiglycative potential of physiologically 
relevant phenolic acids. 
 
BSA: bovine serum albumin, ox-BSA: bovine serum albumin incubated with 10 nM H2O2, PP-BSA: bovine serum albumin 
incubated with phenolic acids mixture; PP: caffeic acid 10nM, p-coumaric acid 8nM, vanillic acid 21nM, protocatechuic 
acid 40nM, 3-hydroxyphenyl acetic acid 160nM and 3,4-dihydroxyphenyl acetic acid 40nM 
 
Fructosamine measurement 
Fructosamine levels were measured at week 2 with the NBT assay, performed in microplates as 
described previously 34. Briefly, samples (30µL) were added to of sodium carbonate buffer (100µL, 
100mM, and pH 10.8) with Nitroblue Tetrazolium (0.25mM). Microplates were incubated for 15 
min at 37oC and measured spectrophometrically against controls at 550nm after 10 and 15 min of 
incubation. The difference between the two readings was used to calculate concentrations. The 
fructosamine analog 1-deoxy-1-morpholinofructose (DMF) was used as a standard. All 
fructosamine measurements were performed in duplicate. Standards and NBT reagent were 
made fresh every week and stored at -20oC and 4oC respectively. All samples were stored at -20oC 
prior to assay. 
Measurement of AGE fluorescence 
AGE fluorescence was measured in diluted samples (1:5) at an excitation wavelength 370nm and 
an emission wavelength 440nm. AGE fluorescence was measured as arbitrary units and in 
duplicate using a SpectraMax M2 plate reader.  
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Protein structure analysis 
Protein tryptophan fluorescence intensity was recorded with a Shimadzu RF-5301 PC 
Spectrofluorophotometer, using 5nm excitation and 10nm emission slit widths. Proteins at a 
concentration of 0.2g/L in PBS were used after dialysis and prior to glycation. The UV spectra of 
the protein, measured using a Perkin Elmer Lambda 25 UV/VIS Spectrometer, indicated a 
maximum absorbance at 277nm for all proteins, which was thereafter used as the excitation 
wavelength for each protein. Changes in maximum emission were compared between proteins in 
a semi-quantitative manner and changes in the emission spectra due to pre-treatment were also 
compared qualitatively. Near UV Circular Dichroism spectra of 1.5g/L protein  and far UV Circular 
Dichroism spectra of 0.2g/L protein were recorded in a 0.5cm and 0.02 cm pathlength quartz 
cuvette, respectively, using a Jasco J-810 spectropolarimeter 35. The UniProt database was used to 
identify structures, sequences and drug binding location on the BSA molecule 
(http://www.uniprot.org/uniprot/P02769). 
 
Statistical analysis 
All combinations of oxidative damage and glycation drivers were tested as six true replicates, 
according to the experiment. Assays were conducted in duplicate. Differences in fructosamine 
production between hydrogen peroxide levels were tested using a one-way ANOVA and Tukey’s 
post-hoc tests, at each glucose level separately. The interaction between glucose levels and 
hydrogen peroxide levels, as well as the overall dose response effect, were studied using two-way 
ANOVA. Statistical analysis was performed using SPSS statistical software package version 19.0.0 
(IBM, SPSS Software, Armonk, NY, USA). 
 
5.3 Results 
 
Using the primary search terms, 436 papers were identified, with 40 excluded as duplicate 
entries. Titles from the remaining 396 articles were screened and 43 were excluded as not 
relevant to the topic of the review (mostly studies focusing on phenylalanine and other phenol 
ring-containing substances). During abstracts screening, 246 reports were removed from the 
analysis with the majority being in-vitro or animal studies’ reports, alongside with reports from 
cross-sectional studies. Review papers, conference proceedings, and reports written in languages 
other than English were also excluded. A total of 107 full papers were screened, leading to the 
exclusion of 28 additional reports. These reports either performed a qualitative analysis of 
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metabolites in plasma or did not provide data on the concentrations of the metabolites measured 
in plasma. The reference list of each publication was screened in order to identify other 
publications from the same study, in case the data on the metabolites concentrations were 
published elsewhere. Finally, two reports (Nieman et al., 2013, Stracke et al., 2010) were excluded 
as phenolic acids were reported as relative concentrations rather than absolute (Figure 5.1). 
A total of 79 published studies satisfied the inclusion criteria and reported plasma levels of 
polyphenol and polyphenol metabolites following a dietary intervention. From those, 9 reports 
focused on longer-term feeding studies while the rest covered acute changes in polyphenol levels 
following a single consumption of a test food (Figure 5.1). Acute trials mainly focused on 
polyphenol bioavailability in the 5-24 hour window following ingestion, while longer-term feeding 
studies investigated changes in polyphenol metabolites levels after 5 days to 8 weeks 
supplementations (Grimm et al., 2006, Koli et al., 2010) (Table 5.1).  
Most studies (Table 5.1) focused on a single food product, from a diverse range including tea 
(black and green) (Henning et al., 2013), coffee (Kempf et al., 2010), olive oil (Oliveras-Lopez et al., 
2012), cocoa (Urpi-Sarda et al., 2009) and berries, either as a juice (Karlsen et al., 2010) or a mixed 
berry diet (Koli et al., 2010). Two studies used extracts instead of a food product (Boyle et al., 
2000, Grimm et al., 2006). Regarding sample treatment prior to phenolic acids measurements, 
only two of the studies measured free phenolic acids (i.e. without employing a prior hydrolysis 
step to derive aglycones from glucuronide and sulfate esters) (Heinrich et al., 2013, Oliveras-
Lopez et al., 2012). One of these two studies did not detect sufficient phenolic acids in plasma for 
quantification, despite using a HPLC/MS (LCQ Fleet quadripole ion-trap MS) detection system 
(Heinrich et al., 2013), and the other focused on hydroxytyrosol as a marker of compliance (olive 
oil intake) (Oliveras-Lopez et al., 2012).  
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Figure 5.8 Flow diagram of the study selection process 
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Table 5.1 Evidence table of long-term supplementation trials measuring phenolic acids in plasma. 
Authors Food Study design Duration Metabolites Hydrolysis Comments 
Heinrich et 
al. (2013) 
Blue honeysuckle berry 
(165g/d) 
Uncontrolled 
(n=10) 
1 wk Below limit No  Low polyphenol 
diet throughout 
Henning et 
al. (2013) 
Black tea 
(6 cups/d) 
Non-blinded RCT, 
parallel 
(n=46) 
3-6 wks 3-hydroxyphenylacetic acid: 261μM 
4- hydroxyphenylacetic acid: 668μM 
3,4-dihydroxyphenylacetic acid: 117μM 
Hippuric acid: 2305μM 
Homovanillic acid: 176μM 
Yes  No dietary info 
Henning et 
al. (2013) 
Green tea 
(6 cups/d) 
Non-blinded RCT, 
parallel 
(n=47) 
3-6 wks 3- hydroxyphenylacetic acid: 338μM 
4- hydroxyphenylacetic acid: 798μM 
3,4-di hydroxyphenylacetic acid: 135μM 
Hippuric acid: 1950μM 
Homovanillic acid: 199μM 
Yes  No dietary info 
Oliveras-
Lopez et al. 
(2012) 
Extra virgin olive oil as a 
fat replacement plus 
50mL raw 
Non-blinded cross 
over 
(n=20) 
 
4 wks Hydroxytyrosol: 487nM No Habitual diet as 
control 
Karlsen et 
al. (2010)  
 Bilberry juice (1L diluted 
in water) 
Non-blinded 
parallel RCT 
(n=63) 
4 wks Quercetin: 43.6nM 
m-coumaric: 12.8nM 
p-coumaric: 27.4nM 
protocatechuic: 99.4nM 
Yes 3wks low 
antioxidant/berry 
diet 
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Kempf et al. 
(2010) 
Coffee 
4 or 8 cups/d (150mL) 
Single blind cross 
over 
(n=47) 
30 d 4cups 
Caffeic acid: 38.3μM 
Dihydrocaffeic acid: 47.9nM 
m-Coumaric acid: 26.4nM 
Dihydro-3-coumaric: 716nM 
Ferulic: 55.1nM 
Isoferulic: 23.5nM 
Dihydroferulic: 93.9nM 
Dihydroisoferulic: 56.5nM 
Dimethoxycinnamic: 77 nM 
3-(3,4-Dimethoxyphenyl)-propionic: 203nM 
8cups 
Caffeic acid: 62.2μM 
Dihydrocaffeic acid: 75.2nM 
m-Coumaric acid: 58.8nM 
Dihydro-3-coumaric: 1583nM 
Ferulic: 67.1nM 
Isoferulic: 49.8nM 
Dihydroferulic: 194.7nM 
Dihydroisoferulic: 90.6nM 
Dimethoxycinnamic: 177.7nM 
3-(3,4-Dimethoxyphenyl)-propionic: 398nM 
Yes No wash out, 
All subjects 
consumed 0 cups 
(1
st
 month), 4 cups 
(2
nd
 month), 8 cups 
(3
rd
 month) 
Koli et al. 
(2010) 
100g bilberries and 
nectar containing 50g 
lingonberries/ 
100g black-currant-
strawberry puree (80% 
black currant) 
 
Non blinded RCT, 
parallel 
(n=72) 
8 wks Quercetin: 40nM 
Caffeic acid: 100nM 
Protocatechuic acid: 120nM 
p-coumaric: 15nM  
Vanillic: 70nM 
3-(3-hydroxyphenyl)-propionic: 800nM 
3-Hydroxyphenylacetic: 275nM 
Homovanillic: 90nM 
3,4-dihydroxyphenylacetic acid: 140nM 
Yes The two 
supplements were 
consumed on an 
alternate day basis 
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Urpi-Sarda 
et al. (2009) 
Cocoa powder 40g/d 
with 500mL skimmed 
milk 
Non-blinded RCT 
Cross-over 
(n=42) 
4 wks 3,4-Dihydroxyphenylpropionic acid: 0.2μM 
3-Hydroxyphenylpropionic acid: 0.23 μM 
3,4-Dihydroxyphenylacetic acid: 0.11μM 
3-hydroxyphenylacetic acid: 0.12 μM 
Phenylacetic acid: 20.32 μM 
p-coumaric acid: 0.03 μM 
caffeic acid: 0.08μM 
Ferulic acid: 0.21 μM 
Protocatechuic acid: 10.52μM 
Vanillic acid: 2.71μM 
4-hydroxybenzoic acid: 9.73μM 
4-Hydroxyhippuric acid: 0.11μM 
3-Hydroxyhippuric acid: 0.48μM 
Yes  No wash-out 
Grimm et 
al. (2006) 
Pine bark extract 
(200mg/d) 
Non-controlled 
(n=5) 
5 d Catechin: 170nM 
Caffeic acid: 13.4nM 
Ferulic acid: 103nM 
Yes Measured 4h after 
the last dose 
Boyle et al. 
(2000) 
Rutin supplement 
(500mg/d) 
Double blind RCT 
parallel 
(n=16) 
6 wks Quercetin: 166nM 
Kaempferol: 5.24nM 
Isorhamnetin: 9.49nM 
Yes  Record flavonoid 
rich food 
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The major phenolic acids identified in the studies were: 3-hydroxyphenylacetic acid (120nM-
338μM), 3,4-dihydroxyphenylacetic acid (110nM-135μM), homovanillic acid (90nM-199μM), m-
coumaric acid (12.8-58.8nM), p-coumaric acid (15-30nM), caffeic acid (13.4nM-62.2μM), 
protocatechuic acid (99.4nM-10.52μM), ferulic acid (55.1-210nM) and vanillic acid (70nM-
2.71μM). The compounds measured and identified all represent concentrations of aglycones after 
hydrolysis and not concentrations of free compounds.  
A combination of 3-hydroxyphenylacetic acid (160nM), 3,4-dihydroxyphenylacetic acid (40nM), 
vanillic acid (20nM), p-coumaric acid (10nM), caffeic acid (10nM) and protocatechuic acid (40nM) 
was selected for the in-vitro glycation of BSA. These phenolic acids represent only a selection of all 
the acids identified in plasma after feeding interventions, but they are the ones for which data on 
absorption and metabolism are more extensive. The glucuronidation of polyphenols and phenolic 
acids may have a negative effect on the antiglycative capacity of the molecules (Xie and Chen, 
2013). These concentrations take into consideration the fact that, phenolic acid levels in all the 
studies in the literature review were measured after hydrolysis, and so a factor was applied to 
estimate what percentage of the reported values would be non-conjugated phenolic acids. 
This percentage was calculated based on findings from previous studies and more specifically, 
data from acute feeding interventions identified during the process of the present literature 
review. From acute feeding interventions measuring both the conjugated and non-conjugated 
form of phenolic acids, only 20-26% of the total caffeic found in plasma after coffee consumption 
is in free form (Nardini et al., 2002, Nardini et al., 2009). Similarly only 25% of the total vanillic 
acid, 40-50% of the total p-coumaric acid and 15-25% of the total ferulic acid are found as free 
phenolic acids(Nardini et al., 2009, Nardini et al., 2006). In the contrary 4-hydroxyphenylacetic 
acid is less extensively metabolised (80% present as free form) (Nardini et al., 2006).  
The published reports were of variable methodological quality. Although the detection systems 
used for phenolic acids measurement were based on mass spectrometry (MS, MS/MS, quadripole 
MS), some studies used less sensitive detection systems like ultraviolet, fluorimetric and 
electrochemical detectors(Kempf et al., 2010, Grimm et al., 2006, Boyle et al., 2000). One of the 
major methodological limitations was that 7 out of 9 studies employed some form of hydrolysis 
prior to phenolic acids determination. The measurement of aglycones following hydrolysis leads 
to a significant increase in the concentrations reported. The only study measuring phenolic acid 
concentrations without hydrolysis did not detect concentrations high enough for quantification 
even with a sensitive quadripole MS system (Heinrich et al., 2013).  
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The variable duration and dose of the compounds tested also make comparisons between the 
studies available difficult. The compounds tested were delivered in various matrices, some as 
supplements (Grimm et al., 2006, Boyle et al., 2000), others as drinks (Henning et al., 2013, Kempf 
et al., 2010, Karlsen et al., 2010, Urpi-Sarda et al., 2009), or whole foods (Heinrich et al., 2013) and 
even as dietary pattern (combination of various food items) (Koli et al., 2010). Such matrices will 
have a significant effect on bioavailabilty and potential long-term changes in absorption through 
changes in gut microbiota cannot be excluded/ controlled for. The lack of successful control 
conditions is another point to be mentioned, as some studies either had no control groups or 
used a cross-over design without allowing for sufficient wash-out periods (Kempf et al., 2010, 
Urpi-Sarda et al., 2009, Grimm et al., 2006). When bioavailability of (poly)phenolic compounds is 
the main focus of the study the lack of a control group may be of lesser importance but not 
allowing for sufficient wash-out periods can introduce a carry-over effect between the 
interventions making difficult to compare between doses/groups tested.  
Finally, as (poly)phenolic compounds are nearly ubiquitous, controlling for the effect of the 
background diet is important when studying bioavailability. In the studies reviewed, background 
diet control was variable ranging from the subjects being requested to abstain from polyphenol 
sources throughout the experimental period (Heinrich et al., 2013, Karlsen et al., 2010) to being 
asked to consume their habitual diet (Oliveras-Lopez et al., 2012). One study requested from the 
participants to avoid food products similar to those provided during the study period (Koli et al., 
2010) and another gave no advice but requested from the participants to keep records of the 
flavonoid rich foods consumed during the study (Boyle et al., 2000). In order to control for the 
effect of background diet, Grimm et al requested from their volunteers to follow a flavonoid free 
diet 24 hours prior to blood sampling (Grimm et al., 2006). Unfortunately three of the studies did 
not provide with any information on whether and how they attempted to control for the effect of 
the background diet (Henning et al., 2013, Urpi-Sarda et al., 2009, Kempf et al., 2010). In this 
instance lack of adequate control of the background diet was not considered as a bias given the 
purpose of the review. 
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In-vitro assessment of antiglycative capacity of phenolic acids 
The antiglycative capacity of phenolic acids was investigated in a two dimensional design. 
Phenolic acids were tested for their capacity to reduce fructosamine production when i) added in 
the reaction solution alongside glucose and H2O2 and ii) when pre-incubated with albumin (BSA) 
prior to the glycation incubation. 
 
Table 5.2 Fructosamine concentration (mM DMF equivalent) after two week incubation with 
hydrogen peroxide or phenolic acids. 
Glucose level (mM) Pre-treatment 
Native 
Mean (SD) 
Pre-oxidised 
Mean (SD) 
Phenolic-rich 
Mean (SD) 
0 0.22 (0.01) 0.23 (0.02) 0.23 (0.02) 
5 0.29 (0.01) 0.32 (0.01) 0.32 (0.02) 
10 0.36 (0.02) 0.41 (0.03)* 0.40 (0.03)* 
0+ H2O2 (10nM) 0.19 (0.04) 0.20 (0.02) 0.23 (0.01) 
5+ H2O2 (10nM) 0.32 (0.03) 0.31 (0.03) 0.28 (0.02)
* 
10+ H2O2 (10nM) 0.40 (0.03) 0.40 (0.04) 0.31 (0.03)
* 
0+Phenolic acids 0.22 (0.01) 0.22 (0.02) 0.22 (0.01) 
5+Phenolic acids 0.31 (0.02) 0.30 (0.02) 0.29 (0.02) 
10+Phenolic acids 0.38 (0.04) 0.38 (0.03) 0.36 (0.03) 
 *p<0.05 vs native  
 
Effect of addition of hydrogen peroxide and phenolic acids in the reaction solution 
Addition of 10nM H2O2 in the reaction solution throughout the incubation has a significant but 
opposing impact on fructosamine production of both native and phenolic pre-incubated albumin. 
Incubation of native albumin in the presence of H2O2 led to significantly higher levels of 
fructosamine at 10mM glucose compared to the glucose-only control (14% increase), whereas a 
reduction in fructosamine production was seen in the phenolic pre-incubated albumin (Table 5.2). 
A two-way ANOVA analysis showed that H2O2 affects fructosamine production of native and 
phenolic pre-incubated albumin independently of glucose (p<0.001 for both albumin forms; H2O2 
plus glucose vs. glucose only control). 
On the contrary addition of phenolic acids in the reaction solution throughout the incubation 
period had no significant effect on fructosamine production compared to glucose alone in any of 
the three albumin forms used (Table 5.2).  
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Effect of protein pre-treatment 
Pre-oxidised and phenolic-preincubated albumin was more prone to glycation than the native 
molecule in the presence of 10mM glucose (p=0.001 and p=0.02, respectively) (Table 5.2). This 
effect was independent of glucose concentration, for both the pre-oxidised and the phenolic-
preincubated albumin (p=0.001, two-way ANOVA). In the presence of H2O2, native and pre-
oxidised albumin showed similar glycation levels (p=0.52; two-way ANOVA).  
Preincubation with phenolic acids, on the other hand, significantly reduced glycation in the 
presence of H2O2 (p=0.001 vs native; two-way ANOVA). This effect was seen at both 5 and 10mM 
glucose (p=0.01 and p<0.001, respectively, vs. native albumin) (Figure 5.3) and the glycation 
reduction was greater with increasing glucose levels (p<0.001 for the interaction pre-
treatment*glucose levels).  
Figure 5.9 Fructosamine concentration (mM DMF equivalent) after two weeks incubation in the 
presence of glucose and H2O2 (10nM) for native, pre-oxidised and phenolic-preincubated BSA (PP-
BSA). 
 
Two-way ANOVA analysis showed a significant effect of phenolic-preincubation inhibiting glycation. 
 *p<0.05 
 
Effect on AGEs production 
After two weeks incubation, AGEs  levels were not higher in any experimental condition 
compared to the 0mM glucose control, but for oxidised BSA exposed to 10mM glucose with 10nM 
H2O2 (p =0.048, 205±15.8 vs.284±76.1 AU ; oxBSA 0mM glucose plus 10nM H2O2 vs. oxBSA 10mM 
glucose plus 10nM H2O2).  
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Effect of protein pre-treatment on protein structure and characteristics 
The circular dichroism (CD) analysis showed no effect of the pre-treatment on the secondary 
protein structure (Figures 5.11 & 5.12). However, exposure to 10nM H2O2 for 8hrs lead to a 25% 
decrease in tryptophan fluorescence. Pre-incubation with phenolic acids for 8hrs resulted to a 
38% reduction, indicative of protein-phenolic acid binding (Figure 5.10). 
Figure 5.10 Emission spectra of 0.2g/L BSA, ox-BSA and PP-BSA at λ=277nm showing the 
quenching effect of protein pre-treatment. Spectra were recorded at pH 7.4. 
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Figure 5.11 Near UV Circular Dichroism spectra of  1.5mg/ml of native BSA (blue), oxidised BSA 
(green) and phenolic-treated BSA (red). Spectra were recorded in a 0.5cm pathlength quartz 
cuvette using a Jasco J-810 spectropolarimeter. 
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Figure 5.12 Far UV Circular Dichroism spectra of  0.2mg/ml of  native BSA (blue), oxidised BSA 
(green) and phenolic-treated BSA (red). Spectra were recorded in a 0.02cm pathlength quartz 
cuvette using a Jasco J-810 spectropolarimeter. 
 
 
 
5.4 Discussion 
 
Our mechanistic study results indicate that pre-treatment of albumin with phenolic acids inhibits 
fructosamine production, especially in the presence of oxidative stress or oxidative damage. This 
antiglycative activity was apparent when comparing the glycation achieved using phenolic-
enriched albumin to those with the native and pre-oxidised BSA. A two-way ANOVA analysis 
showed that, in the presence of H2O2, albumin pre-incubated with phenolic acids had a 
significantly lower fructosamine content compared to the native BSA and the pre-oxidised BSA 
molecule. Phenolic acid preincubation only offered protection against fructosamine production in 
the presence of H2O2 10nM: it provided no protection against glycation by glucose alone. In the 
presence of H2O2, the antiglycative activity of phenolic acid pre-incubation was greater with 
higher glucose levels (10% vs. 22.5% decrease at 5 and 10mM glucose respectively). No effect was 
seen for AGEs production, with the exception of pre-oxidised BSA exposed to a combination of 
10nM H2O2 and 10mM glucose. This maybe due to the duration of the experiment, too short to 
lead to AGEs formation in the given glucose concentrations. 
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 In contrast with most of the literature to date, which suggests that polyphenols and phenolic 
acids added to the incubation solution provide potent antiglycative activity (Lunceford and 
Gugliucci, 2005, Kim and Kim, 2003, Bousova et al., 2005, Wu and Yen, 2005, Nagasawa et al., 
2003), our results show this to be unlikely. In the previous investigations, concentrations used 
were non-physiological, with the lowest glucose concentration being 30mM (>5-6 fold higher than 
normoglycaemia), generating higher glycation than our use of physiologically relevant 5 and 10 
mM concentrations, representative of normoglycaemic and diabetic conditions respectively 
(Vlassopoulos et al., 2013b). Our results suggest that pre-incubation of albumin with phenolic 
acids is the most likely mechanism to offer protection against glycation in a physiologically 
relevant system. Pre-incubation of BSA with either 10nM H2O2 or phenolic acids did not affect the 
secondary structure of the molecule but both led to the reduction of tryptophan fluorescence. 
Tryptophan is an established oxidation target in the BSA molecule (Guedes et al., 2009), and 
oxidation would modify its fluorescence.  The BSA molecule has only two tryptophans: one inside 
a α-helix in domain I and another one inside the hydrophobic binding pocket of domain II 
(Majorek et al., 2012, Tayeh et al., 2009). A proposed mechanism of action from our result 
involves steric hindrance, with phenolic acids binding in a BSA locum which includes a tryptophan 
and consequently preventing the amino acids in this locum are to participate in oxidation and 
subsequent glycation reactions. (since BSA oxidation increases its susceptibility to glycation 
(Vlassopoulos et al., 2013).  
The literature review highlighted that 3-hydroxyphenylacetic acid, 3,4-dihydroxyphenylacetic acid, 
homovanillic acid, m-coumaric acid, p-coumaric acid, caffeic acid, protocatechuic acid, ferulic acid 
and vanillic acid are most commonly detected in plasma after long-term feeding interventions. 
Concentrations of phenolic acids ranged between 13.4nM-338.0μM. The majority of the studies 
measured phenolic acid levels as aglycones after hydrolysis of conjugated phenolic acids. This 
could have led towards a systematic overestimation of phenolic acid levels. Phenolic acids are 
subject to extensive rapid metabolism (Scalbert et al., 2002, Scalbert and Williamson, 2000) and 
since the chemical properties of their conjugates are often different, even opposite, from those of 
the aglycones (Xie and Chen, 2013) it is important for in-vitro studies to take their relative 
abundance into consideration. More in-vivo studies, reporting phenolic acid levels as aglycones 
and conjugates separately, are needed.  
Nonetheless, the results of the literature review showcase that the use of food extracts or food-
derived polyphenol molecules in mechanistic studies focusing on human metabolism is likely to be 
of limited physiological relevance. The parent compounds commonly used for in vitro studies are 
rarely found in circulation, while metabolites like phenolic acids are found in potentially important 
concentrations in the nM to μM range. These metabolites are also not seen in isolation, but in 
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fairly consistent combinations of phenylacetic acids, caffeic acid, vanillic acid and protocatechuic 
acid.  
Despite increasing evidence that a very limited fraction of dietary polyphenols are absorbed, with 
low levels of metabolites circulating for limited amount of time, in-vitro models to-date utilise 
designs that make them irrelevant to physiology outside the gut lumen (Daiponmak et al., 2014, 
Harris et al., 2014, Ito et al., 2014, Dorsey and Greenspan, 2014). Most of these reports used 
supra-physiological glucose and albumin concentrations (Daiponmak et al., 2014, Dorsey and 
Greenspan, 2014, Harris et al., 2014) as well as methanolic extracts of food products (Ho et al., 
2013, Cervato et al., 2000, Hegde et al., 2002). While of importance for the food industry (Zhang 
et al., 2014), they hold limited translational value for human health and may confuse our 
understanding of the role of glycation in health and disease. Here, a combination of caffeic acid, 
p-coumaric acid, vanillic acid, protocatechuic acid, 3-hydroxyphenyl acetic acid, and 3,4-
dihydroxyphenyl acetic acid was chosen to replicate physiological conditions, according to the 
systematic review. 
This study has several limitations. The in-vitro design is in itself limiting and translation to 
physiology must still be cautious. Concentrations were chosen to mimic physiology for glucose, 
H2O2, and phenolic acids but this made it impossible to draw conclusions on the effect of 
individual phenolic acid on glycation. Not all our results fit a simple mechanistic explanation. It is 
intriguing that our results suggest that phenolic-preincubated albumin was more prone to 
glycation than native albumin, in the presence of 10mM glucose. We can offer no plausible 
mechanism to explain this, which may have been a random or chance effect. Nonetheless, this 
study has provided evidence to extend the published literature, showing that research into the 
antiglycative capacity of polyphenols is still possible at physiologically relevant concentrations of 
phenolic acids, and at physiological glucose concentrations, much lower than have been shown to 
generate glycation previously. 
 
5.5 Conclusion 
 
Phenolic acids have the capacity to modulate early stages of protein glycation under 
normoglycaemic and at physiogical concentrations. Incubation with phenolic acids prior to 
glycation significantly inhibits the process in the presence of oxidative stress. Designing in-vitro 
studies with a high degree of physiological relevance is very important in order to reach 
biologically sound conclusions. 
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Chapter 6: Polyphenol intake and maternal glycation during 
pregnancy. Maternal diet and glycoxidation as risk factors for 
complications and neonatal anthropometry in obese pregnancies 
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Abstract 
 
Background: Improved redox status and polyphenols have been shown to reduce glycation in-
vitro. In pregnancy, maternal glycation and sRAGE levels can be used as diagnostic markers for 
complications and may be relevant to fetal programming. The association between diet and 
glycation in pregnancy and their effect on maternal and neonatal health are still to be explored. 
Methods: Samples and data from the UPBEAT study trial (n=117) were analysed. Plasma 
fructosamine, plasma sRAGE, urinary Ferric Reducing Ability of Plasma (FRAP), urinary Total 
Phenol (TP)and urinary Advanced Oxidised Protein Products (AOPPs) were measured at 16-18+6 
and 27-28+6 weeks gestation. Dietary recalls were used to calculate fruit and vegetable and 
polyphenol intake at the same timepoints. Data were analysed to identify associations between 
dietary variables and biochemical markers, as well as their relationships with diagnosis of 
complications. Associations between maternal variables and neonatal anthropometry were also 
investigated. 
Results: Fructosamine and AOPPs fell by 3 and 22%, respectively between 16-18+6 and 27-28+6 
weeks gestation. Women in the lowest quartile of total polyphenol intake had 8% greater 
fructosamine levels compared to those in the top quartile. Total polyphenol intake was negatively 
correlated with sRAGE levels. Diagnosis of severe preeclampsia was associated with elevated 
AOPPs. Maternal polyphenol intake was positively correlated with birth weight, while maternal 
glycoxidation showed the opposite relationship. 
Conclusion: This study is the first to demonstrate an association between polyphenol intake and 
glycation during pregnancy, with an impact on neonatal outcome measures. Maternal 
glycoxidation is a promising marker of pre-eclampsia and neonatal anthropometry.   
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6.1 Introduction 
 
Nearly a third of all women are overweight or obese at the time of conception, with the 
prevalence of BMI≥30 during pregnancy reaching 20% (Kim et al., 2007, Huda et al., 2010, 
Heslehurst et al., 2010, Heslehurst et al., 2007). Increased adiposity during pregnancy is 
associated with higher risk of developing gestational diabetes and preeclampsia (Huda et al., 
2010, Baeten et al., 2001, Heslehurst et al., 2008). Moreover,  nearly 50% of obese pregnant 
women will require assisted delivery, caesarean section or instrumental delivery (Weiss et al., 
2004, Chu et al., 2007, Leung et al., 2008, Janga et al., 2011, Sydsjo et al., 2010), alongside a 
generally  increased length of hospital stay (Mamun et al., 2011, Galtier-Dereure et al., 2000). 
The increased health risk from obesity during pregnancy does not only affect the mother, but it 
has a substantial impact on the fetus, both in utero (stillbirth, congenital anomalies) and during 
the neonatal period (Heerwagen et al., 2010, Tenenbaum-Gavish and Hod, 2013, Leddy et al., 
2008). Children born to obese mothers are more likely to be born large for gestational age 
(Mutsaerts et al., 2014, Oza-Frank and Keim, 2013, Li et al., 2013, Rasmussen et al., 2014, 
Heslehurst et al., 2008, Ray et al., 2001). They are also more likely to be born with insulin 
resistance (Catalano et al., 2009), to present with meconium aspiration (Magann et al., 2013) and 
to require medical attention in the first days of life (Minsart et al., 2013, Aimukhametova et al., 
2012, Ray et al., 2001). 
Inflammation and protein glycation have been proposed as candidate diagnostic markers of 
obesity-related complications during pregnancy (Romero et al., 2007, Haedersdal et al., 2013, 
Nicholson et al., 2013, Sado et al., 2011, Harsem et al., 2008). Glycation is the non-enzymatic 
condensation of a sugar moiety on protein/lipid molecule (Maillard, 1912, Hodge, 1953), and 
although it has been established as a marker of disease pathogenesis in diabetes (Sabanayagam et 
al., 2009, Yan et al., 2003), it only recently attracted attention in the context of normoglycaemia, 
with both epidemiological and mechanistic data to support a positive impact of oxidative stress 
on physiological protein glycation (Selvin et al., 2005, Selvin et al., 2010, Vlassopoulos et al., 
2013a, Vlassopoulos et al., 2013b). A systematic review of the literature showed a positive 
relationship between glycation, measured as HbA1c, and cardiovascular disease risk for non-
diabetic individuals (see Chapter1).  
In pregnancy, conditions like PCOS and diabetes, both associated with higher glycation levels, 
have also been associated with higher risk of complications (Roos et al., 2011). Maternal glycation 
levels correlate strongly with IVF success and neonatal glycation levels at birth and 6 months after 
birth (Jinno et al., 2011, Boutzios et al., 2013). Activation of RAGE has been proposed as a 
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pathway leading to the development of preeclampsia both through increased concentrations of 
RAGE ligands and higher expression of the RAGE gene (Naruse et al., 2012, Cooke et al., 2003). 
High levels of sRAGE are associated with lower likelihood of success following assisted 
reproduction and low quality of embryonic development (Malickova et al., 2010, Bonetti et al., 
2013). During the course of a healthy pregnancy, sRAGe levels are generally decreased compared 
to non-pregnant controls, but sRAGE values are not static as they peak during the 2nd trimester 
compared to 1st and 3rd trimester (Germanova et al., 2010). Changes in sRAGE levels may have a 
predictive values in terms of pregnancy complications as they seem to be consistently increased 
in women who developed preeclampsia (Germanova et al., 2010, Oliver et al., 2011, Kwon et al., 
2011) and decreased in women who experienced preterm labour (Bastek et al., 2012, Germanova 
et al., 2010). 
AGEs are implicated in disease pathogenesis through RAGE mediated action (Yan et al., 2003, 
Jandeleit-Dahm et al., 2008). RAGE is a multi-ligand cell-surface immunoglobulin, with the ability 
to initiate injury-like intracellular events, mainly expression of genes related to inflammation and 
oxidative stress (Schmidt et al., 1995, Hofmann et al., 1999, Kislinger et al., 1999). When activated 
by AGEs, RAGE can lead to increased ROS production and higher inflammation (IL-6, TNF-α) via 
NfκB activation (Coughlan et al., 2009, Vazzana et al., 2009, Schmidt et al., 2000). sRAGE, a 
molecule homologous to RAGE (Vazzana et al., 2009, Chen et al., 2014, Maillard-Lefebvre et al., 
2009, Raucci et al., 2008), has the capacity to bind on AGEs and act as a scavenger not allowing 
circulating AGEs to bind on RAGE (Raucci et al., 2008, Lindsey et al., 2009, Koyama et al., 2007, 
Maillard-Lefebvre et al., 2009). 
Lifestyle and diet can have a significant impact on glycation levels in normoglycaemia. Higher 
intake of vitamins C and E, and higher vegetable intake, have all been associated with lower levels 
of HbA1c in normoglycaemic subjects (Bates et al., 2004, Samaha et al., 2003, Sargeant et al., 
2000, Vlassopoulos et al., 2013a, Boeing et al., 2000). Similarly, polyphenol supplementation may 
lead to a reduction in HbA1c levels but the evidence is still inconclusive. Conversely, higher 
saturated fat intake and smoking have been related with higher HbA1c levels (Harding et al., 
2001, Vlassopoulos et al., 2013a, Clair et al., 2011), while intakes of carbohydrates, protein, fibre 
and lower physical have no effect on glycation levels (Boeing et al., 2000, Sahyoun et al., 2005). 
The UPBEAT trial is a randomised controlled multi-centre nutritional intervention. Participants in 
the intervention arm of UPBEAT were offered an 8-week intervention aiming to reduce the 
dietary glycaemic index (GI) and increase physical activity, to be compared with standard care. 
The reduction in glycaemic index was to be achieved by higher consumption of low glycaemic 
index foods and replacement of sugar-sweetened beverages with low GI alternatives. Alongside, 
GI reduction women in the intervention arm were asked to replace saturated fats with mono and 
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polyunsaturated fats (MUFA, PUFA). As low glycaemic food products like wholemeal cereal, 
vegetables and legumes are also high in antioxidant compounds (Ludwig, 2002, Slavin, 2003, Hu, 
2003, Jenkins et al., 2002) we hypothesised that women in the intervention arm could benefit 
from an improved redox status, compared to the control. With the potential to reduce saturated 
fat intake and increase the intake of fruit, vegetables and antioxidant compounds, the dietary 
intervention offered through the UPBEAT trial could have an impact on glycation markers. 
So far, little is known about how nutrition and other lifestyle factors can impact on glycation and 
sRAGE levels of pregnant women. Even less evidence is available to link dietary habits, 
biochemical parameters and obesity-related complication during pregnancy. This study aimed to 
assess the following research questions: 1) Whether dietary fruit and vegetable, as well as 
antioxidant intake, in obese pregnant women modulate glycation in the mother and 2) whether 
maternal glycation and sRAGE levels are associated with pregnancy complications and newborn 
anthropometry. 
6.2 Methods 
  
Study design and participants 
Samples and data were obtained from the UPBEAT pilot study. UPBEAT is a RCT studying the 
effect of a lifestyle intervention aimed to reduce glycemic index on pregnancy complications and 
neonatal health. The full protocol with details has been published elsewhere (Briley et al., 2014, 
Poston et al., 2013). In summary, women with a BMI ≥30 kg/m2 and a singleton pregnancy were 
recruited during the 15-17+6 weeks gestation and randomised to either the control (n=59) or 
intervention group (n=58). Potentially eligible participants attending clinics for general antenatal 
care were approached by research midwives in four UK study centres in urban settings (the 
Southern General Hospital and Princess Royal Maternity Hospital, Glasgow; the Royal Victoria 
Infirmary, Newcastle; Guys’ and St Thomas’ NHS Foundation Trust and King’s College Hospital 
Foundation Trust, London). The intervention group received an 8-week long training, based on 
control theory with elements of social cognitive theory. Participants attended weekly group 
sessions delivered by trained midwives, from approximately 19 weeks gestation. Using an 
exchange system, women were recommended to increase consumption of foods with low dietary 
GI and to reduce consumption of sugar sweetened beverages (primary goal), and to reduce 
saturated fat intake. The aim was for the dietary changes to be achieved in an isocaloric manner, 
so women were given information on how to exchange high GI food items for low GI equivalents 
without reducing their total energy intake. Women in the intervention group were also prompted 
to monitor their physical activity and set goals in order to increase it. Participants were asked to 
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maintain the changes achieved during the intervention period for the remainder of the 
pregnancy. Women in the control group were recruited at the same time-point and asked to 
revisit at 27-28+6 weeks gestation. This report used samples and data from the UPBEAT study pilot 
(n=108), which were available at the time of the analysis.  The full trial is currently ongoing with 
an anticipated sample size of 1,546 participants by the end of April 2014. 
Maternal pregnancy and newborn outcome data 
Data recorded by the UPBEAT team as part of routine clinical practice included diagnosis of 
preeclampsia, gestational diabetes, gestational age at delivery and mode of delivery among 
others. Newborn variables included birthweight, customised birthweight centile and neonatal 
anthropometry. Newborn data used for the current analysis focused on the newborn being 
characterised as small for gestational age (SGA) or macrosomic/ large for gestational age (LGA). 
Customised birthweight centiles were calculated correcting for gestational age, maternal 
ethnicity, weight and height in early pregnancy, parity and infant sex. LGA was defined >90th 
customised birthweight centile; SGA as ≤10th customised birthweight centile.  
Dietary Assessment 
Dietary assessment was performed by research midwives trained in dietary assessment 
techniques, using a triple pass 24-hour dietary recall method and a short FFQ to determine dietary 
intake at baseline, post-intervention and follow-up visits. Dietary coding was undertaken by a 
research dietician and entered into the study database using McCance and Widdowson 
“Composition of Foods” (6th edition) food codes. The nutritional analysis software WISP 3.0 
(Tinuviel Software) was used to evaluate nutrient composition of the diet. Values for the 24 hour 
recall data which were obtained twice for each gestational period (one week apart) were 
averaged. When participants provided one recall per timepoint, this was treated as the 
representative intake at that timepoint.  
Fruit & vegetable consumption 
Intake of fruit and vegetables in portions per day was calculated directly from the dietary recalls. 
Fruit and vegetable consumption was calculated as consumption of whole fruit and whole 
vegetable as well as fruit and vegetable composites. Fruit composites included any dish that was 
based on fruit products or included fruits. Consumption of jams, juices, smoothies, tarts, fruit 
cakes etc. was analysed as fruit composites. Similarly all dishes containing vegetable and/or 
vegetable compotes/pastes were analysed as vegetable composites. Bouillons and vegetable 
stocks were not included in the analysis. Food products containing both fruit and vegetables were 
analysed under both categories respectively. A representative sample of minimum three recipes 
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was used to calculate the proportion corresponding to fruit/vegetable per recipe. Percentages 
were calculated based on uncooked net weight with added water if provided in the recipe. Fruit 
and vegetable intake was calculated as 80g portions or 120mL portions for juices. 
Polyphenol intake 
Total polyphenol intake at each timepoint was calculated, based specifically on fruit, vegetable, 
vegetable composite and fruit composite consumption, plus food items rich in polyphenols like 
wines, teas, coffees, infusions, cocoa products and spices. For each food item, a total polyphenol 
value per 100g was assigned based on data obtained through the PhenolExplorer database 
(Rothwell et al., 2012). Analysis was only performed as total polyphenol intake and not as intake 
of polyphenol subclasses (eg flavonoids, phenolic acids etc.) 
Lifestyle and socio-demographic data; anthropometry; blood and urine sample collection 
At the randomisation visit, participants completed a series of questionnaires assessing 
socioeconomic status, living arrangements, employment etc. as well as lifestyle factors including 
smoking and number of cigarettes smoked per day among other variables of interest. Weight, 
height and waist circumference were measured using standard protocols. Blood and spot urine 
samples were collected following an overnight fast at each timepoint. Blood and urine samples 
were aliquoted and stored at -80oC.  
Laboratory analysis 
Fructosamine values were measured on a clinically validated platform (c311, Roche Diagniostics, 
Burgess Hill, UK) in using the manufacturers’ quality controls and calibration materials. Levels of 
plasma sRAGE were measured using an enzyme linked immunosorbent assay (ELISA) using the 
manufacturers calibrators and protocols (RayBioTech Inc., Norcross, Georgia, USA). Urinary levels 
of Total Phenol (TP) and Ferric Reducing Ability of Plasma (FRAP) and Advanced Oxidation Protein 
Products (AOPPs) were also measured for each timepoint. Briefly, for the TP analysis, the method 
of Singleton and Rossi  with modification (Singleton and Rossi, 1965): Folin-Ciocaletau reagent 
(1:10) was prepared and 100μL of this was added to 20μL of sample or standard in a 96-well plate, 
followed by 70μL distilled water. After 5 minutes an additional 70μL sodium carbonate solution 
(1.1M) was added. After a 2 hour incubation step absorbance was measured at 765nm against 
gallic acid calibrators (0-500μg/mL in methanol).  For the FRAP measurement, the method of 
Benzie and Stain (Benzie and Strain, 1996) was followed with the following modifications: 225 μL 
FRAP Reagent (2mM ferric chloride hexahydrate, 1mM 2,4,6-tripyridyl-s-triazine in acetate buffer, 
pH 3.6) were added to 25μL sample or standards. Absorbance was measured at 593nm after four-
minute incubation against Fe 2+ (ferrous sulphate heptahydrate) calibrators (0 - 1.0mM). For the 
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measurement of urinary AOPPs the method of Witko et al. was used (WitkoSarsat et al., 1996) 
with modification: urine samples were diluted 1:5 in PBS. In a 96-well plate 10μL potassium iodide 
(1.16M) were added to 200μL of sample (diluted 1:5) or standard followed by 20μL acetic acid.  
Absorbance was measured immediately at 340nm against chloramine-T standards (0-100μM). All 
measurements were performed in duplicate and the coefficient of variation (CV%) for every assay 
was <10%. 
Statistical analysis 
Data were checked for normality and homoscedasticity using the Kolmogorov-Smirnoff test, and 
for skewness. The Student’s t-test, one way-ANOVA and χ2 (or their non-parametric equivalents) 
were used to examine the differences among groups. Relationships between continuous variables 
were tested using Pearson’s/Spearman’s correlation. Tukey’s post-hoc test was used to adjust for 
multiple comparisons. Changes in dietary intake over the study were compared between the two 
groups using Repeated Measures ANOVA. All analyses were performed using PASW Statistics 
19.0.0 (IBM, SPSS Software, Armonk, NY, USA) and statistical significance was taken as p<0.05. 
6.3 Results 
 
Women in the intervention and control groups were similar in terms of age, height, weight, BMI 
and WC. No significant differences were observed between ethnicity, parity, smoking habits, 
relationship status and living arrangements between the two groups. 
Table 6.1 Fruit, vegetable and polyphenol intake of participants before and after the intervention 
  
Control Intervention 
p-value 
    (n=55) (n=53) 
Whole vegetable intake 
(80g portions/d) 
Before 0.70±0.7 0.83±0.9 
 After 1.35±1.6 0.91±0.8 
 Control vs. Intervention (RMANOVA) 0.41 
Whole fruit intake  
(80g portions/d) 
Before 1.41±1.1 1.81±1.8 
 After 1.61±1.6 1.37±1.5 
 Control vs. Intervention (RMANOVA) 0.53 
Total F&V intake  
(80g portions/d) 
Before 4.15±1.8 5.16±2.6 
 After 5.06±3.1 4.94±3.6 
 Control vs. Intervention (RMANOVA) 0.05 
Total F&V intake excl 
juice,jam,smoothie  
(80g portions/d) 
Before 2.83±1.6 3.16±2.1 
 After 3.52±2.7 3.03±1.9 
 Control vs. Intervention (RMANOVA) 0.97 
Total polyphenol intake 
(mg/d) 
Before 449.45±419.4 431.16±368.4 
 After 465.03±567.1 486.71±476.9 
 Control vs. Intervention (RMANOVA) 0.98 
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At baseline, whole fruit intake ranged from 0 to 8.7portions/d and whole vegetable intake ranged 
from 0 to 3.7portions/d. The total intake of fruit and vegetables (fruit and vegetables included) 
ranged from 0.5 to 15.7portions/d with substantial contribution from jams, juices and smoothies 
(consumption range 0-10.2portions/d). At baseline, the two groups had similar whole fruit intake 
(portions/d: 1.5±1.2 vs. 1.7±1.6, control vs. intervention; p=0.29) and whole vegetable intake 
(portions/d: 1.2±1.5 vs. 0.9±0.8, control vs. intervention; p=0.07). At baseline, the total fruit and 
vegetable intake of the intervention group was significantly higher than the control (p=0.01) but 
only when fruit composites from juices, jams and smoothies were included. Without fruit 
composites, the remaining fruit and vegetable intake was reduced by more than one and a half 
portions in both groups, no difference between intervention and control (p=0.29) (Table 6.1). The 
total polyphenol intakes of individuals, ranged between 1.71mg/day and 2175.14mg/day at 
baseline with a median intake of 306.58mg/day. 
Repeated measures ANOVA analysis showed that there were no significant differences in the 
dietary changes during the 8-week intervention period between the intervention and control 
group, despite within-group changes (Table 6.1). 
With no evidence that the intervention altered the dietary habits in terms of fruit and vegetable 
and polyphenol intake, for the remainder of the analysis the control and intervention groups were 
merged and studied cross-sectionally. From this point onwards, instead of referring to control and 
intervention groups, the results will be presented as associations at 16-18+6 weeks and 27-28+6 
weeks gestation.  
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Association between lifestyle/dietary parameters and glycation-related markers 
Fructosamine and urinary AOPPs levels fell significantly by about 3% and 22%, respectively, 
between 16-18+6 weeks and 27-28+6 weeks gestation (p<0.001 and p=0.03, respectively). A similar 
reduction was shown for urinary FRAP levels, while sRAGE and TP levels remained unchanged 
(Table 6.2).  
Table 6.2 Levels of glycation and antioxidant status markers at 16-18+6 and 27-28+6 weeks 
gestation 
 Week Gestation  
 
16-18+6 27-28+6 
p-value 
 
Mean±SD Mean±SD 
Fructosamine (μM) 195.79±17.9 189.51±18.9 <0.001 
AOPPs (μM) 18.27±12.0 14.17±8.1 0.03 
Total Phenol (μg/mL gallic acid equiv) 236.88±80.7 209.62±72.8 0.07 
FRAP (mM Fe2+ equiv.) 1.26±0.7 1.17±0.6 0.02 
sRAGE (pg/mL) 203.69±110.7 191.02±104.7 0.05 
 
Women with higher BMI at baseline had lower glycation, measured as fructosamine, at 16-18+6 
gestation (p=0.03). No difference in glycation levels were seen, though, between different BMI 
groups. At 27-28+6 weeks gestation there was no relationship between BMI and glycation levels.  
No relationship was found between BMI and AOPPs or sRAGE levels. 
Smoking (n=7) was inversely correlated with fructosamine values at 16-18+6 and 27-28+6 weeks 
gestation (p=0.02 and p=0.003, respectively). Current smokers had lower fructosamine levels than 
those who never smoked, especially at 27-28+6 weeks gestation (p=0.051 and p=0.004 at 16-18+6 
and 27-28+6 weeks respectively) (Figure 6.1). Women who were smoking during pregnancy also 
had significantly higher urinary AOPPs at 27-28+6weeks gestation than never smokers (p=0.02). No 
difference among the smoking groups were seen at 16-18+6 weeks gestation (p=0.25) (Figure 6.2). 
No association was found between smoking and sRAGE values (p=0.57, 16-18+6wks; p=0.53, 27-
28+6wks). 
At 16-18+6 weeks gestation, TP values were positively correlated with AOPPs values (r=0.57, 
p<0.001) and so were FRAP values (r=0.22, p=0.02). Levels of fructosamine and sRAGE were not 
correlated with any other variables. Similar findings were documented at 27-28+6 weeks gestation 
with positive correlations between TP, FRAP and AOPPs levels (r=0.67, p<0.001 and r=0.23, p=0.02 
for TP and FRAP respectively). At this timepoint, there was no detectable correlation between 
urinary TP levels and sRAGE using the p-value cut-off of 0.05, (r=-0.19, p=0.056). However, when 
women were split in quartiles of TP values, those in the highest quartile of urinary TP, had 
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significantly higher urinary AOPPs (p<0.001) and lower sRAGE concentrations, at 16-18+6 weeks 
gestation (p=0.04) (Table3). The same was documented for AOPPs at 27-28+6 weeks gestation (TP 
Q1 vs Q4, p<0.001) but the relationship between TP and sRAGE levels was no longer significant 
(p=0.09). No differences were seen among women in the higher quartile of urinary FRAP values 
and those in the lowest quartile in terms of AOPPs, fructosamine and sRAGE levels at any 
timepoint. 
Figure 6.13 Fructosamine levels according to smoking status at 16-18+6 and 27-28+6 weeks 
gestation 
 
 
Figure 6.14 AOPPs levels according to smoking status at 16-18+6 and 27-28+6 weeks gestation 
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Among the dietary variables, there was no significant interaction between fruit and vegetable 
intake and fructosamine levels at any time point. That was also the case for urinary AOPPs values. 
Consuming more than 5 portions of fruit and vegetable per day did not have an impact on 
fructosamine, AOPPs, sRAGE and FRAP values at either timepoint.  
On the other hand, total polyphenol intake was negatively correlated with fructosamine values at 
16-18+6 and 27-28+6 weeks gestation (r=-0.21, p=0.003 and r=-0.27, p=0.008 respectively), 
although no association was found between total polyphenol intake and urinary AOPPs. A 
negative correlation between total polyphenol intake and sRAGE levels was observed at 27-28+6 
weeks gestation (r=-0.26, p=0.01) but not at 16-18+6 weeks gestation (r=0.03, p=0.79). When split 
in quartiles according to dietary polyphenol intake, those with the highest intake (Q4), had 
significantly lower fructosamine and sRAGE levels (p=0.01 and p=0.03, respectively) at 27-28+6 
weeks gestation than those with the lowest polyphenol intake (Q1) but not at 16-18+6 weeks 
gestation (Figure 6.3). 
 
Figure 6.15 Fructosamine and sRAGE levels according to quartile total polyphenol intake at 27-
28+6 weeks gestation 
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Associations between maternal diet, biomarkers and pregnancy complications  
Prevalences of pregnancy complications are shown in Table 6.3. The development of 
preeclampsia was not associated with maternal AOPPs, fructosamine, sRAGE, FRAP and TP values 
neither at 16-18+6 weeks nor at 27-28+6 weeks gestation. Maternal dietary habits, in terms of fruit 
and vegetable intake or total polyphenol intake were also not associated with the development of 
preeclampsia. On the other hand, women who developed severe preeclampsia had higher AOPPs 
at 27-28+6 weeks gestation (p=0.01). No association was found between severe preeclampsia and 
the dietary habits investigated.  
Table 6.33 Prevalence of pregnancy complications and adverse neonatal anthropometry 
Pregnancy complications Without 
n (%) 
With 
n (%) 
Preeclampsia 96 (92.3) 8(7.7) 
Severe Preeclampsia 99 (95.2) 5 (4.8) 
Gestational Diabetes 79 (85.9) 13 (14.1) 
Neonatal Anthropometry   
Macrosomia 90 (89.1) 11 (12.9) 
Small-for-Gestational Age 88 (87.1) 13(12.9) 
 
Women diagnosed with gestational diabetes were more likely to have elevated fructosamine 
values at 27-28+6 weeks gestation (p=0.01). Being diagnosed with gestational diabetes was also 
associated with lower total fruit and vegetable consumption at 16-18+6 weeks gestation (p=0.05) 
and the same trend was seen for 27-28+6 weeks gestation (p=0.052). Women who were diagnosed 
with gestational diabetes were also more likely to have lower total polyphenol intake at 27-28+6 
weeks gestation (614.8±712.6 vs 315.3±321.7 mg/d, p=0.048) 
Associations between maternal diet, biomarkers and neonatal outcomes 
Prevalences of neonatal macrosomia and being born small for gestational age are reported in 
Table 6.3. No association was found between maternal dietary habits or maternal AOPPs, 
fructosamine, sRAGE, FRAP and TP values and the likelihood of giving birth to a macrosomic or a 
small for gestational age infant. A positive correlation between total polyphenol intake at 27-28+6 
weeks gestation and neonatal birth weight was documented (r=0.18, p=0.03), but this association 
did not reach significance when women were split in quartiles of polyphenol intake (p=0.11). 
Maternal AOPPs at 27-28+6 weeks gestation were negatively correlated with neonatal head 
circumference (r=-0.27, p=0.01) while a similar association with neonatal birth weight (r=-0.19) 
did not reach significance (p=0.06).   
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6.4 Discussion 
 
This is, to our best knowledge, the first study to focus on the interactions of lifestyle/dietary 
habits with glycation markers in obese pregnant women and their effect on maternal and 
neonatal health. Higher total polyphenol intake was negatively associated with fructosamine 
values during pregnancy. On the other hand, higher urinary TP values and smoking were 
associated with higher levels of AOPPs.  No study, to-date, has focused on the role of diet on 
sRAGE levels. We showed for the first time that total polyphenol intake and urinary TP are 
inversely related with sRAGE values during pregnancy. In terms of pregnancy complications, diet 
only had an impact on the development of GDM, as women with lower total fruit and vegetable 
intake and lower total polyphenol intake were more likely to be diagnosed with GDM. From the 
parameters tested none had a significant relationship with pre-eclampsia diagnosis, but increased 
levels of AOPPs during the 3rd trimester (27-28+6 weeks gestation) were found in women 
diagnosed with severe pre-eclampsia. Glycation markers have previously been associated with 
neonatal anthropometry (Kurishita et al., 1994) and in the current analysis, we found a positive 
relationship between maternal total polyphenol intake and neonatal birth weight. The opposite 
was documented for AOPPs, which were negatively correlated with neonatal birth weight and 
head circumference. The results of this analysis are the first to indicate a relationship between 
maternal AOPPs and neonatal anthropometry. Previous reports suggest that prematurity is 
associated with higher AOPPs in the neonate which correlate with maternal AOPPs levels 
(Argüelles et al., 2006, Buonocore et al., 2000). In that respect our results agree with the 
literature that elevated AOPPs may be a risk factor for fetal development. 
The associations between dietary variables and/or the biomarkers of interest were not consistent 
throughout gestation. In fact, levels of protein glycoxidation themselves fluctuated during 
gestation, with AOPPs and fructosamine significantly decreasing from 16-18+6 to 27-28+6 weeks 
gestation and a similar yet not significant trend observed for sRAGE levels. These results are in 
agreement with previous reports showing a decrease in fructosamine and AOPPs values during 
the course of pregnancy, with the exception of women who developed gestational diabetes (Li 
and Yang, 2006, Fialova et al., 2006, Agarwal et al., 2011, Hiramatsu et al., 2012, Germanova et 
al., 2010). The fluctuations in biomarkers levels during gestation are likely to be related to the 
physiological changes of pregnancy. Due to these changes an analysis where data from both 
timepoints would be pulled together to increase the statistical power would not be appropriate. 
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The negative relationships between BMI and smoking with glycation marker fructosamine were 
surprising, as previous data in non-pregnant controls showed opposite relationships (Vlassopoulos 
et al., 2013a, Clair et al., 2011). However, they are in fact in agreement with earlier reports in 
pregnant women, also showing inverse impacts of smoking and BMI on fructosamine levels 
(Hiramatsu et al., 2012). Obesity during pregnancy is a risk factors for proteinuria (Macdonald-
Wallis et al., 2011, Gribble et al., 1995, Voigt et al., 2011), which could reduce fructosamine by 
reducing albumin half-life in circulation; unfortunately no data were available at the time of this 
analysis to investigate this hypothesis. Literature to-date suggests that smoking is associated with 
lower proteinuria during pregnancy, which is contradictory to our findings (Macdonald-Wallis et 
al., 2011, Gribble et al., 1995, Voigt et al., 2011). In this small cohort of obese pregnant women, 
smoking during pregnancy was uncommon, only 7% of the subjects, and it was associated with 
significantly higher BMI than non-smokers (p=0.002, data not shown). As the sample size of the 
current study was not large enough for regression analysis to be performed, it is possible that 
smoking, here, is a co-variate for higher BMI, rather than a risk factor on its own right. Glycation is 
directly dependent on protein half-life (Austin et al., 1987, Lapolla et al., 2005) and hence lower 
fructosamine values in smokers and those with a BMI>40 could merely be an indication of 
increased protein loss instead of a true reduction in glycation. Expressing fructosamine values as a 
ratio of fructosamine μmole per mg plasma albumin should be considered as a measure to 
account for changes in plasma protein concentrations.  
Looking at AOPPs concentrations, it becomes evident that smoking is associated with significantly 
higher levels of protein damage, especially during the third trimester. AOPPs are a marker of 
protein oxidation and potentially glycoxidation, as they include several chromophores like 
carbonyls and pentosidine (Capeillere-Blandin et al., 2004, Kalousová et al., 2005). AOPPs have 
similarities with AGEs as they share formation pathways through oxidative stress but are not 
solely a marker of glycation (Kalousová et al., 2005), which could explain the difference in results 
obtain from AOPPs measurement and fructosamine measurements. As AOPPs could be derived by 
a variety of oxidative processes, they can exhibit high variability among individuals (Codoñer-
Franch et al., 2012, Matteucci et al., 2001, Qing et al., 2012), which is the case in our analysis 
(Figures 1 - 2).  
Greater dietary polyphenol intake was associated with lower levels of glycation, measured as 
fructosamine levels, in our analysis, but the same was not seen for measures of fruit and 
vegetable intake. Even though fruit and vegetables are the main source of polyphenols in the diet, 
other food products such as spices, tea, coffee and infusions can be significant sources of 
polyphenol in populations with relatively low fruit and vegetable intakes. In the current analysis, 
the correlation between total polyphenol intake and fruit and vegetable consumption was poor, 
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which indicates that other dietary components are the key polyphenol sources. Previous reports 
have shown a significant reduction in HbA1c levels in prediabetic individuals after polyphenol 
supplementation (Fukino et al., 2008, Cho et al., 2012) but the evidence is far from being 
conclusive as studies in healthy volunteers do not support this finding (Evans M., 2012, Miyazaki 
et al., 2013).  
When studying the impact of polyphenols in health, researchers are faced with two common 
problems: 1) obtaining accurate and representative data of dietary intake and 2) identifying 
suitable biomarkers of polyphenol intake (Spencer et al., 2008, Ovaskainen et al., 2008, Perez-
Jimenez et al., 2010, Mennen et al., 2006). The estimation of the dietary intake of any nutrient 
based on recall data is dependent on the quality of information provided by the participant, the 
quality of information available for the food composition and evidently the tools used to obtain 
and analyse food records. In dietary research, 7-day food records are still considered the gold 
standard methodology to obtain intake data (Tucker, 2007). This practise has been criticised as 
being strenuous for the participants as well as time-consuming for researcher to analyse the data 
(Spencer et al., 2008, Tucker, 2007). Instead of 7-day records, multi-pass dietary recalls have been 
utilised extensively in research. Although recalls are more practical for both researcher and 
participants, they are dependent on the participants’ memory and may also not be representative 
of the overall dietary habits (Basiotis et al., 1987, Buzzard et al., 1996, Thompson F. E., 2008). 
Under-reporting of the dietary intake is a common source of error in dietary recalls and obese 
participants are more likely to under-report than normal weight participants (Poppitt et al., 1998, 
Heitmann and Lissner, 1995, Lichtman et al., 1992, Braam et al., 1998). The Goldberg cut-off has 
been used in order to assess under-reporting (Goldberg et al., 1991). In the current analysis since 
all the population is of a BMI>30, it was assumed that the degree of under-reporting would be 
comparable between participants and hence it was not included in the confounding factors. 
The second source of error in dietary recalls is introduced in the analysis of the data obtained. In 
the case of polyphenols, dietary intakes are based on food composition data, which are most 
often than not a poor representation of the actual values as they fail to incorporate details like 
seasonality, plant variety, method of preparation that have an important impact on polyphenol 
content (Spencer et al., 2008, Hammerstone et al., 2000, Spanos et al., 1990). The use of food 
composition data like PhenolExplorer also present with difficulties as the databases do not always 
include the totality of items consumed by the participants. In the case of this analysis, the 
completeness of the databases was sufficient as only five food items (exotic fruits) were not 
included in the databases and these items were only consumed once and in limited quantities by 
selected participants. 
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The use of plasma or urinary biomarkers for polyphenol intake has been proposed as a way to 
overcome the problems of dietary estimates. TP has been established as a fast and convenient 
way to measure polyphenol content in urine and plasma, showing acceptable correlation with 
dietary intake (Medina-Remon et al., 2009, Medina-Remon et al., 2012). Nonetheless, it is a non-
specific assay with interference being introduced by sugars, aromatic amines, organic acids, iron, 
protein and other substances like AGEs present in the urine (Roura et al., 2006). Urinary levels of 
individual (poly)phenols have been proposed as an alternative approach but there is not sufficient 
data at the moment to securely suggest which metabolites would be suitable for the assessment 
of polyphenol intake in epidemiological settings (Spencer et al., 2008, Nielsen et al., 2002, de 
Vries et al., 1998). 
The aforementioned possible errors and biases could provide explanation between the different 
results obtained in the present studies among variables like total polyphenol intake, fruit and 
vegetable intake and TP/FRAP levels. Another potential explanation could be the small sample 
size. Previous epidemiological studies have managed to detect relationships between fruit and 
vegetable intake and glycation markers but they employed larger samples  (Vlassopoulos et al., 
2013a). Also in the current analysis the two groups (control and intervention) had a significantly 
different fruit and vegetable intake at randomisation. This difference was no longer present at the 
end of the intervention as the control group increased its intake and the intervention group’s 
intake remained unchanged. This could be either a directly attributed to the intervention itself 
(the increased in fruit and vegetable intake seen in the control group is from higher jam, juice and 
smoothie food groups restricted for the intervention group) or it could be merely a regression 
towards the mean. In the case of the latter, the difference observed in baseline is merely out of 
chance and that would mean that there was no true change in any of the groups during the 8-
week intervention period. The same analysis in the full trial will have the potential to detect 
changes with a smaller effect size and will also allow for the data to be corrected for confounding 
factors.  
6.5 Conclusion 
 
This unique study has highlighted that polyphenol consumption may be negatively associated 
with glycation. The level of glycation was 8% greater in the lowest quartile of total polyphenol 
intake compared to the top quartile. Overall total polyphenol intake explained only 5% of variance 
in glycation. It also provided with preliminary data to link maternal glycoxidation with pregnancy 
complications and a link between maternal polyphenol consumption and glycoxidation with 
neonatal anthropometry. 
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Chapter 7: General discussion and implications for future research 
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In the past 60 years, the median age of the entire world population has increased by 5 years,  and  
over 25% of the world population is now older than 45 years (WHO, 2014). Ageing and chronic 
diseases are the main medical concerns in the developed world (Sweet, 2011, WHO, 2010, WHO, 
2011). The identification of early signs of disease pathogenesis is vital for prevention and 
targeting populations at risk in order to reduce morbidity and mortality. Glycation is well-
established as an index of control, or otherwise, and a predictor of end-organ damage, for people 
with type 2 diabetes, an d has been already identified as a marker of chronic disease pathogenesis 
even in the absence of diabetes (Selvin et al., 2005, Selvin et al., 2014, Selvin et al., 2010, Adams 
et al., 2009, van't Riet et al., 2012). The process of glycation is therefore relevant to health and 
disease throughout the lifecycle, with the potential to modify health trajectories (Nedic et al., 
2013, Smith et al., 1995, Wolff et al., 1991). 
At the beginning of the work for this thesis (2010), evidence was beginning to be raised to suggest 
that since glycation levels  vary considerably, in normoglycaemic, non-diabetic  individuals, 
glycation cannot be solely be related to glucose levels (Selvin et al., 2010). The impact of oxidative 
stress in the production of AGEs and intermediate glycation products had been already 
established (Ahmed et al., 2005, Duran-Jimenez et al., 2009, Thornalley et al., 1984, Thornalley, 
2003b) and early reports allowed for speculations about a relationship between early glycation 
and oxidative stress (Selvaraj et al., 2008, Jain, 1998, Jain and Palmer, 1997). At the same time, 
mechanistic studies were supporting the epidemiological evidence by suggesting that antioxidant 
vitamins and (poly)phenols have anti-glycative properties (Jain and Palmer, 1997, Kazeem et al., 
2012, Verzelloni et al., 2011a, Xie and Chen, 2013, Xi et al., 2008). 
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This thesis has employed a systematic methodology incorporating skills across the full breadth of 
Human Nutrition (basic laboratory sciences, clinical trials and epidemiology) with the aim to 
establish the relationship between early glycation and oxidative stress in normoglycaemia in an 
iterative scientific progression: 
1. Existing epidemiological data were used to identify relationships between proxies for 
redox status and early glycation in non-diabetic individuals. 
 
2. The associations from epidemiology were explored in mechanistic laboratory studies with 
high physiological relevance (using physiological concentrations and conditions) to better 
characterise the associations between oxidative stress/ antioxidants and early glycation. 
 
3. Clinical trial data and biological samples were analysed from a randomised controlled 
dietary advice trial in obese pregnant women, a group at risk from higher glycation and 
oxidative stress.   This study provided a sample cohort advised to follow dietary and 
lifestyle habits with the potential to modulate multiple glycation markers and maternal 
and neonatal health. 
 
7.1 Research questions and answers 
 
This section summarises the Research Questions posed following the literature review (Chapter 
1), and the answers provided by the current thesis. 
RQ1: Is redox status associated with glycation in normoglycaemic individuals?  
The current thesis showed in chapter 3 that redox status has an important impact on protein 
glycation in absence of diabetes. Habits like smoking, associated with increased oxidative stress, 
were shown to be positively associated with HbA1c levels, in a large epidemiological study. These 
findings were independent of other factors like age, sex, BMI and WC and were consistent with 
previous reports (Clair et al., 2011). The new data also suggested that vegetable intake, a habit 
associated with improved redox status, had the opposite (negative) correlation with HbA1c levels, 
although the relatively narrow range of vegetable consumptions had a weaker correlation. 
Currently, some 10 million adults are smoking in the UK. Despite a reduction in the prevalence of 
smoking in the last 40 years, 200,000 young people aged 11-15 years commence smoking 
annually. Over the same period, consumptions of fruit a vegetables have fallen, and this trend 
continues: a 4-6% reduction in the purchase of fresh and processed fruit and vegetable was 
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reported between 2008 and 2013, with only a quarter of the population meeting the '5-a-DAY' 
target (five portions of 80gr). This adverse combination of lifestyle habits has marked socio-
economic impact, contributing to health inequalities.  Individuals in lower income groups are 
twice as likely to be smokers, and they consume 50% less fruit and vegetable than the more 
affluent (HSCIC, 2013, AOS, 2013). The clustering of smoking and poor diet quality is not a novel 
finding but it is still a major source of health inequalities and by promoting glycation it would 
accelerate biological ageing in this population. 
The measurement of HbA1c has been established as the gold-standard method for glucose 
monitoring, based on the assumption that it is mainly a reflection of glycaemia, with long-term 
exposure to glucose determining the circulating concentration. This is crudely true for people with 
diabetes, although HbA1c still varies despite similar glycaemia as indicated by frequent blood 
glucose testing.  HbA1c is also important clinically as a strong predictor of the multiple clinical 
complications of diabetes.  The finding that oxidative stress can have a potential positive impact 
on HbA1c levels is thus of substantial importance for clinical practice. The present thesis has 
demonstrated that smoking is associated with higher HbA1c levels, and smokers are more likely to 
have HbA1c in the 'pre-diabetic' range, an effect which appears probably independent of 
glycaemia.  The Scottish Health Survey did not include data for blood glucose concentrations, so it 
was impossible to conclude securely whether this association was completely independent of 
glycaemia. Nonetheless, we provided evidence for increased HbA1c levels with smoking even in a 
subgroup of the population with good glycaemic control and low systemic inflammation. This 
population group is unlikely to be experiencing any dysregulation in glucose handling that could 
lead to impaired fasting or post-prandial glucose. Therefore these results are suggestive of a 
glucose independent association between smoking and HbA1c. Such associations imply an 
important margin of misclassification of smokers as pre-diabetics using HbA1c, as compared to 
the alternative diagnostic criteria based on OGTT.  The issue of misclassification of diabetes using 
HbA1c has been previously debated among clinicians (Bonora and Tuomilehto, 2011) and a recent 
meta-analysis highlighted the fact that smokers as a group are more likely to be misclassified as 
diabetic than non-smokers based on HbA1c levels (Soulimane et al., 2014).  The present thesis 
provides an explanation.  Misclassification of diabetes is important.  It can affect treatment 
choices and risk management, leading to further financial implications for the health system, and 
it also has psychological implications for patients and their families (de Lusignan et al., 2012).  
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RQ2: Could oxidation promote fructosamine production in the presence of physiological glucose 
concentrations? 
RQ2a: Are oxidised proteins more prone to glycation than the native forms? 
Glycation is a complex and multi factorial process. Therefore, it is difficult to obtain mechanistic 
data from in-vivo investigations. Mechanisms of glycation have traditionally been studied using in-
vitro models with limited physiological relevance. The use of supra-physiologically high glucose 
levels, low protein concentrations and variable incubation durations are some of the key issue 
resulting in evidence from in-vitro studies being treated cautiously (Bourdon et al., 1999, Chesne 
et al., 2006, Kim and Kim, 2003, Tarwadi and Agte, 2011). In this thesis we aimed to develop a 
physiologically relevant setting where the interactions between oxidative stress and glycation 
could be studied.  
We showed that exposure to H2O2, at a physiological concentration, was associated with higher 
early glycation at two and four weeks incubation, independently of glucose levels. More 
importantly at glucose concentration representative of normoglycaemia (5mM) oxidative stress 
was a prerequisite for significant amounts of glycation to be detected. These findings are in 
keeping with the hypothesis generated from epidemiology and further support the speculation 
that glycation, especially fructosamine, might well be a marker of oxidative stress in 
normoglycaemia. A novel and important finding of this investigation was that oxidative damage 
had the capacity to promote glycation even if the two did not take place simultaneously. No 
previous study so far has proposed a mechanism according to which protein/ amino acid 
oxidation makes the molecule more prone to glycative damage and it is a field requiring further 
research. The dogma to-date suggests that glycated proteins are more prone to oxidation but the 
opposite pathway is poorly characterised.  
Oxidative damage is more likely to happen before glycative damage, as glycation is a slow process 
as opposed to oxidation which can happen rapidly especially intracellularly and perhaps at 
locations closer to the mitochondria which generate free radicals. Moreover, even though early 
glycative damage can be repaired enzymatically by the removal of the fructosamine moiety 
(Delpierre et al., 2002, Delpierre et al., 2000), repair of oxidative damage is based on proteolysis 
(Costa et al., 2007, Friguet, 2006). These indicate that accumulation of oxidative damage is more 
likely to accumulate prior to glycation, making glycation a secondary damage especially in 
normoglycaemia. 
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RQ3: Can phenolic acids reduce glycation in a physiologically relevant in-vitro system? 
The same in-vitro setting was utilised to explore the potential of phenolic acids to reduce 
glycation. The antiglycative properties of (poly)phenols have attracted attention lately but no 
exact mechanism of action is established. The structures required of (poly)phenols in order to 
exhibit antiglycative capacities were described in a recent review of the literature and 
interestingly the same structures are associated with higher antioxidant capacities as well (Xie and 
Chen, 2013). Prior in-vitro investigations, on the other hand, did not manage to see a link 
between antioxidant properties and antiglycative properties, which led to the speculation that 
bonding of phenolic acids on the protein may be offering ‘physical protection’ against glycation 
(Verzelloni et al., 2011a).  
Both these mechanisms were tested in our experimental setting and we provided with evidence 
that phenolic acids are more likely to inhibit glycation through protein-phenolic acid interactions 
rather than as antioxidants. Our results suggest that addition of phenolic acids in the solution 
during the incubation with glucose did not have an impact on glycation but pre-incubation of 
albumin with phenolic acids led to significant reduction in early glycation when the protein was 
exposed to a combination of glucose and H2O2. Once again the study was designed to replicate 
physiology to the highest possible degree. A systematic review of the literature was performed 
prior to the experiment, which informed the choice of phenolic acids used and their 
concentrations as well as those of glucose and of H2O2.  
Apart from the interesting mechanistic data provided from the in-vitro experiments, they are also 
important in terms of methodology for human nutrition research. These studies within the 
present thesis are proof that mechanistic studies with a high relevance to physiology are not 
impossible to achieve and they should become the usual expected standard in research. Many in 
vitro studies are conducted using phenolic compounds such as quercetin, which are simply not 
absorbed by the gastrointestinal tract, or metabolised before they ever reach 'target' tissue.  
Many studies use completely inappropriate supraphysiological concentrations in order to achieve 
results.  The findings of these studies are often contradicting current thinking and that is an 
important finding as the use of supra-physiological conditions may lead to the false speculation of 
the potential mechanisms taking place in physiology.  In the present case, the previous studies of 
glycation had to employ very high glucose concentrations because the complexity of glycation, 
and involvement of oxidative mechanisms, had not been appreciated. 
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RQ4: Is polyphenol intake negatively correlated to glycation markers in a population at high risk of 
oxidative stress? 
RQ4a: Is polyphenol intake and/or glycation related to maternal health or pregnancy 
complications? 
RQ4b: Is maternal polyphenol intake and/or maternal glycation related to neonatal health? 
 
Even though mechanistic data are pointing towards a negative association between (poly)phenols 
and glycation, experimental and epidemiological studies are still inconclusive. The majority of 
epidemiological studies lack information on polyphenol intake and intervention trials often have 
small sample sizes. We hypothesised based on our previous findings that populations with 
increased oxidative stress will be at high risk of glycation. Such populations would be most likely 
to benefit from a higher polyphenol intake in terms of glycation regulation. Glycation, although a 
marker of ageing and diabetes, has recently attracted attention as a marker of health trajectories 
throughout the lifecycle and especially during pregnancy for its potential to regulate maternal and 
neonatal health. A cohort of obese pregnant women was identified and markers of glycation and 
glycoxidation were studied for potential associations with polyphenol intake and fruit and 
vegetable intake. The same markers were also assessed in terms of their involvement in 
determining maternal health during pregnancy and complications, as well as being associated 
with neonatal health. 
We found that higher polyphenol intake was indeed associated with lower glycation and 
glycoxidation in the mother. There was also a negative association between polyphenol intake 
and the development of GDM but not pre-eclampsia. The was a weak (r=0.2) but significant 
correlation showing that, mothers with higher polyphenol intake gave birth to heavier babies, but 
the association did not persist when diagnosis of macrosomia was the outcome of interest.  
Glycation and glycoxidation fluctuated significantly in the course of gestation and maternal 
glycoxidation was significantly higher in women who developed severe pre-eclampsia. Higher 
maternal glycoxidation (AOPPs levels) was also related to giving birth to lighter babies with a 
smaller head circumference. 
 We showed that monitoring glycoxidation may be an important step towards the improvement 
of complication diagnosis in pregnancy, but fluctuations during pregnancy (reduction during the 
3rd trimester) will have to be taken into consideration. Glycoxidation and maternal polyphenol 
intake were identified as potential factors of fetal programming especially in terms of 
anthropometry, but studies in larger cohorts are needed in order to reach a clear conclusion.  
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Interventional protocols during pregnancy usually rely on improving dietary quality or monitoring 
the weight gain in order to deliver benefits to the mother and the baby without exposing them to 
risk. In the case of obese pregnancies, such manipulations may be useful but the main risk factor, 
which is obesity, is still not addressed.  Interventions aiming towards a weight reduction of more 
than 5%, with maintenance of the loss, are associated with significant health benefits, even 
diabetes reversal (Penn et al., 2013, Lim et al., 2011, Wing et al., 2011, Blackburn, 1995). Weight 
loss interventions prior to conception may be more effective in protecting the mother and the 
baby than intervention modifying the quality of diet alone.  
 
7.2 Considerations for the future 
 
Although the importance of glycation as a marker of disease pathogenesis outside of diabetes is 
becoming clearer, it is not yet fully understood. More epidemiological studies are required to 
describe the interactions between oxidative stress and glycation, especially in normoglycaemia. 
The relatively small effect sizes obtained from the analyses as part of this PhD indicate that future 
investigations will require large sample sizes to have adequate power and also to allow for 
successful adjustment for confounders. Studies focusing on glycation have so far only focused on 
traditional glycation markers and rather neglected the importance of sRAGE and RAGE activation 
in disease pathogenesis, even though they constitute a major pathway of pathogenesis.  
As far as polyphenol and antioxidant trials are concerned, there is still much improvement to be 
done in terms of study design before conclusions can be reached. If the working hypothesis is that 
polyphenols will exert health benefits via their antioxidant capacity, at least in susceptible 
individuals, then markers to document such improvements should be included and results on 
glycation markers, like HbA1c, should be discussed alongside oxidative stress improvements. The 
measurement of oxidative stress markers, like F2-isoprostanes,  8-hydroxydeoxyguanosine (8-OH-
dG), the Comet assay and measurement of protein carbonyls would allow for sensitive and 
reproducible measurement of lipid, DNA and protein oxidation, providing a better understanding 
of the oxidative stress status compared to the commonly used TBARS assay (Freese et al., 1999, 
Hodgson et al., 2002, Janero, 1990, Frei and Higdon, 2003). Unfortunately, the validity of oxidative 
stress markers has been a source of disagreement among scientists (Halliwell, 2007, Halliwell, 
1994) and no gold-standard method has been identified so far (Dalle-Donne et al., 2006). In that 
context, it is important to highlight that according to the results of this thesis, HbA1c levels 
themselves might be a novel marker of oxidative stress. The measurement of HbA1c or 
fructosamine combined with measurements of blood glucose, ideally both fasting and 2-hour 
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blood glucose, could be used to identify increased oxidative stress. Future studies should be 
designed to address this question, as it would valuably inform both research and clinical practice.  
Sample size and targeting the correct population are two more aspect of study design to be 
considered. The regulation of redox status is vital for health, with many endogenous regulatory 
mechanisms, and chronic diseases are likely to reflect only very small perturbations. Dietary 
factors are likely to play minor parts in regulation of such an important element of the milieu 
interieur, although subgroups may be more dependent on external factors.  Polyphenol 
supplementation in a relatively healthy population is likely to have at best subtle effect on health 
markers and hence studies with large sample sizes greater than a hundred are likely to be needed 
(Cicero et al., 2008). The majority of the studies to-date fall short of that sample size and are 
hence likely to be underpowered. As a result, beta-errors are likely, and one should be very 
careful when concluding that polyphenol supplementation has no effect on glycation. The current 
literature may just describe a lack of power to detect such an effect (if any). Another 
consideration could be to target the trials towards populations with increased oxidative stress (i.e. 
obese, smokers), or to identify population subgroups which might have greater susceptibility to 
oxidative stress with greater dependence on dietary antioxidants. . Such a population may 
experience a greater benefit in their redox status from polyphenol (or other) supplementation, 
with the possibility of a knock-on protective effect on glycation markers.   This is only a hypothesis 
and evidence to support this suggestion is not available. 
A very important improvement in future study quality will relate to the information available 
about the supplement used. So far, reports from supplementation studies rarely report in detail 
the exact composition of the supplements used. Information on the polyphenol composition, the 
exact dose of each compound, the matrix used to deliver them and even some prior bioavailability 
data are needed if the results from different trials are to be compared and robust conclusions 
drawn.  
 Glycation markers should be picked carefully and the study duration should be sufficient to 
detect changes. Studies with duration shorter than the biomarker’s half-life are not suitable to 
represent any changes. Fructosamine measurements for a study with duration less than 14-28 
days and HbA1c measurements before a 90-day window are most likely to be unable to detect 
any changes. The field of proteomics and metabolomics are also of great importance in glycation 
research, since every protein is ultimately a glycation target analysing changes in patterns of 
protein damage maybe more effective in drawing conclusion compared to single protein 
approaches. 
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Finally, when searching for benefits from a polyphenol supplementation trial, one should keep in 
mind that physical protein damage is only one pathway of glycation-related pathogenesis. RAGE 
mediated events are also key in the pathogenesis of diseases and are so far under-studied. 
Studies on epithelial cells and adipocytes suggest that plant derived polyphenol like silymarin, 
apigenin, diosmin, epigallocatechin gallate, tyrosol and quercetin have the capacity to reduce 
glycation related inflammation, especially TNF-alpha levels (Chandler et al., 2010, Kawaguchi et 
al., 2011, Biesalski, 2007) as well as nitric oxide production as a response to RAGE stimulation 
(Chandler et al., 2010). Although cell culture experiments can be set-up to study the interaction of 
polyphenols, glycation and inflammation, this is a more complicated task in-vivo. Measurement of 
sRAGE alongside the measurement of AGEs is not currently a common practice. Studies in 
pregnant women and patients with juvenile idiopathic arthritis (JIA) have showed that sRAGE 
levels may be more important that AGE levels to predict disease activity and complications (Yu et 
al., 2012, Myles et al., 2011). Also the calculation of a sRAGE/AGE ratio is a new concept that 
attempts to serve as a proxy for AGEs available to bind with RAGE (McNair et al., 2010, Ng et al., 
2013). With little being known about sRAGE modulation, it is becoming evident that new glycation 
related markers need to be used to effectively describe the impact of glycation on health. 
 
7.3 Research questions arising from this thesis 
 
Based on the results of this thesis, the following further research questions appear to be valid, 
hitherto unanswered and of potential importance to inform practice or policy (among others): 
 Is the epidemiological association between oxidative stress and glycation truly 
independent of glucose levels? 
 Which is the exact mechanism t for protein oxidation prior to exposure to glucose to 
promote glycation?  Are oxidised amino acids more susceptible to glycative damage? 
 Is the protection offered by phenolic acids against glycation mediated through ‘physical 
protection’ of glycation sites?  If yes, which phenolic acids most effectively bind on the 
albumin molecule and is the bonding covalent or not? 
 Can nutritional interventions to increase polyphenol intake improve maternal and 
neonatal health during pregnancy?  Are there epigenetic effects? 
 Does weight loss prior to conception reduce risk of complications for obese women, and 
improve neonatal health?  Does this reflect redox status in pregnancy? 
  
108 
 
References 
 
ABDEL-WAHAB, Y. H., O'HARTE, F. P., BARNETT, C. R. & FLATT, P. R. 1997. Characterization of 
insulin glycation in insulin-secreting cells maintained in tissue culture. J Endocrinol, 152, 
59-67. 
ADA 2011. Diagnosis and classification of diabetes mellitus. Diabetes Care, 34 Suppl 1, S62-9. 
ADAMS, R. J., APPLETON, S. L., HILL, C. L., WILSON, D. H., TAYLOR, A. W., CHITTLEBOROUGH, C. R., 
GILL, T. K. & RUFFIN, R. E. 2009. Independent association of HbA(1c) and incident 
cardiovascular disease in people without diabetes. Obesity (Silver Spring), 17, 559-63. 
AGARWAL, M. M., DHATT, G. S., OTHMAN, Y. & LJUBISAVLJEVIC, M. R. 2011. Gestational Diabetes: 
An Evaluation of Serum Fructosamine as a Screening Test in a High-Risk Population. 
Gynecologic and Obstetric Investigation, 71, 207-212. 
AHMAD, M. S., PISCHETSRIEDER, M. & AHMED, N. 2007. Aged garlic extract and S-allyl cysteine 
prevent formation of advanced glycation endproducts. Eur J Pharmacol, 561, 32-8. 
AHMED, M. U., THORPE, S. R. & BAYNES, J. W. 1986. Identification of N-Epsilon-
Carboxymethyllysine as a Degradation Product of Fructoselysine in Glycated Protein. 
Journal of Biological Chemistry, 261, 4889-4894. 
AHMED, N., BABAEI-JADIDI, R., HOWELL, S. K., THORNALLEY, P. J. & BEISSWENGER, P. J. 2005. 
Glycated and Oxidized Protein Degradation Products Are Indicators of Fasting and 
Postprandial Hyperglycemia in Diabetes. Diabetes Care, 28, 2465-2471. 
AHMED, N. & THORNALLEY, P. J. 2002. Chromatographic assay of glycation adducts in human 
serum albumin glycated in vitro by derivatization with 6-aminoquinolyl-N-
hydroxysuccinimidyl-carbamate and intrinsic fluorescence. Biochem J, 364, 15-24. 
AIMUKHAMETOVA, G., UKYBASOVA, T., HAMIDULLINA, Z., ZHUBANYSHEVA, K., HARUN-OR-
RASHID, M., YOSHIDA, Y., KASUYA, H. & SAKAMOTO, J. 2012. The impact of maternal 
obesity on mother and neonatal health: study in a tertiary hospital of Astana, Kazakhstan. 
Nagoya J Med Sci, 74, 83-92. 
ALBERG, A. 2002. The influence of cigarette smoking on circulating concentrations of antioxidant 
micronutrients. Toxicology, 180, 121-37. 
ALTER, D. A., WIJEYSUNDERA, H. C., FRANKLIN, B., AUSTIN, P. C., CHONG, A., OH, P. I., TU, J. V. & 
STUKEL, T. A. 2012. Obesity, lifestyle risk-factors, and health service outcomes among 
healthy middle-aged adults in Canada. BMC Health Serv Res, 12, 238. 
AMADORI, M. 1931. Atti R. Acad. Nuz. Lincei Mem. Cl. Scr. Fic. Mat. Nut, 13, 72. 
AMERICAN DIABETES, A. 2000. Screening for type 2 diabetes. Diabetes Care, 23 Suppl 1, S20-3. 
AMERICAN DIABETES, A. 2011. Diagnosis and classification of diabetes mellitus. Diabetes Care, 34 
Suppl 1, S62-9. 
AMERICAN DIABETES, A., EUROPEAN ASSOCIATION FOR THE STUDY OF, D., INTERNATIONAL 
FEDERATION OF CLINICAL, C., LABORATORY, M. & INTERNATIONAL DIABETES, F. 2007. 
Consensus statement on the worldwide standardisation of the HbA1c measurement. 
Diabetologia, 50, 2042-3. 
ANDERSON, S. S., TSILIBARY, E. C. & CHARONIS, A. S. 1993. Nonenzymatic Glycosylation-Induced 
Modifications of Intact Bovine Kidney Tubular Basement-Membrane. Journal of Clinical 
Investigation, 92, 3045-3052. 
ANONYMOUS 1995. The relationship of glycemic exposure (HbA1c) to the risk of development 
and progression of retinopathy in the diabetes control and complications trial. Diabetes, 
44, 968-83. 
AOKI, H., NAGAO, J., UEDA, T., STRONG, J. M., SCHONLAU, F., YU-JING, S., LU, Y. & HORIE, S. 2012. 
Clinical assessment of a supplement of Pycnogenol(R) and L-arginine in Japanese patients 
with mild to moderate erectile dysfunction. Phytother Res, 26, 204-7. 
AOS, A. O. S. 2013. Smoking statistics  
109 
 
ARGÜELLES, S., MACHADO, M. J., AYALA, A., MACHADO, A. & HERVÍAS, B. 2006. Correlation 
between circulating biomarkers of oxidative stress of maternal and umbilical cord blood 
at birth. Free Radical Research, 40, 565-570. 
AUSTIN, G. E., MULLINS, R. H. & MORIN, L. G. 1987. Non-enzymic glycation of individual plasma 
proteins in normoglycemic and hyperglycemic patients. Clin Chem, 33, 2220-4. 
BAETEN, J. M., BUKUSI, E. A. & LAMBE, M. 2001. Pregnancy complications and outcomes among 
overweight and obese nulliparous women. American Journal of Public Health, 91, 436-
440. 
BAILEY, A. J., SIMS, T. J., AVERY, N. C. & MILES, C. A. 1993. Chemistry of collagen cross-links: 
glucose-mediated covalent cross-linking of type-IV collagen in lens capsules. Biochem J, 
296 ( Pt 2), 489-96. 
BAKER, J. R., ZYZAK, D. V., THORPE, S. R. & BAYNES, J. W. 1993. Mechanism of fructosamine assay: 
evidence against role of superoxide as intermediate in nitroblue tetrazolium reduction. 
Clin Chem, 39, 2460-5. 
BANINI, A. E., BOYD, L. C., ALLEN, J. C., ALLEN, H. G. & SAULS, D. L. 2006. Muscadine grape 
products intake, diet and blood constituents of non-diabetic and type 2 diabetic subjects. 
Nutrition, 22, 1137-45. 
BARNABY, O. S., CERNY, R. L., CLARKE, W. & HAGE, D. S. 2011. Quantitative analysis of glycation 
patterns in human serum albumin using 16O/18O-labeling and MALDI-TOF MS. Clin Chim 
Acta, 412, 1606-15. 
BARR, E. L., BOYKO, E. J., ZIMMET, P. Z., WOLFE, R., TONKIN, A. M. & SHAW, J. E. 2009. Continuous 
relationships between non-diabetic hyperglycaemia and both cardiovascular disease and 
all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study. 
Diabetologia, 52, 415-24. 
BARTH, S. W., KOCH, T. C., WATZL, B., DIETRICH, H., WILL, F. & BUB, A. 2012. Moderate effects of 
apple juice consumption on obesity-related markers in obese men: impact of diet-gene 
interaction on body fat content. Eur J Nutr, 51, 841-50. 
BASIOTIS, P. P., WELSH, S. O., CRONIN, F. J., KELSAY, J. L. & MERTZ, W. 1987. Number of days of 
food intake records required to estimate individual and group nutrient intakes with 
defined confidence. J Nutr, 117, 1638-41. 
BASTA, G., SCHMIDT, A. M. & DE CATERINA, R. 2004. Advanced glycation end products and 
vascular inflammation: implications for accelerated atherosclerosis in diabetes. 
Cardiovasc Res, 63, 582-92. 
BASTEK, J. A., BROWN, A. G., FOREMAN, M. N., MCSHEA, M. A., ANGLIM, L. M., ADAMCZAK, J. E. & 
ELOVITZ, M. A. 2012. The soluble receptor for advanced glycation end products can 
prospectively identify patients at greatest risk for preterm birth. Journal of Maternal-Fetal 
& Neonatal Medicine, 25, 1762-1768. 
BASTYR, E. J., STUART, C. A., BRODOWS, R. G., SCHWARTZ, S., GRAF, C. J., ZAGAR, A., ROBERTSON, 
K. E. & GRP, I. S. 2000. Therapy focused on lowering postprandial glucose, not fasting 
glucose, may be superior for lowering HbA(1c). Diabetes Care, 23, 1236-1241. 
BASU, A., NEWMAN, E. D., BRYANT, A. L., LYONS, T. J. & BETTS, N. M. 2013. Pomegranate 
polyphenols lower lipid peroxidation in adults with type 2 diabetes but have no effects in 
healthy volunteers: a pilot study. J Nutr Metab, 2013, 708381. 
BATES, C. J., LEAN, M. E., MANSOOR, M. A. & PRENTICE, A. 2004. Nutrient intakes; biochemical 
and risk indices associated with Type 2 diabetes and glycosylated haemoglobin, in the 
British National Diet and Nutrition Survey of people aged 65 years and over. Diabet Med, 
21, 677-84. 
BAYNES, J. W. 1991. Role of Oxidative Stress in Development of Complications in Diabetes. 
Diabetes, 40, 405-412. 
BAYNES, J. W. 2002. The Maillard hypothesis on aging: time to focus on DNA. Ann N Y Acad Sci, 
959, 360-7. 
BEISSWENGER, P. J., HOWELL, S. K., O’DELL, R. M., WOOD, M. E., TOUCHETTE, A. D. & 
SZWERGOLD, B. S. 2001. α-Dicarbonyls Increase in the Postprandial Period and Reflect the 
Degree of Hyperglycemia. Diabetes Care, 24, 726-732. 
110 
 
BENZIE, I. F. & STRAIN, J. J. 1996. The ferric reducing ability of plasma (FRAP) as a measure of 
"antioxidant power": the FRAP assay. Anal Biochem, 239, 70-6. 
BERROU, J., TOSTIVINT, I., VERRECCHIA, F., BERTHIER, C., BOULANGER, E., MAUVIEL, A., MARTI, H. 
P., WAUTIER, M. P., WAUTIER, J. L., RONDEAU, E. & HERTIG, A. 2009. Advanced glycation 
end products regulate extracellular matrix protein and protease expression by human 
glomerular mesangial cells. Int J Mol Med, 23, 513-20. 
BHAGWAT, S. A., HAYTOWITZ, D.B., HOLDEN, J.M. 2013. USDA database for the flavonoid content 
of selected foods, Release 3.1. USA: USDA. 
BIESALSKI, H. K. 2007. Polyphenols and inflammation: basic interactions. Curr Opin Clin Nutr 
Metab Care, 10, 724-8. 
BIESALSKI, H. K., GRUNE, T., TINZ, J., ZOLLNER, I. & BLUMBERG, J. B. 2010. Reexamination of a 
meta-analysis of the effect of antioxidant supplementation on mortality and health in 
randomized trials. Nutrients, 2, 929-49. 
BIXBY, M., SPIELER, L., MENINI, T. & GUGLIUCCI, A. 2005. Ilex paraguariensis extracts are potent 
inhibitors of nitrosative stress: a comparative study with green tea and wines using a 
protein nitration model and mammalian cell cytotoxicity. Life Sci, 77, 345-58. 
BLACKBURN, G. 1995. Effect of Degree of Weight Loss on Health Benefits. Obesity Research, 3, 
211s-216s. 
BLAKE, G. J., PRADHAN, A. D., MANSON, J. E., WILLIAMS, G. R., BURING, J., RIDKER, P. M. & 
GLYNN, R. J. 2004. Hemoglobin A(1c) level and future cardiovascular events among 
women. Archives of Internal Medicine, 164, 757-761. 
BLOCK, G., DIETRICH, M., NORKUS, E. P., MORROW, J. D., HUDES, M., CAAN, B. & PACKER, L. 2002. 
Factors Associated with Oxidative Stress in Human Populations. American Journal of 
Epidemiology, 156, 274-285. 
BOBBINK, I. W., DE BOER, H. C., TEKELENBURG, W. L., BANGA, J. D. & DE GROOT, P. G. 1997. Effect 
of extracellular matrix glycation on endothelial cell adhesion and spreading: involvement 
of vitronectin. Diabetes, 46, 87-93. 
BOEING, H., WEISGERBER, U. M., JECKEL, A., ROSE, H. J. & KROKE, A. 2000. Association between 
glycated hemoglobin and diet and other lifestyle factors in a nondiabetic population: 
cross-sectional evaluation of data from the Potsdam cohort of the European Prospective 
Investigation into Cancer and Nutrition Study. Am J Clin Nutr, 71, 1115-22. 
BONDIA-PONS, I., RYAN, L. & MARTINEZ, J. A. 2012. Oxidative stress and inflammation 
interactions in human obesity. Journal of Physiology and Biochemistry, 68, 701-711. 
BONETTI, T. C., BORGES, E., JR., BRAGA, D. P., IACONELLI, A., JR., KLEINE, J. P. & SILVA, I. D. 2013. 
Intrafollicular soluble receptor for advanced glycation end products (sRAGE) and embryo 
quality in assisted reproduction. Reprod Biomed Online, 26, 62-7. 
BONORA, E. & TUOMILEHTO, J. 2011. The Pros and Cons of Diagnosing Diabetes With A1C. 
Diabetes Care, 34, S184-S190. 
BOOTH, A. A., KHALIFAH, R. G., TODD, P. & HUDSON, B. G. 1997. In vitro kinetic studies of 
formation of antigenic advanced glycation end products (AGEs) - Novel inhibition of post-
Amadori glycation pathways. Journal of Biological Chemistry, 272, 5430-5437. 
BOURDON, E., LOREAU, N. & BLACHE, D. 1999. Glucose and free radicals impair the antioxidant 
properties of serum albumin. The FASEB Journal, 13, 233-244. 
BOUSOVA, I., MARTIN, J., JAHODAR, L., DUSEK, J., PALICKA, V. & DRSATA, J. 2005. Evaluation of in 
vitro effects of natural substances of plant origin using a model of protein glycoxidation. 
Journal of Pharmaceutical and Biomedical Analysis, 37, 957-962. 
BOUTZIOS, G., LIVADAS, S., PIPERI, C., VITORATOS, N., ADAMOPOULOS, C., HASSIAKOS, D., 
IAVAZZO, C. & DIAMANTI-KANDARAKIS, E. 2013. Polycystic ovary syndrome offspring 
display increased oxidative stress markers comparable to gestational diabetes offspring. 
Fertil Steril, 99, 943-50. 
BOYLE, S. P., DOBSON, V. L., DUTHIE, S. J., HINSELWOOD, D. C., KYLE, J. A. M. & COLLINS, A. R. 
2000. Bioavailability and efficiency of rutin as an antioxidant: a human supplementation 
study. European Journal of Clinical Nutrition, 54, 774-782. 
111 
 
BRAAM, L. A. J. L. M., OCKÉ, M. C., BUENO-DE-MESQUITA, H. B. & SEIDELL, J. C. 1998. 
Determinants of Obesity-related Underreporting of Energy Intake. American Journal of 
Epidemiology, 147, 1081-1086. 
BREWER, N., WRIGHT, C. S., TRAVIER, N., CUNNINGHAM, C. W., HORNELL, J., PEARCE, N. & 
JEFFREYS, M. 2008. A New Zealand linkage study examining the associations between A1C 
concentration and mortality. Diabetes Care, 31, 1144-9. 
BRIGGS, A. D. M., MIZDRAK, A. & SCARBOROUGH, P. 2013. A statin a day keeps the doctor away: 
comparative proverb assessment modelling study. BMJ, 347. 
BRILEY, A. L., BARR, S., BADGER, S., BELL, R., CROKER, H., GODFREY, K. M., HOLMES, B., 
KINNUNEN, T. I., NELSON, S. M., OTENG-NTIM, E., PATEL, N., ROBSON, S. C., SANDALL, J., 
SANDERS, T., SATTAR, N., SEED, P. T., WARDLE, J. & POSTON, L. 2014. A complex 
intervention to improve pregnancy outcome in obese women; the UPBEAT randomised 
controlled trial. BMC Pregnancy Childbirth, 14, 74. 
BRILEY, A. L., HOLMES, B., KINNUNEN, T. I., CROKER, H., BELL, R., SANDERS, T., WARDLE, J., 
SANDALL, J., ROBSON, S., SATTAR, N., POSTON, L., NELSON, S. & BARR, S. 2011. 
Development of a Complex Intervention To Improve Outcome in Obese Pregnancies; the 
UPBEAT Protocol. Reproductive Sciences, 18, 143a-143a. 
BROMLEY C, B. P., GIVEN L, EDS. The Scottish Health Survey 2008. Edinburgh:The Scottish 
Government,2009. 
BROMLEY C, S. K., SHELTON N, EDS. The Scottish Health Survey 2003. Edinburgh:The Scottish 
Executive,2005. 
BROWN, A. L., LANE, J., COVERLY, J., STOCKS, J., JACKSON, S., STEPHEN, A., BLUCK, L., COWARD, A. 
& HENDRICKX, H. 2009. Effects of dietary supplementation with the green tea polyphenol 
epigallocatechin-3-gallate on insulin resistance and associated metabolic risk factors: 
randomized controlled trial. Br J Nutr, 101, 886-94. 
BROWNLEE, M., CERAMI, A. & VLASSARA, H. 1988. Advanced Products of Nonenzymatic 
Glycosylation and the Pathogenesis of Diabetic Vascular-Disease. Diabetes-Metabolism 
Reviews, 4, 437-451. 
BROWNLEE, M., VLASSARA, H., KOONEY, A., ULRICH, P. & CERAMI, A. 1986. Aminoguanidine 
prevents diabetes-induced arterial wall protein cross-linking. Science, 232, 1629-32. 
BUONOCORE, G., PERRONE, S., LONGINI, M., TERZUOLI, L. & BRACCI, R. 2000. Total hydroperoxide 
and advanced oxidation protein products in preterm hypoxic babies. Pediatr Res, 47, 221-
4. 
BUZZARD, I. M., FAUCETT, C. L., JEFFERY, R. W., MCBANE, L., MCGOVERN, P., BAXTER, J. S., 
SHAPIRO, A. C., BLACKBURN, G. L., CHLEBOWSKI, R. T., ELASHOFF, R. M. & WYNDER, E. L. 
1996. Monitoring Dietary Change in a Low-Fat Diet Intervention Study: Advantages of 
Using 24-Hour Dietary Recalls vs Food Records. Journal of the American Dietetic 
Association, 96, 574-579. 
CAI, W., HE, J. C., ZHU, L., CHEN, X., WALLENSTEIN, S., STRIKER, G. E. & VLASSARA, H. 2007. 
Reduced oxidant stress and extended lifespan in mice exposed to a low glycotoxin diet: 
association with increased AGER1 expression. Am J Pathol, 170, 1893-902. 
CAI, W., HE, J. C., ZHU, L., CHEN, X., ZHENG, F., STRIKER, G. E. & VLASSARA, H. 2008. Oral 
glycotoxins determine the effects of calorie restriction on oxidant stress, age-related 
diseases, and lifespan. Am J Pathol, 173, 327-36. 
CAMARGO, J. L., STIFFT, J. & GROSS, J. L. 2006. The effect of aspirin and vitamins C and E on 
HbA1c assays. Clin Chim Acta, 372, 206-9. 
CAPEILLERE-BLANDIN, C., GAUSSON, V., DESCAMPS-LATSCHA, B. & WITKO-SARSAT, V. 2004. 
Biochemical and spectrophotometric significance of advanced oxidized protein products. 
Biochim Biophys Acta, 1689, 91-102. 
CATALANO, P. M., PRESLEY, L., MINIUM, J. & HAUGUEL-DE MOUZON, S. 2009. Fetuses of Obese 
Mothers Develop Insulin Resistance in Utero. Diabetes Care, 32, 1076-1080. 
CELEC, P., HODOSY, J., PALFFY, R., GARDLIK, R., HALCAK, L. & OSTATNIKOVA, D. 2013. The short-
term effects of soybean intake on oxidative and carbonyl stress in men and women. 
Molecules, 18, 5190-200. 
112 
 
CERAMI, C., FOUNDS, H., NICHOLL, I., MITSUHASHI, T., GIORDANO, D., VANPATTEN, S., LEE, A., 
ALABED, Y., VLASSARA, H., BUCALA, R. & CERAMI, A. 1997. Tobacco smoke is a source of 
toxic reactive glycation products. Proceedings of the National Academy of Sciences of the 
United States of America, 94, 13915-13920. 
CERVATO, G., CARABELLI, M., GERVASIO, S., CITTERA, A., CAZZOLA, R. & CESTARO, B. 2000. 
ANTIOXBDANT PROPERTIES OF OREGANO (ORIGANUM VULGARE) LEAF EXTRACTS. Journal 
of Food Biochemistry, 24, 453-465. 
CHANDLER, D., WOLDU, A., RAHMADI, A., SHANMUGAM, K., STEINER, N., WRIGHT, E., 
BENAVENTE-GARCIA, O., SCHULZ, O., CASTILLO, J. & MUNCH, G. 2010. Effects of plant-
derived polyphenols on TNF-alpha and nitric oxide production induced by advanced 
glycation endproducts. Mol Nutr Food Res, 54 Suppl 2, S141-50. 
CHEN, C.-Y., ABELL, A. M., MOON, Y. S. & KIM, K.-H. 2012. An Advanced Glycation End Product 
(AGE)-Receptor for AGEs (RAGE) Axis Restores Adipogenic Potential of Senescent 
Preadipocytes through Modulation of p53 Protein Function. Journal of Biological 
Chemistry, 287, 44498-44507. 
CHEN, L.-H., ZHU, W.-F., LIANG, L., YANG, X.-Z., WANG, C.-L., ZHU, Y.-R. & FU, J.-F. 2014. 
Relationship between glycated haemoglobin and subclinical atherosclerosis in obese 
children and adolescents. Archives of Disease in Childhood, 99, 39-45. 
CHENG, H. H., LAI, M. H., HOU, W. C. & HUANG, C. L. 2004. Antioxidant effects of chromium 
supplementation with type 2 diabetes mellitus and euglycemic subjects. J Agric Food 
Chem, 52, 1385-9. 
CHESNE, S., RONDEAU, P., ARMENTA, S. & BOURDON, E. 2006. Effects of oxidative modifications 
induced by the glycation of bovine serum albumin on its structure and on cultured 
adipose cells. Biochimie, 88, 1467-77. 
CHETYRKIN, S., MATHIS, M., PEDCHENKO, V., SANCHEZ, O. A., MCDONALD, W. H., HACHEY, D. L., 
MADU, H., STEC, D., HUDSON, B. & VOZIYAN, P. 2011. Glucose Autoxidation Induces 
Functional Damage to Proteins via Modification of Critical Arginine Residues. 
Biochemistry, 50, 6102-6112. 
CHO, Y.-Y., BAEK, N.-I., CHUNG, H.-G., JEONG, T.-S., LEE, K. T., JEON, S.-M., KIM, H.-J., MCGREGOR, 
R. A. & CHOI, M.-S. 2012. Randomized controlled trial of Sajabalssuk (Artemisia princeps 
Pampanini) to treat pre-diabetes. European Journal of Integrative Medicine, 4, e299-e308. 
CHOI, S. Y., JUNG, S. H., LEE, H. S., PARK, K. W., YUN, B. S. & LEE, K. W. 2008. Glycation inhibitory 
activity and the identification of an active compound in Plantago asiatica extract. 
Phytotherapy Research, 22, 323-329. 
CHOWDHURY, T. A. & LASKER, S. S. 1998. Elevated glycated haemoglobin in non-diabetic patients 
is associated with an increased mortality in myocardial infarction. Postgraduate Medical 
Journal, 74, 480-481. 
CHU, S. Y., KIM, S. Y., SCHMID, C. H., DIETZ, P. M., CALLAGHAN, W. M., LAU, J. & CURTIS, K. M. 
2007. Maternal obesity and risk of cesarean delivery: a meta-analysis. Obesity Reviews, 8, 
385-394. 
CHUGH, S. S., WALLNER, E. I. & KANWAR, Y. S. 2003. Renal development in high-glucose ambience 
and diabetic embryopathy. Semin Nephrol, 23, 583-92. 
CICERO, A. F. G., NASCETTI, S., LOPEZ-SABATER, M. C., ELOSUA, R., SALONEN, J. T., NYYSSONEN, K., 
POULSEN, H. E., ZUNFT, H. J. F., KIESEWETTER, H., DE LA TORRE, K., COVAS, M. I., 
KAIKKONEN, J., MURSU, J., KOENBICK, C., BAUMLER, H., GADDI, A. V. & GRP, E. S. 2008. 
Changes in LDL fatty acid composition as a response to olive oil treatment are inversely 
related to lipid oxidative damage: The EUROLIVE study. Journal of the American College of 
Nutrition, 27, 314-320. 
CLAIR, C., BITTON, A., MEIGS, J. B. & RIGOTTI, N. A. 2011. Relationships of Cotinine and Self-
Reported Cigarette Smoking With Hemoglobin A(1c) in the US. Diabetes Care, 34, 2250-
2255. 
CODOÑER-FRANCH, P., TAVÁREZ-ALONSO, S., MURRIA-ESTAL, R., TORTAJADA-GIRBÉS, M., SIMÓ-
JORDÁ, R. & ALONSO-IGLESIAS, E. 2012. Elevated advanced oxidation protein products 
113 
 
(AOPPs) indicate metabolic risk in severely obese children. Nutrition, Metabolism and 
Cardiovascular Diseases, 22, 237-243. 
COOKE, C. L., BROCKELSBY, J. C., BAKER, P. N. & DAVIDGE, S. T. 2003. The receptor for advanced 
glycation end products (RAGE) is elevated in women with preeclampsia. Hypertens 
Pregnancy, 22, 173-84. 
COOPER, A. J., FOROUHI, N. G., YE, Z., BUIJSSE, B., ARRIOLA, L., BALKAU, B., BARRICARTE, A., 
BEULENS, J. W., BOEING, H., BUCHNER, F. L., DAHM, C. C., DE LAUZON-GUILLAIN, B., 
FAGHERAZZI, G., FRANKS, P. W., GONZALEZ, C., GRIONI, S., KAAKS, R., KEY, T. J., MASALA, 
G., NAVARRO, C., NILSSON, P., OVERVAD, K., PANICO, S., RAMON QUIROS, J., 
ROLANDSSON, O., ROSWALL, N., SACERDOTE, C., SANCHEZ, M. J., SLIMANI, N., SLUIJS, I., 
SPIJKERMAN, A. M., TEUCHER, B., TJONNELAND, A., TUMINO, R., SHARP, S. J., 
LANGENBERG, C., FESKENS, E. J., RIBOLI, E., WAREHAM, N. J. & INTERACT, C. 2012. Fruit 
and vegetable intake and type 2 diabetes: EPIC-InterAct prospective study and meta-
analysis. Eur J Clin Nutr, 66, 1082-92. 
COSTA, V., QUINTANILHA, A. & MORADAS-FERREIRA, P. 2007. Protein oxidation, repair 
mechanisms and proteolysis in Saccharomyces cerevisiae. IUBMB Life, 59, 293-8. 
COUGHLAN, M. T., THORBURN, D. R., PENFOLD, S. A., LASKOWSKI, A., HARCOURT, B. E., SOURRIS, 
K. C., TAN, A. L., FUKAMI, K., THALLAS-BONKE, V., NAWROTH, P. P., BROWNLEE, M., 
BIERHAUS, A., COOPER, M. E. & FORBES, J. M. 2009. RAGE-induced cytosolic ROS promote 
mitochondrial superoxide generation in diabetes. J Am Soc Nephrol, 20, 742-52. 
CREAGER, M. A., LÜSCHER, T. F., OF, P. W. T. A., COSENTINO, F. & BECKMAN, J. A. 2003. Diabetes 
and Vascular Disease: Pathophysiology, Clinical Consequences, and Medical Therapy: Part 
I. Circulation, 108, 1527-1532. 
CROZIER, A., JAGANATH, I. B. & CLIFFORD, M. N. 2009. Dietary phenolics: chemistry, bioavailability 
and effects on health. Natural Product Reports, 26, 1001-1043. 
DAI, J., JONES, D. P., GOLDBERG, J., ZIEGLER, T. R., BOSTICK, R. M., WILSON, P. W., MANATUNGA, 
A. K., SHALLENBERGER, L., JONES, L. & VACCARINO, V. 2008. Association between 
adherence to the Mediterranean diet and oxidative stress. Am J Clin Nutr, 88, 1364-70. 
DAIPONMAK, W., SENAKUN, C. & SIRIAMORNPUN, S. 2014. Antiglycation capacity and antioxidant 
activities of different pigmented Thai rice. International Journal of Food Science & 
Technology, n/a-n/a. 
DALLAS, C., GERBI, A., ELBEZ, Y., CAILLARD, P., ZAMARIA, N. & CLOAREC, M. 2013. Clinical Study to 
Assess the Efficacy and Safety of a Citrus Polyphenolic Extract of Red Orange, Grapefruit, 
and Orange (Sinetrol-XPur) on Weight Management and Metabolic Parameters in Healthy 
Overweight Individuals. Phytother Res. 
DALLE-DONNE, I., ROSSI, R., COLOMBO, R., GIUSTARINI, D. & MILZANI, A. 2006. Biomarkers of 
Oxidative Damage in Human Disease. Clinical Chemistry, 52, 601-623. 
DARNELL, H. L., ARNOLD, B., ZIPURSKY, S. L., PAUL, M., DAVID, B. & JAMES 2000. Protein 
Glycosylation in the ER and Golgi Complex. W. H. Freeman. 
DAVIE, S. J., GOULD, B. J. & YUDKIN, J. S. 1992. Effect of vitamin C on glycosylation of proteins. 
Diabetes, 41, 167-73. 
DE LA MAZA, M. P., URIBARRI, J., OLIVARES, D., HIRSCH, S., LEIVA, L., BARRERA, G. & BUNOUT, D. 
2008. Weight increase is associated with skeletal muscle immunostaining for advanced 
glycation end products, receptor for advanced glycation end products, and oxidation 
injury. Rejuvenation Res, 11, 1041-8. 
DE LUSIGNAN, S., SADEK, N., MULNIER, H., TAHIR, A., RUSSELL-JONES, D. & KHUNTI, K. 2012. 
Miscoding, misclassification and misdiagnosis of diabetes in primary care. Diabetic 
Medicine, 29, 181-189. 
DE VEGT, F., DEKKER, J. M., RUHE, H. G., STEHOUWER, C. D. A., NIJPELS, G., BOUTER, L. M. & 
HEINE, R. J. 1999. Hyperglycaemia is associated with all-cause and cardiovascular 
mortality in the Hoorn population: the Hoorn Study. Diabetologia, 42, 926-931. 
DE VRIES, J. H., HOLLMAN, P. C., MEYBOOM, S., BUYSMAN, M. N., ZOCK, P. L., VAN STAVEREN, W. 
A. & KATAN, M. B. 1998. Plasma concentrations and urinary excretion of the antioxidant 
114 
 
flavonols quercetin and kaempferol as biomarkers for dietary intake. The American 
Journal of Clinical Nutrition, 68, 60-5. 
DEGROOT, J. 2004. Advanced glycation endproducts in the development of osteoarthritis. Annals 
of the Rheumatic Diseases, 63, 31-31. 
DEL RIO, D., COSTA, L. G., LEAN, M. E. & CROZIER, A. 2010. Polyphenols and health: what 
compounds are involved? Nutr Metab Cardiovasc Dis, 20, 1-6. 
DELPIERRE, G., COLLARD, F., FORTPIED, J. & VAN SCHAFTINGEN, E. 2002. Fructosamine 3-kinase is 
involved in an intracellular deglycation pathway in human erythrocytes. Biochemical 
Journal, 365, 801-808. 
DELPIERRE, G., RIDER, M. H., COLLARD, F., STROOBANT, V., VANSTAPEL, F., SANTOS, H. & VAN 
SCHAFTINGEN, E. 2000. Identification, cloning, and heterologous expression of a 
mammalian fructosamine-3-kinase. Diabetes, 49, 1627-34. 
DEN ENGELSEN, C., VAN DEN DONK, M., GORTER, K. J., SALOME, P. L. & RUTTEN, G. E. 2012. 
Advanced glycation end products measured by skin autofluorescence in a population with 
central obesity. Dermatoendocrinol, 4, 33-8. 
DEO, P., GLENN, J. V., POWELL, L. A., STITT, A. W. & AMES, J. M. 2009. Upregulation of oxidative 
stress markers in human microvascular endothelial cells by complexes of serum albumin 
and digestion products of glycated casein. J Biochem Mol Toxicol, 23, 364-72. 
DIAMANTI-KANDARAKIS, E., PIPERI, C., PATSOURIS, E., KORKOLOPOULOU, P., PANIDIS, D., 
PAWELCZYK, L., PAPAVASSILIOU, A. G. & DULEBA, A. J. 2007. Immunohistochemical 
localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in 
polycystic and normal ovaries. Histochem Cell Biol, 127, 581-9. 
DORSEY, P. G. & GREENSPAN, P. 2014. Inhibition of Nonenzymatic Protein Glycation by 
Pomegranate and Other Fruit Juices. J Med Food. 
DUNCAN, B. B., SCHMIDT, M. I., PANKOW, J. S., BALLANTYNE, C. M., COUPER, D., VIGO, A., 
HOOGEVEEN, R., FOLSOM, A. R. & HEISS, G. 2003. Low-Grade Systemic Inflammation and 
the Development of Type 2 Diabetes: The Atherosclerosis Risk in Communities Study. 
Diabetes, 52, 1799-1805. 
DURAN-JIMENEZ, B., DOBLER, D., MOFFATT, S., RABBANI, N., STREULI, C. H., THORNALLEY, P. J., 
TOMLINSON, D. R. & GARDINER, N. J. 2009. Advanced glycation end products in 
extracellular matrix proteins contribute to the failure of sensory nerve regeneration in 
diabetes. Diabetes, 58, 2893-903. 
EDWARDS, B. K., WARD, E., KOHLER, B. A., EHEMAN, C., ZAUBER, A. G., ANDERSON, R. N., JEMAL, 
A., SCHYMURA, M. J., LANSDORP-VOGELAAR, I., SEEFF, L. C., VAN BALLEGOOIJEN, M., 
GOEDE, S. L. & RIES, L. A. G. 2010. Annual report to the nation on the status of cancer, 
1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, 
screening, and treatment) to reduce future rates. Cancer, 116, 544-573. 
EL-SALEM, K., AMMARI, F., KHADER, Y. & DHAIMAT, O. 2007. Elevated glycosylated hemoglobin is 
associated with subclinical neuropathy in neurologically asymptomatic type-2 diabetic 
patients: A prospective study. European Journal of Neurology, 14, 251-251. 
ESPOSITO, K., DI PALO, C., MAIORINO, M. I., PETRIZZO, M., BELLASTELLA, G., SINISCALCHI, I. & 
GIUGLIANO, D. 2011. Long-term effect of mediterranean-style diet and calorie restriction 
on biomarkers of longevity and oxidative stress in overweight men. Cardiol Res Pract, 
2011, 293916. 
EVANS M., S. P. A. G. N. 2012. Bioavailability of Citrus Polymethoxylated Flavones and Their 
Biological Role in Metabolic Syndrome and Hyperlipidemia. In: NOREDDIN, D. A. (ed.) 
Readings in Advanced Pharmacokinetics - Theory, Methods and Applications. InTech. 
FAGARD, R. H. & NILSSON, P. M. 2009. Smoking and diabetes--the double health hazard! Prim 
Care Diabetes, 3, 205-9. 
FESTA, A., D'AGOSTINO, R., WILLIAMS, K., KARTER, A. J., MAYER-DAVIS, E. J., TRACY, R. P. & 
HAFFNER, S. M. 2001. The relation of body fat mass and distribution to markers of chronic 
inflammation. International journal of obesity and related metabolic disorders : journal of 
the International Association for the Study of Obesity, 25, 1407-1415. 
115 
 
FIALOVA, L., MALBOHAN, I., KALOUSOVA, M., SOUKUPOVA, J., KROFTA, L., STIPEK, S. & ZIMA, T. 
2006. Oxidative stress and inflammation in pregnancy. Scand J Clin Lab Invest, 66, 121-7. 
FINESCHI, S., DE CUNTO, G., FACCHINETTI, F., CIVELLI, M., IMBIMBO, B. P., CARNINI, C., VILLETTI, 
G., LUNGHI, B., STOCHINO, S., GIBBONS, D. L., HAYDAY, A., LUNGARELLA, G. & CAVARRA, 
E. 2013. Receptor for advanced glycation end products contributes to postnatal 
pulmonary development and adult lung maintenance program in mice. Am J Respir Cell 
Mol Biol, 48, 164-71. 
FOROUHI, N. G., SATTAR, N. & MCKEIGUE, P. M. 2001. Relation of C-reactive protein to body fat 
distribution and features of the metabolic syndrome in Europeans and South Asians. 
International journal of obesity and related metabolic disorders : journal of the 
International Association for the Study of Obesity, 25, 1327-1331. 
FREESE, R., BASU, S., HIETANEN, E., NAIR, J., NAKACHI, K., BARTSCH, H. & MUTANEN, M. 1999. 
Green tea extract decreases plasma malondialdehyde concentration but does not affect 
other indicators of oxidative stress, nitric oxide production, or hemostatic factors during a 
high-linoleic acid diet in healthy females. European Journal of Nutrition, 38, 149-157. 
FREI, B. & HIGDON, J. V. 2003. Antioxidant activity of tea polyphenols in vivo: Evidence from 
animal studies. Journal of Nutrition, 133, 3275s-3284s. 
FREI, B., YAMAMOTO, Y., NICLAS, D. & AMES, B. N. 1988. Evaluation of an isoluminol 
chemiluminescence assay for the detection of hydroperoxides in human blood plasma. 
Anal Biochem, 175, 120-30. 
FRIGUET, B. 2006. Oxidized protein degradation and repair in ageing and oxidative stress. FEBS 
Letters, 580, 2910-2916. 
FRÖHLICH, M., SUND, M., LÖWEL, H., IMHOF, A., HOFFMEISTER, A. & KOENIG, W. 2003. 
Independent association of various smoking characteristics with markers of systemic 
inflammation in men: Results from a representative sample of the general population 
(MONICA Augsburg Survey 1994/95). European Heart Journal, 24, 1365-1372. 
FU, M. X., WELLS-KNECHT, K. J., BLACKLEDGE, J. A., LYONS, T. J., THORPE, S. R. & BAYNES, J. W. 
1994. Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, 
mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes, 43, 676-83. 
FUKINO, Y., IKEDA, A., MARUYAMA, K., AOKI, N., OKUBO, T. & ISO, H. 2008. Randomized 
controlled trial for an effect of green tea-extract powder supplementation on glucose 
abnormalities. Eur J Clin Nutr, 62, 953-60. 
FUKINO, Y., SHIMBO, M., AOKI, N., OKUBO, T. & ISO, H. 2005. Randomized controlled trial for an 
effect of green tea consumption on insulin resistance and inflammation markers. J Nutr 
Sci Vitaminol (Tokyo), 51, 335-42. 
GAENS, K. H., STEHOUWER, C. D. & SCHALKWIJK, C. G. 2013. Advanced glycation endproducts and 
its receptor for advanced glycation endproducts in obesity. Curr Opin Lipidol, 24, 4-11. 
GAENS, K. H. J., NIESSEN, P. M. G., RENSEN, S. S., BUURMAN, W. A., GREVE, J. W. M., DRIESSEN, 
A., WOLFS, M. G. M., HOFKER, M. H., BLOEMEN, J. G., DEJONG, C. H., STEHOUWER, C. D. 
A. & SCHALKWIJK, C. G. 2012. Endogenous formation of Nε-(carboxymethyl)lysine is 
increased in fatty livers and induces inflammatory markers in an in vitro model of hepatic 
steatosis. Journal of hepatology, 56, 647-655. 
GALKINA, E. & LEY, K. 2006. Leukocyte recruitment and vascular injury in diabetic nephropathy. 
Journal of the American Society of Nephrology, 17, 368-377. 
GALTIER-DEREURE, F., BOEGNER, C. & BRINGER, J. 2000. Obesity and pregnancy: complications 
and cost. The American Journal of Clinical Nutrition, 71, 1242s-1248s. 
GERMANOVA, A., KOUCKY, M., HAJEK, Z., PARIZEK, A., ZIMA, T. & KALOUSOVA, M. 2010. Soluble 
receptor for advanced glycation end products in physiological and pathological 
pregnancy. Clin Biochem, 43, 442-6. 
GEROLDI, D., FALCONE, C., EMANUELE, E., D'ANGELO, A., CALCAGNINO, M., BUZZI, M. P., SCIOLI, 
G. A. & FOGARI, R. 2005. Decreased plasma levels of soluble receptor for advanced 
glycation end-products in patients with essential hypertension. J Hypertens, 23, 1725-9. 
GKOGKOLOU, P. & BOHM, M. 2012. Advanced glycation end products: Key players in skin aging? 
Dermatoendocrinol, 4, 259-70. 
116 
 
GOLDBERG, G. R., BLACK, A. E., JEBB, S. A., COLE, T. J., MURGATROYD, P. R., COWARD, W. A. & 
PRENTICE, A. M. 1991. Critical evaluation of energy intake data using fundamental 
principles of energy physiology: 1. Derivation of cut-off limits to identify under-recording. 
Eur J Clin Nutr, 45, 569-81. 
GOLDBERG, T., CAI, W., PEPPA, M., DARDAINE, V., BALIGA, B. S., URIBARRI, J. & VLASSARA, H. 
2004. Advanced glycoxidation end products in commonly consumed foods. Journal of the 
American Dietetic Association, 104, 1287-1291. 
GOLDSTEIN, D. E., LITTLE, R. R., LORENZ, R. A., MALONE, J. I., NATHAN, D., PETERSON, C. M. & 
SACKS, D. B. 2004. Tests of glycemia in diabetes. Diabetes Care, 27, 1761-73. 
GOVERNMENT, T. S. 2008. Better Coronary Heart Disease and Stroke Care - a consultation 
document. 
GRIBBLE, R. K., FEE, S. C. & BERG, R. L. 1995. The value of routine urine dipstick screening for 
protein at each prenatal visit. American Journal of Obstetrics and Gynecology, 173, 214-
217. 
GRIMM, T., SKRABALA, R., CHOVANOVA, Z., MUCHOVA, J., SUMEGOVA, K., LIPTAKOVA, A., 
DURACKOVA, Z. & HOGGER, P. 2006. Single and multiple dose pharmacokinetics of 
maritime pine bark extract (pycnogenol) after oral administration to healthy volunteers. 
BMC Clin Pharmacol, 6, 4. 
GRUNDY, S. M., CLEEMAN, J. I., MERZ, C. N., BREWER, H. B., JR., CLARK, L. T., HUNNINGHAKE, D. 
B., PASTERNAK, R. C., SMITH, S. C., JR. & STONE, N. J. 2004. Implications of recent clinical 
trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. 
Circulation, 110, 227-39. 
GUEDES, S., VITORINO, R., DOMINGUES, R., AMADO, F. & DOMINGUES, P. 2009. Oxidation of 
bovine serum albumin: identification of oxidation products and structural modifications. 
Rapid Commun Mass Spectrom, 23, 2307-15. 
GUERIN-DUBOURG, A., CATAN, A., BOURDON, E. & RONDEAU, P. 2012. Structural modifications of 
human albumin in diabetes. Diabetes Metab, 38, 171-8. 
GUGLIUCCI, A., BASTOS, D. H., SCHULZE, J. & SOUZA, M. F. 2009. Caffeic and chlorogenic acids in 
Ilex paraguariensis extracts are the main inhibitors of AGE generation by methylglyoxal in 
model proteins. Fitoterapia, 80, 339-44. 
GUL, A., RAHMAN, M. A., SALIM, A. & SIMJEE, S. U. 2009. Advanced glycation end products in 
senile diabetic and nondiabetic patients with cataract. J Diabetes Complications, 23, 343-
8. 
GUTIERREZ, R. M. P. 2012. Inhibition of Advanced Glycation End-Product Formation by Origanum 
majorana L. In Vitro and in Streptozotocin-Induced Diabetic Rats. Evidence-Based 
Complementary and Alternative Medicine. 
HAEDERSDAL, S., SALVIG, J. D., AABYE, M., THORBALL, C. W., RUHWALD, M., LADELUND, S., 
EUGEN-OLSEN, J. & SECHER, N. J. 2013. Inflammatory markers in the second trimester 
prior to clinical onset of preeclampsia, intrauterine growth restriction, and spontaneous 
preterm birth. Inflammation, 36, 907-13. 
HALLIWELL, B. 1994. Free radicals, antioxidants, and human disease: curiosity, cause, or 
consequence? The Lancet, 344, 721-724. 
HALLIWELL, B. 2007. Biochemistry of oxidative stress. Biochem Soc Trans, 35, 1147-50. 
HAMMERSTONE, J. F., LAZARUS, S. A. & SCHMITZ, H. H. 2000. Procyanidin content and variation in 
some commonly consumed foods. J Nutr, 130, 2086S-92S. 
HAN, T. S., SATTAR, N. & LEAN, M. 2006. ABC of obesity. Assessment of obesity and its clinical 
implications. BMJ, 333, 695-8. 
HAO, L., NOGUCHI, S., KAMADA, Y., SASAKI, A., MATSUDA, M., SHIMIZU, K., HIRAMATSU, Y. & 
NAKATSUKA, M. 2008. Adverse effects of advanced glycation end products on embryonal 
development. Acta Med Okayama, 62, 93-9. 
HARDING, A.-H., SARGEANT, L. A., WELCH, A., OAKES, S., LUBEN, R. N., BINGHAM, S., DAY, N. E., 
KHAW, K.-T. & WAREHAM, N. J. 2001. Fat Consumption and HbA1c Levels: The EPIC-
Norfolk Study. Diabetes Care, 24, 1911-1916. 
117 
 
HARDING, A. H., DAY, N. E., KHAW, K. T., BINGHAM, S. A., LUBEN, R. N., WELSH, A. & WAREHAM, 
N. J. 2004. Habitual fish consumption and glycated haemoglobin: the EPIC-Norfolk study. 
Eur J Clin Nutr, 58, 277-84. 
HARDING, J. J. & BESWICK, H. T. 1988. The possible contribution of glucose autoxidation to 
protein modification of diabetes. Biochem J, 249, 617-8. 
HARRIS, C., CUERRIER, A., LAMONT, E., HADDAD, P., ARNASON, J., BENNETT, S. L. & JOHNS, T. 
2014. Investigating Wild Berries as a Dietary Approach to Reducing the Formation of 
Advanced Glycation Endproducts: Chemical Correlates of In Vitro Antiglycation Activity. 
Plant Foods for Human Nutrition, 1-7. 
HARRIS, C. S., BEAULIEU, L. P., FRASER, M. H., MCINTYRE, K. L., OWEN, P. L., MARTINEAU, L. C., 
CUERRIER, A., JOHNS, T., HADDAD, P. S., BENNETT, S. A. & ARNASON, J. T. 2011. Inhibition 
of advanced glycation end product formation by medicinal plant extracts correlates with 
phenolic metabolites and antioxidant activity. Planta Med, 77, 196-204. 
HARSEM, N. K., BRAEKKE, K., TORJUSSEN, T., HANSSEN, K. & STAFF, A. C. 2008. Advanced glycation 
end products in pregnancies complicated with diabetes mellitus or preeclampsia. 
Hypertens Pregnancy, 27, 374-86. 
HASHIM, Y. Z., ENG, M., GILL, C. I., MCGLYNN, H. & ROWLAND, I. R. 2005. Components of olive oil 
and chemoprevention of colorectal cancer. Nutr Rev, 63, 374-86. 
HEERWAGEN, M. J. R., MILLER, M. R., BARBOUR, L. A. & FRIEDMAN, J. E. 2010. Maternal obesity 
and fetal metabolic programming: a fertile epigenetic soil. American Journal of Physiology 
- Regulatory, Integrative and Comparative Physiology, 299, R711-R722. 
HEGDE, P., CHANDRAKASAN, G. & CHANDRA, T. 2002. Inhibition of collagen glycation and 
crosslinking in vitro by methanolic extracts of Finger millet (Eleusine coracana) and Kodo 
millet (Paspalum scrobiculatum). Journal of Nutritional Biochemistry, 13, 517. 
HEINRICH, J., VALENTOVA, K., VACEK, J., PALIKOVA, I., ZATLOUKALOVA, M., KOSINA, P., 
ULRICHOVA, J., VRBKOVA, J. & SIMANEK, V. 2013. Metabolic profiling of phenolic acids 
and oxidative stress markers after consumption of Lonicera caerulea L. fruit. J Agric Food 
Chem, 61, 4526-32. 
HENNING, S. M., WANG, P., ABGARYAN, N., VICINANZA, R., DE OLIVEIRA, D. M., ZHANG, Y., LEE, 
R.-P., CARPENTER, C. L., ARONSON, W. J. & HEBER, D. 2013. Phenolic acid concentrations 
in plasma and urine from men consuming green or black tea and potential 
chemopreventive properties for colon cancer. Molecular Nutrition & Food Research, 57, 
483-492. 
HEITMANN, B. L. & LISSNER, L. 1995. Dietary underreporting by obese individuals--is it specific or 
non-specific? Bmj, 311, 986-9. 
HERMSDORFF, H. H., PUCHAU, B., VOLP, A. C., BARBOSA, K. B., BRESSAN, J., ZULET, M. A. & 
MARTINEZ, J. A. 2011. Dietary total antioxidant capacity is inversely related to central 
adiposity as well as to metabolic and oxidative stress markers in healthy young adults. 
Nutr Metab (Lond), 8, 59. 
HESLEHURST, N., ELLS, L. J., SIMPSON, H., BATTERHAM, A., WILKINSON, J. & SUMMERBELL, C. D. 
2007. Trends in maternal obesity incidence rates, demographic predictors, and health 
inequalities in 36,821 women over a 15-year period. Bjog, 114, 187-94. 
HESLEHURST, N., RANKIN, J., WILKINSON, J. R. & SUMMERBELL, C. D. 2010. A nationally 
representative study of maternal obesity in England, UK: trends in incidence and 
demographic inequalities in 619 323 births, 1989-2007. Int J Obes (Lond), 34, 420-8. 
HESLEHURST, N., SIMPSON, H., ELLS, L. J., RANKIN, J., WILKINSON, J., LANG, R., BROWN, T. J. & 
SUMMERBELL, C. D. 2008. The impact of maternal BMI status on pregnancy outcomes 
with immediate short-term obstetric resource implications: a meta-analysis. Obes Rev, 9, 
635-83. 
HIRAMATSU, Y., SHIMIZU, I., OMORI, Y. & NAKABAYASHI, M. 2012. Determination of reference 
intervals of glycated albumin and hemoglobin A1c in healthy pregnant Japanese women 
and analysis of their time courses and influencing factors during pregnancy. Endocr J, 59, 
145-51. 
118 
 
HO, S.-C., CHANG, P.-W., TONG, H.-T. & YU, P.-Y. 2013. Inhibition of Fluorescent Advanced 
Glycation End-Products and N-Carboxymethyllysine Formation by Several Floral Herbal 
Infusions. International Journal of Food Properties, 17, 617-628. 
HODGE, J. E. 1953. Dehydrated Foods - Chemistry of Browning Reactions in Model Systems. 
Journal of Agricultural and Food Chemistry, 1, 928-943. 
HODGE, J. E. 1955. The Amadori rearrangement. Adv Carbohydr Chem, 10, 169-205. 
HODGSON, J. M., CROFT, K. D., MORI, T. A., BURKE, V., BEILIN, L. J. & PUDDEY, I. B. 2002. Regular 
ingestion of tea does not inhibit in vivo lipid peroxidation in humans. Journal of Nutrition, 
132, 55-58. 
HOFMANN, M. A., DRURY, S., FU, C. F., QU, W., TAGUCHI, A., LU, Y., AVILA, C., KAMBHAM, N., 
BIERHAUS, A., NAWROTH, P., NEURATH, M. F., SLATTERY, T., BEACH, D., MCCLARY, J., 
NAGASHIMA, M., MORSER, J., STERN, D. & SCHMIDT, A. M. 1999. RAGE mediates a novel 
proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides. 
Cell, 97, 889-901. 
HOLT, E. M., STEFFEN, L. M., MORAN, A., BASU, S., STEINBERGER, J., ROSS, J. A., HONG, C.-P. & 
SINAIKO, A. R. 2009. Fruit and Vegetable Consumption and Its Relation to Markers of 
Inflammation and Oxidative Stress in Adolescents. Journal of the American Dietetic 
Association, 109, 414-421. 
HOU, T. H., CHUNG, J. P., CHEN, S. S. & CHANG, T. L. 2013. Antioxidation and antiglycation of 95% 
ethanolic extracts prepared from the leaves of black nightshade (Solanum nigrum). Food 
Science and Biotechnology, 22, 839-844. 
HOWARD, G. J. & WEBSTER, T. F. 2013. Contrasting theories of interaction in epidemiology and 
toxicology. Environ Health Perspect, 121, 1-6. 
HSCIC, H. A. S. C. I. C. 2013. Statistics on Obesity, Physical Activity and Diet: England, 2013. 
HU, F. B. 2003. Plant-based foods and prevention of cardiovascular disease: an overview. The 
American Journal of Clinical Nutrition, 78, 544S-551S. 
HUDA, S. S., BRODIE, L. E. & SATTAR, N. 2010. Obesity in pregnancy: prevalence and metabolic 
consequences. Seminars in Fetal and Neonatal Medicine, 15, 70-76. 
HULSMANS, M. & HOLVOET, P. 2010. The vicious circle between oxidative stress and 
inflammation in atherosclerosis. Journal of Cellular and Molecular Medicine, 14, 70-78. 
HUNG, T.-H., LO, L.-M., CHIU, T.-H., LI, M.-J., YEH, Y.-L., CHEN, S.-F. & HSIEH, T. S.-T. A. 2010. A 
Longitudinal Study of Oxidative Stress and Antioxidant Status in Women With 
Uncomplicated Pregnancies Throughout Gestation. Reproductive Sciences, 17, 401-409. 
HUNT, J. V. & WOLFF, S. P. 1991. Oxidative Glycation and Free-Radical Production - a Causal 
Mechanism of Diabetic Complications. Free Radical Research Communications, 12-3, 115-
123. 
HUNTER, S. J., BOYD, A. C., O'HARTE, F. P., MCKILLOP, A. M., WIGGAM, M. I., MOONEY, M. H., 
MCCLUSKEY, J. T., LINDSAY, J. R., ENNIS, C. N., GAMBLE, R., SHERIDAN, B., BARNETT, C. R., 
MCNULTY, H., BELL, P. M. & FLATT, P. R. 2003. Demonstration of glycated insulin in 
human diabetic plasma and decreased biological activity assessed by euglycemic-
hyperinsulinemic clamp technique in humans. Diabetes, 52, 492-8. 
ILCHMANN, A., BURGDORF, S., SCHEURER, S., WAIBLER, Z., NAGAI, R., WELLNER, A., YAMAMOTO, 
Y., YAMAMOTO, H., HENLE, T., KURTS, C., KALINKE, U., VIETHS, S. & TODA, M. 2010. 
Glycation of a food allergen by the Maillard reaction enhances its T-cell immunogenicity: 
role of macrophage scavenger receptor class A type I and II. J Allergy Clin Immunol, 125, 
175-83 e1-11. 
INABA, M., OKUNO, S., KUMEDA, Y., YAMADA, S., IMANISHI, Y., TABATA, T., OKAMURA, M., 
OKADA, S., YAMAKAWA, T., ISHIMURA, E., NISHIZAWA, Y. & GROUP, A. T. O. C. E. R. 2007. 
Glycated Albumin Is a Better Glycemic Indicator than Glycated Hemoglobin Values in 
Hemodialysis Patients with Diabetes: Effect of Anemia and Erythropoietin Injection. 
Journal of the American Society of Nephrology, 18, 896-903. 
ISIK, B., CEYLAN, A. & ISIK, R. 2007. Oxidative stress in smokers and non-smokers. Inhal Toxicol, 19, 
767-9. 
119 
 
ITO, H., LI, P., KOREISHI, M., NAGATOMO, A., NISHIDA, N. & YOSHIDA, T. 2014. Ellagitannin 
oligomers and a neolignan from pomegranate arils and their inhibitory effects on the 
formation of advanced glycation end products. Food Chemistry, 152, 323-330. 
IWASHIMA, Y., ETO, M., HATA, A., KAKU, K., HORIUCHI, S., USHIKUBI, F. & SANO, H. 2000. 
Advanced glycation end products-induced gene expression of scavenger receptors in 
cultured human monocyte-derived macrophages. Biochemical and Biophysical Research 
Communications, 277, 368-380. 
JAIN, S. K. 1998. Glutathione and glucose-6-phosphate dehydrogenase deficiency can increase 
protein glycosylation. Free Radic Biol Med, 24, 197-201. 
JAIN, S. K. & PALMER, M. 1997. The effect of oxygen radicals metabolites and vitamin E on 
glycosylation of proteins. Free Radic Biol Med, 22, 593-6. 
JANDELEIT-DAHM, K., WATSON, A. & SORO-PAAVONEN, A. 2008. The AGE/RAGE axis in diabetes-
accelerated atherosclerosis. Clin Exp Pharmacol Physiol, 35, 329-34. 
JANERO, D. R. 1990. Malondialdehyde and Thiobarbituric Acid-Reactivity as Diagnostic Indexes of 
Lipid-Peroxidation and Peroxidative Tissue-Injury. Free Radical Biology and Medicine, 9, 
515-540. 
JANGA, D., PARISAEI, M. & ERSKINE, K. 2011. Revisiting instrumental vaginal delivery rates in 
obese pregnant women. Archives of Disease in Childhood - Fetal and Neonatal Edition, 96, 
Fa88. 
JENKINS, D. J., KENDALL, C. W., AUGUSTIN, L. S., FRANCESCHI, S., HAMIDI, M., MARCHIE, A., 
JENKINS, A. L. & AXELSEN, M. 2002. Glycemic index: overview of implications in health 
and disease. The American Journal of Clinical Nutrition, 76, 266S-273S. 
JINNO, M., TAKEUCHI, M., WATANABE, A., TERUYA, K., HIROHAMA, J., EGUCHI, N. & MIYAZAKI, A. 
2011. Advanced glycation end-products accumulation compromises embryonic 
development and achievement of pregnancy by assisted reproductive technology. Hum 
Reprod, 26, 604-10. 
JOGLEKAR, M. M., PANASKAR, S. N., CHOUGALE, A. D., KULKARNI, M. J. & ARVINDEKAR, A. U. 
2013. A novel mechanism for antiglycative action of limonene through stabilization of 
protein conformation. Molecular BioSystems, 9, 2463-2472. 
JOHNSON, R. B. & ONWUEGBUZIE, A. J. 2004. Mixed Methods Research: A Research Paradigm 
Whose Time Has Come. Educational Researcher, 33, 14-26. 
JURANEK, I. & BEZEK, S. 2005. Controversy of free radical hypothesis: reactive oxygen species--
cause or consequence of tissue injury? Gen Physiol Biophys, 24, 263-78. 
KALOUSOVÁ, M., ZIMA, T., TESAŘ, V., DUSILOVÁ-SULKOVÁ, S. & ŠKRHA, J. 2005. Advanced 
glycoxidation end products in chronic diseases—clinical chemistry and genetic 
background. Mutation Research/Fundamental and Molecular Mechanisms of 
Mutagenesis, 579, 37-46. 
KARIMI, J., GOODARZI, M. T., TAVILANI, H., KHODADADI, I. & AMIRI, I. 2012. Increased receptor 
for advanced glycation end products in spermatozoa of diabetic men and its association 
with sperm nuclear DNA fragmentation. Andrologia, 44 Suppl 1, 280-6. 
KARLSEN, A., PAUR, I., BØHN, S., SAKHI, A., BORGE, G., SERAFINI, M., ERLUND, I., LAAKE, P., 
TONSTAD, S. & BLOMHOFF, R. 2010. Bilberry juice modulates plasma concentration of NF-
κB related inflammatory markers in subjects at increased risk of CVD. European Journal of 
Nutrition, 49, 345-355. 
KAWAGUCHI, K., MATSUMOTO, T. & KUMAZAWA, Y. 2011. Effects of antioxidant polyphenols on 
TNF-alpha-related diseases. Curr Top Med Chem, 11, 1767-79. 
KAZEEM, M., AKANJI, M., HAFIZUR, R. M. & CHOUDHARY, M. 2012. Antiglycation, antioxidant and 
toxicological potential of polyphenol extracts of alligator pepper, ginger and nutmeg from 
Nigeria. Asian Pac J Trop Biomed, 2, 727-32. 
KEANEY, J. F., LARSON, M. G., VASAN, R. S., WILSON, P. W. F., LIPINSKA, I., COREY, D., MASSARO, J. 
M., SUTHERLAND, P., VITA, J. A. & BENJAMIN, E. J. 2003. Obesity and Systemic Oxidative 
Stress: Clinical Correlates of Oxidative Stress in The Framingham Study. Arteriosclerosis, 
Thrombosis, and Vascular Biology, 23, 434-439. 
120 
 
KELLOW, N. J. & SAVIGE, G. S. 2013. Dietary advanced glycation end-product restriction for the 
attenuation of insulin resistance, oxidative stress and endothelial dysfunction: a 
systematic review. Eur J Clin Nutr, 67, 239-48. 
KEMPF, K., HERDER, C., ERLUND, I., KOLB, H., MARTIN, S., CARSTENSEN, M., KOENIG, W., 
SUNDVALL, J., BIDEL, S., KUHA, S. & TUOMILEHTO, J. 2010. Effects of coffee consumption 
on subclinical inflammation and other risk factors for type 2 diabetes: a clinical trial. Am J 
Clin Nutr, 91, 950-7. 
KENT, M. J., LIGHT, N. D. & BAILEY, A. J. 1985. Evidence for glucose-mediated covalent cross-
linking of collagen after glycosylation in vitro. Biochem J, 225, 745-52. 
KHAW, K. T., WAREHAM, N., BINGHAM, S., LUBEN, R., WELCH, A. & DAY, N. 2004a. Association of 
hemoglobin A1c with cardiovascular disease and mortality in adults: the European 
prospective investigation into cancer in Norfolk. Ann Intern Med, 141, 413-20. 
KHAW, K. T., WAREHAM, N., BINGHAM, S., LUBEN, R., WELCH, A. & DAY, N. 2004b. Preliminary 
communication: glycated hemoglobin, diabetes, and incident colorectal cancer in men 
and women: a prospective analysis from the European prospective investigation into 
cancer-Norfolk study. Cancer Epidemiol Biomarkers Prev, 13, 915-9. 
KIHO, T., USUI, S., HIRANO, K., AIZAWA, K. & INAKUMA, T. 2004. Tomato paste fraction inhibiting 
the formation of advanced glycation end-products. Biosci Biotechnol Biochem, 68, 200-5. 
KIM, H. Y. & KIM, K. 2003. Protein glycation inhibitory and antioxidative activities of some plant 
extracts in vitro. Journal of Agricultural and Food Chemistry, 51, 1586-1591. 
KIM, S. Y., DIETZ, P. M., ENGLAND, L., MORROW, B. & CALLAGHAN, W. M. 2007. Trends in Pre-
pregnancy Obesity in Nine States, 1993–2003. Obesity, 15, 986-993. 
KISLINGER, T., FU, C. F., HUBER, B., QU, W., TAGUCHI, A., YAN, S. D., HOFMANN, M., YAN, S. F., 
PISCHETSRIEDER, M., STERN, D. & SCHMIDT, A. M. 1999. N-epsilon-(carboxymethyl)lysine 
adducts of proteins are ligands for receptor for advanced glycation end products that 
activate cell signaling pathways and modulate gene expression. Journal of Biological 
Chemistry, 274, 31740-31749. 
KLEIN, R., KLEIN, B. E., MOSS, S. E. & CRUICKSHANKS, K. J. 1994. The Wisconsin Epidemiologic 
Study of diabetic retinopathy. XIV. Ten-year incidence and progression of diabetic 
retinopathy. Arch Ophthalmol, 112, 1217-28. 
KLEIN, R., KLEIN, B. E., MOSS, S. E. & CRUICKSHANKS, K. J. 1998. The Wisconsin Epidemiologic 
Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic 
retinopathy and associated risk factors in type 1 diabetes. Ophthalmology, 105, 1801-15. 
KLEIN, R. L., LAIMINS, M. & LOPES-VIRELLA, M. F. 1995. Isolation, characterization, and 
metabolism of the glycated and nonglycated subfractions of low-density lipoproteins 
isolated from type I diabetic patients and nondiabetic subjects. Diabetes, 44, 1093-8. 
KOENIG, R. J., BLOBSTEIN, S. H. & CERAMI, A. 1977. Structure of carbohydrate of hemoglobin AIc. J 
Biol Chem, 252, 2992-7. 
KOENIG, R. J., PETERSON, C. M., JONES, R. L., SAUDEK, C., LEHRMAN, M. & CERAMI, A. 1976a. 
Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. N Engl J Med, 
295, 417-20. 
KOENIG, R. J., PETERSON, C. M., KILO, C., CERAMI, A. & WILLIAMSON, J. R. 1976b. Hemoglobin AIc 
as an indicator of the degree of glucose intolerance in diabetes. Diabetes, 25, 230-2. 
KOGA, M. & KASAYAMA, S. 2010. Clinical impact of glycated albumin as another glycemic control 
marker. Endocrine Journal, 57, 751-762. 
KOLI, R., ERLUND, I., JULA, A., MARNIEMI, J., MATTILA, P. & ALFTHAN, G. 2010. Bioavailability of 
Various Polyphenols from a Diet Containing Moderate Amounts of Berries†. Journal of 
Agricultural and Food Chemistry, 58, 3927-3932. 
KONTOGIANNI, V. G., CHARISIADIS, P., MARGIANNI, E., LAMARI, F. N., GEROTHANASSIS, I. P. & 
TZAKOS, A. G. 2013. Olive Leaf Extracts Are a Natural Source of Advanced Glycation End 
Product Inhibitors. Journal of Medicinal Food, 16, 817-822. 
KOYAMA, H., YAMAMOTO, H. & NISHIZAWA, Y. 2007. RAGE and soluble RAGE: potential 
therapeutic targets for cardiovascular diseases. Mol Med, 13, 625-35. 
121 
 
KRONE, C. A. & ELY, J. T. 2004. Ascorbic acid, glycation, glycohemoglobin and aging. Med 
Hypotheses, 62, 275-9. 
KURISHITA, M., NAKASHIMA, K. & KOZU, H. 1994. A retrospective study of glucose metabolism in 
mothers of large babies. Diabetes Care, 17, 649-52. 
KWON, J. H., KIM, Y. H., KWON, J. Y. & PARK, Y. W. 2011. Clinical significance of serum sRAGE and 
esRAGE in women with normal pregnancy and preeclampsia. J Perinat Med, 39, 507-13. 
LANDGRAF, R. 2004. The relationship of postprandial glucose to HbA1c. Diabetes/Metabolism 
Research and Reviews, 20, S9-S12. 
LAPOLLA, A., TRALDI, P. & FEDELE, D. 2005. Importance of measuring products of non-enzymatic 
glycation of proteins. Clin Biochem, 38, 103-15. 
LAVIE, L. 2009. Oxidative Stress—A Unifying Paradigm in Obstructive Sleep Apnea and 
Comorbidities. Progress in Cardiovascular Diseases, 51, 303-312. 
LEAN, M. E., ANDERSON, A. S., MORRISON, C. & CURRALL, J. 2003. Evaluation of a dietary targets 
monitor. Eur J Clin Nutr, 57, 667-73. 
LEAN, M. E. J., HAN, T. S. & MORRISON, C. E. 1995. Waist Circumference as a Measure for 
Indicating Need for Weight Management. British Medical Journal, 311, 158-161. 
LEDDY, M. A., POWER, M. L. & SCHULKIN, J. 2008. The impact of maternal obesity on maternal 
and fetal health. Rev Obstet Gynecol, 1, 170-8. 
LEDL, F. & SCHLEICHER, E. 1990. New Aspects of the Maillard Reaction in Foods and in the Human-
Body. Angewandte Chemie-International Edition, 29, 565-594. 
LEPAPE, A., GUITTON, J. D. & MUH, J. P. 1981. Modifications of Glomerular Basement-Membrane 
Cross-Links in Experimental Diabetic Rats. Biochemical and Biophysical Research 
Communications, 100, 1214-1221. 
LESGARDS, J. F., DURAND, P., LASSARRE, M., STOCKER, P., LESGARDS, G., LANTEAUME, A., PROST, 
M. & LEHUCHER-MICHEL, M. P. 2002. Assessment of lifestyle effects on the overall 
antioxidant capacity of healthy subjects. Environ Health Perspect, 110, 479-86. 
LEUNG, T. Y., LEUNG, T. N., SAHOTA, D. S., CHAN, O. K., CHAN, L. W., FUNG, T. Y. & LAU, T. K. 
2008. Trends in maternal obesity and associated risks of adverse pregnancy outcomes in a 
population of Chinese women. BJOG: An International Journal of Obstetrics & 
Gynaecology, 115, 1529-1537. 
LI, D., DEVARAJ, S., FULLER, C., BUCALA, R. & JIALAL, I. 1996. Effect of alpha-tocopherol on LDL 
oxidation and glycation: in vitro and in vivo studies. Journal of Lipid Research, 37, 1978-86. 
LI, K. & YANG, H. X. 2006. Value of fructosamine measurement in pregnant women with abnormal 
glucose tolerance. Chin Med J (Engl), 119, 1861-5. 
LI, N., LIU, E., GUO, J., PAN, L., LI, B., WANG, P., LIU, J., WANG, Y., LIU, G., BACCARELLI, A. A., HOU, 
L. & HU, G. 2013. Maternal prepregnancy body mass index and gestational weight gain on 
pregnancy outcomes. PLoS One, 8, e82310. 
LI, W., OTA, K., NAKAMURA, J., NARUSE, K., NAKASHIMA, E., OISO, Y. & HAMADA, Y. 2008. A BRIEF 
COMMUNICATION: Antiglycation Effect of Gliclazide on In Vitro AGE Formation from 
Glucose and Methylglyoxal. Experimental Biology and Medicine, 233, 176-179. 
LICHTMAN, S. W., PISARSKA, K., BERMAN, E. R., PESTONE, M., DOWLING, H., OFFENBACHER, E., 
WEISEL, H., HESHKA, S., MATTHEWS, D. E. & HEYMSFIELD, S. B. 1992. Discrepancy 
between self-reported and actual caloric intake and exercise in obese subjects. N Engl J 
Med, 327, 1893-8. 
LIM, E. L., HOLLINGSWORTH, K. G., ARIBISALA, B. S., CHEN, M. J., MATHERS, J. C. & TAYLOR, R. 
2011. Reversal of type 2 diabetes: normalisation of beta cell function in association with 
decreased pancreas and liver triacylglycerol. Diabetologia, 54, 2506-14. 
LIN, J., RIDKER, P. M., RIFAI, N., LEE, I. M., MANSON, J. E., BURING, J. E. & ZHANG, S. M. M. 2006. A 
prospective study of hemoglobin A1c concentrations and risk of breast cancer in women. 
Cancer Research, 66, 2869-2875. 
LINDSEY, J. B., CIPOLLONE, F., ABDULLAH, S. M. & MCGUIRE, D. K. 2009. Receptor for advanced 
glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. 
Diabetes and Vascular Disease Research, 6, 7-14. 
122 
 
LUDWIG, D. S. 2002. The glycemic index: Physiological mechanisms relating to obesity, diabetes, 
and cardiovascular disease. JAMA, 287, 2414-2423. 
LUMLEY, T., DIEHR, P., EMERSON, S. & CHEN, L. 2002. The importance of the normality 
assumption in large public health data sets. Annu Rev Public Health, 23, 151-69. 
LUNCEFORD, N. & GUGLIUCCI, A. 2005. Ilex paraguariensis extracts inhibit AGE formation more 
efficiently than green tea. Fitoterapia, 76, 419-427. 
LYNCH, J. W., KAPLAN, G. A., COHEN, R. D., TUOMILEHTO, J. & SALONEN, J. T. 1996. Do 
cardiovascular risk factors explain the relation between socioeconomic status, risk of all-
cause mortality, cardiovascular mortality, and acute myocardial infarction? Am J 
Epidemiol, 144, 934-42. 
LYONS, T. J. 1993. Glycation and oxidation: a role in the pathogenesis of atherosclerosis. Am J 
Cardiol, 71, 26B-31B. 
MACDONALD-WALLIS, C., LAWLOR, D. A., HERON, J., FRASER, A., NELSON, S. M. & TILLING, K. 
2011. Relationships of risk factors for pre-eclampsia with patterns of occurrence of 
isolated gestational proteinuria during normal term pregnancy. PLoS One, 6, e22115. 
MAGANN, E. F., DOHERTY, D. A., SANDLIN, A. T., CHAUHAN, S. P. & MORRISON, J. C. 2013. The 
effects of an increasing gradient of maternal obesity on pregnancy outcomes. Aust N Z J 
Obstet Gynaecol, 53, 250-7. 
MAJOREK, K. A., POREBSKI, P. J., DAYAL, A., ZIMMERMAN, M. D., JABLONSKA, K., STEWART, A. J., 
CHRUSZCZ, M. & MINOR, W. 2012. Structural and immunologic characterization of 
bovine, horse, and rabbit serum albumins. Mol Immunol, 52, 174-82. 
MAILLARD-LEFEBVRE, H., BOULANGER, E., DAROUX, M., GAXATTE, C., HUDSON, B. I. & LAMBERT, 
M. 2009. Soluble receptor for advanced glycation end products: a new biomarker in 
diagnosis and prognosis of chronic inflammatory diseases. Rheumatology, 48, 1190-1196. 
MAILLARD, L. 1912. Action des acides amines sur les sucres: Formation des melanoidines par voie 
methodologique. Comptes Rendus de l’Academie des Sciences, 156, 148-149. 
MALICKOVA, K., JAROSOVA, R., REZABEK, K., FAIT, T., MASATA, J., JANATKOVA, I., ZIMA, T. & 
KALOUSOVA, M. 2010. Concentrations of sRAGE in serum and follicular fluid in assisted 
reproductive cycles--a preliminary study. Clin Lab, 56, 377-84. 
MALLIDIS, C., AGBAJE, I., ROGERS, D., GLENN, J., MCCULLOUGH, S., ATKINSON, A. B., STEGER, K., 
STITT, A. & MCCLURE, N. 2007. Distribution of the receptor for advanced glycation end 
products in the human male reproductive tract: prevalence in men with diabetes mellitus. 
Hum Reprod, 22, 2169-77. 
MALLIDIS, C., AGBAJE, I. M., ROGERS, D. A., GLENN, J. V., PRINGLE, R., ATKINSON, A. B., STEGER, 
K., STITT, A. W. & MCCLURE, N. 2009. Advanced glycation end products accumulate in the 
reproductive tract of men with diabetes. Int J Androl, 32, 295-305. 
MAMUN, A., CALLAWAY, L., O'CALLAGHAN, M., WILLIAMS, G., NAJMAN, J., ALATI, R., CLAVARINO, 
A. & LAWLOR, D. 2011. Associations of maternal pre-pregnancy obesity and excess 
pregnancy weight gains with adverse pregnancy outcomes and length of hospital stay. 
BMC Pregnancy and Childbirth, 11, 62. 
MANACH, C., SCALBERT, A., MORAND, C., REMESY, C. & JIMENEZ, L. 2004. Polyphenols: food 
sources and bioavailability. Am J Clin Nutr, 79, 727-47. 
MANACH, C., WILLIAMSON, G., MORAND, C., SCALBERT, A. & REMESY, C. 2005. Bioavailability and 
bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. American 
Journal of Clinical Nutrition, 81, 230S-242S. 
MARANGON, K., HERBETH, B., LECOMTE, E., PAUL-DAUPHIN, A., GROLIER, P., CHANCERELLE, Y., 
ARTUR, Y. & SIEST, G. 1998. Diet, antioxidant status, and smoking habits in French men. 
The American Journal of Clinical Nutrition, 67, 231-9. 
MATSUMOTO, T., TSURUMOTO, T., BABA, H., OSAKI, M., ENOMOTO, H., YONEKURA, A., SHINDO, 
H. & MIYATA, T. 2007. Measurement of advanced glycation endproducts in skin of 
patients with rheumatoid arthritis, osteoarthritis, and dialysis-related 
spondyloarthropathy using non-invasive methods. Rheumatology International, 28, 157-
160. 
123 
 
MATSUSHITA, K., BLECKER, S., PAZIN, A., BERTONI, A., CHANG, P. P., CORESH, J. & SELVIN, E. 2010. 
The Association of Hemoglobin A1c With Incident Heart Failure Among People Without 
Diabetes: The Atherosclerosis Risk in Communities Study. Diabetes, 59, 2020-2026. 
MATTEUCCI, E., BIASCI, E. & GIAMPIETRO, O. 2001. Advanced oxidation protein products in 
plasma: stability during storage and correlation with other clinical characteristics. Acta 
Diabetol, 38, 187-9. 
MAYNE, S. T. 2003. Antioxidant Nutrients and Chronic Disease: Use of Biomarkers of Exposure and 
Oxidative Stress Status in Epidemiologic Research. The Journal of Nutrition, 133, 933S-
940S. 
MCCARTER, R. J., HEMPE, J. M., GOMEZ, R. & CHALEW, S. A. 2004. Biological variation in HbA1c 
predicts risk of retinopathy and nephropathy in type 1 diabetes. Diabetes Care, 27, 1259-
64. 
MCNAIR, E. D., WELLS, C. R., QURESHI, M., BASRAN, R., PEARCE, C., ORVOLD, J., DEVILLIERS, J. & 
PRASAD, K. 2010. Soluble Receptors for Advanced Glycation End Products (sRAGE) as a 
Predictor of Restenosis Following Percutaneous Coronary Intervention. Clinical 
Cardiology, 33, 678-685. 
MCPHERSON, K., STEEL, C. M. & DIXON, J. M. 2000. ABC of breast diseases. Breast cancer-
epidemiology, risk factors, and genetics. BMJ, 321, 624-8. 
MEDINA-REMON, A., BARRIONUEVO-GONZALEZ, A., ZAMORA-ROS, R., ANDRES-LACUEVA, C., 
ESTRUCH, R., MARTINEZ-GONZALEZ, M. A., DIEZ-ESPINO, J. & LAMUELA-RAVENTOS, R. M. 
2009. Rapid Folin-Ciocalteu method using microtiter 96-well plate cartridges for solid 
phase extraction to assess urinary total phenolic compounds, as a biomarker of total 
polyphenols intake. Anal Chim Acta, 634, 54-60. 
MEDINA-REMON, A., TRESSERRA-RIMBAU, A., ARRANZ, S., ESTRUCH, R. & LAMUELA-RAVENTOS, 
R. M. 2012. Polyphenols excreted in urine as biomarkers of total polyphenol intake. 
Bioanalysis, 4, 2705-13. 
MEIGS, J. B., NATHAN, D. M., D'AGOSTINO, R. B. & WILSON, P. W. F. 2002. Fasting and 
postchallenge glycemia and cardiovascular disease risk - The framingham offspring study. 
Diabetes Care, 25, 1845-1850. 
MENNEN, L. I., SAPINHO, D., ITO, H., BERTRAIS, S., GALAN, P., HERCBERG, S. & SCALBERT, A. 2006. 
Urinary flavonoids and phenolic acids as biomarkers of intake for polyphenol-rich foods. 
British Journal of Nutrition, 96, 191-198. 
MENZEL, E. J. & REIHSNER, R. 1996. Comparison of the effect of different inhibitors of the non-
enzymatic glycation of rat tail tendons and bovine serum albumin. Ann Clin Biochem, 33 ( 
Pt 3), 241-8. 
MINSART, A.-F., BUEKENS, P., DE SPIEGELAERE, M. & ENGLERT, Y. 2013. Neonatal outcomes in 
obese mothers: a population-based analysis. BMC Pregnancy and Childbirth, 13, 36. 
MIYAZAKI, R., KOTANI, K., AYABE, M., TSUZAKI, K., SHIMADA, J., SAKANE, N., TAKASE, H., 
ICHIKAWA, H., YONEI, Y. & ISHII, K. 2013. Minor effects of green tea catechin 
supplementation on cardiovascular risk markers in active older people: a randomized 
controlled trial. Geriatr Gerontol Int, 13, 622-9. 
MOHARIR, A., PECK, S. H., BUDDEN, T. & LEE, S. Y. 2013. The Role of N-Glycosylation in Folding, 
Trafficking, and Functionality of Lysosomal Protein CLN5. PLoS ONE, 8, e74299. 
MONAMI, M., LAMANNA, C., LAMBERTUCCI, L., LONGO, R., COCCA, C., ADDANTE, F., LOTTI, E., 
MASOTTI, G., MARCHIONNI, N. & MANNUCCI, E. 2006. Fasting and post-prandial glycemia 
and their correlation with glycated hemoglobin in type 2 diabetes. Journal of 
Endocrinological Investigation, 29, 619-624. 
MONNIER, L., LAPINSKI, H. & COLETTE, C. 2003. Contributions of fasting and postprandial plasma 
glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients - 
Variations with increasing levels of HbA(1c). Diabetes Care, 26, 881-885. 
MONNIER, V. M. 1989. Toward a Maillard reaction theory of aging. Prog Clin Biol Res, 304, 1-22. 
MORETTI, M., PHILLIPS, M., ABOUZEID, A., CATANEO, R. N. & GREENBERG, J. 2004. Increased 
breath markers of oxidative stress in normal pregnancy and in preeclampsia. American 
Journal of Obstetrics and Gynecology, 190, 1184-1190. 
124 
 
MORIARTY, S. E., SHAH, J. H., LYNN, M., JIANG, S., OPENO, K., JONES, D. P. & STERNBERG, P. 2003. 
Oxidation of glutathione and cysteine in human plasma associated with smoking. Free 
Radic Biol Med, 35, 1582-8. 
MOUTON, P. R., CHACHICH, M. E., QUIGLEY, C., SPANGLER, E. & INGRAM, D. K. 2009. Caloric 
restriction attenuates amyloid deposition in middle-aged dtg APP/PS1 mice. Neurosci Lett, 
464, 184-7. 
MUELLER, G. A., MALEKI, S. J., JOHNSON, K., HURLBURT, B. K., CHENG, H., RUAN, S., NESBIT, J. B., 
POMES, A., EDWARDS, L. L., SCHORZMAN, A., DETERDING, L. J., PARK, H., TOMER, K. B., 
LONDON, R. E. & WILLIAMS, J. G. 2013. Identification of Maillard reaction products on 
peanut allergens that influence binding to the receptor for advanced glycation end 
products. Allergy, 68, 1546-1554. 
MUELLER, S., RIEDEL, H. D. & STREMMEL, W. 1997. Determination of catalase activity at 
physiological hydrogen peroxide concentrations. Anal Biochem, 245, 55-60. 
MULLEN, W., ARCHEVEQUE, M.-A., EDWARDS, C. A., MATSUMOTO, H. & CROZIER, A. 2008. 
Bioavailability and Metabolism of Orange Juice Flavanones in Humans: Impact of a Full-Fat 
Yogurt. Journal of Agricultural and Food Chemistry, 56, 11157-11164. 
MUNCH, G., WESTCOTT, B., MENINI, T. & GUGLIUCCI, A. 2012. Advanced glycation endproducts 
and their pathogenic roles in neurological disorders. Amino Acids, 42, 1221-1236. 
MURAKI, I., IMAMURA, F., MANSON, J. E., HU, F. B., WILLETT, W. C., DAM, R. M. V. & SUN, Q. 
2013. Fruit consumption and risk of type 2 diabetes: results from three prospective 
longitudinal cohort studies. BMJ, 347. 
MUTSAERTS, M. A., GROEN, H., BUITER-VAN DER MEER, A., SIJTSMA, A., SAUER, P. J., LAND, J. A., 
MOL, B. W., CORPELEIJN, E. & HOEK, A. 2014. Effects of paternal and maternal lifestyle 
factors on pregnancy complications and perinatal outcome. A population-based birth-
cohort study: the GECKO Drenthe cohort. Hum Reprod, 29, 824-34. 
MYINT, P. K., SINHA, S., WAREHAM, N. J., BINGHAM, S. A., LUBEN, R. N., WELCH, A. A. & KHAW, K. 
T. 2007. Glycated hemoglobin and risk of stroke in people without known diabetes in the 
European Prospective Investigation into Cancer (EPIC)-Norfolk prospective population 
study: a threshold relationship? Stroke, 38, 271-5. 
MYLES, A., VISWANATH, V., SINGH, Y. P. & AGGARWAL, A. 2011. Soluble Receptor for Advanced 
Glycation Endproducts Is Decreased in Patients with Juvenile Idiopathic Arthritis (ERA 
Category) and Inversely Correlates with Disease Activity and S100A12 Levels. Journal of 
Rheumatology, 38, 1994-1999. 
NAGASAWA, T., TABATA, N., ITO, Y., NISHIZAWA, N., AIBA, Y. & KITTS, D. D. 2003. Inhibition of 
glycation reaction in tissue protein incubations by water soluble rutin derivative. 
Molecular and Cellular Biochemistry, 249, 3-10. 
NAKAMURA, T., SATO, E., FUJIWARA, N., KAWAGOE, Y., SUZUKI, T., UEDA, Y., YAMADA, S., SHOJI, 
H., TAKEUCHI, M., UEDA, S., MATSUI, T., ADACHI, H., OKUDA, S. & YAMAGISHI, S. 2009. 
Circulating levels of advanced glycation end products (AGE) and interleukin-6 (IL-6) are 
independent determinants of serum asymmetric dimethylarginine (ADMA) levels in 
patients with septic shock. Pharmacol Res, 60, 515-8. 
NAMBIAR, S., VISWANATHAN, S., ZACHARIAH, B., HANUMANTHAPPA, N., AGRAWAL, A. & 
NADARADJAN, R. D. 2012. Possible Modulation of Glycated Protein Levels in 
Prehypertension by Lipid Peroxides. Clin Exp Hypertens. 
NARDINI, M., CIRILLO, E., NATELLA, F. & SCACCINI, C. 2002. Absorption of phenolic acids in 
humans after coffee consumption. J Agric Food Chem, 50, 5735-41. 
NARDINI, M., FORTE, M., VRHOVSEK, U., MATTIVI, F., VIOLA, R. & SCACCINI, C. 2009. White Wine 
Phenolics Are Absorbed and Extensively Metabolized in Humans. Journal of Agricultural 
and Food Chemistry, 57, 2711-2718. 
NARDINI, M., NATELLA, F., SCACCINI, C. & GHISELLI, A. 2006. Phenolic acids from beer are 
absorbed and extensively metabolized in humans. Journal of Nutritional Biochemistry, 17, 
14-22. 
NARUSE, K., SADO, T., NOGUCHI, T., TSUNEMI, T., YOSHIDA, S., AKASAKA, J., KOIKE, N., OI, H. & 
KOBAYASHI, H. 2012. Peripheral RAGE (receptor for advanced glycation endproducts)-
125 
 
ligands in normal pregnancy and preeclampsia: novel markers of inflammatory response. J 
Reprod Immunol, 93, 69-74. 
NATHAN, D. M., KUENEN, J., BORG, R., ZHENG, H., SCHOENFELD, D., HEINE, R. J. & GRP, A. S. 2008. 
Translating the A1C assay into estimated average glucose values. Diabetes Care, 31, 1473-
1478. 
NAUDI, A., JOVE, M., AYALA, V., CASSANYE, A., SERRANO, J., GONZALO, H., BOADA, J., PRAT, J., 
PORTERO-OTIN, M. & PAMPLONA, R. 2012. Cellular dysfunction in diabetes as 
maladaptive response to mitochondrial oxidative stress. Exp Diabetes Res, 2012, 696215. 
NEDIC, O., RATTAN, S. I., GRUNE, T. & TROUGAKOS, I. P. 2013. Molecular effects of advanced 
glycation end products on cell signalling pathways, ageing and pathophysiology. Free 
Radic Res, 47 Suppl 1, 28-38. 
NETTLETON, J. A., HARNACK, L. J., SCRAFFORD, C. G., MINK, P. J., BARRAJ, L. M. & JACOBS, D. R., 
JR. 2006. Dietary flavonoids and flavonoid-rich foods are not associated with risk of type 2 
diabetes in postmenopausal women. J Nutr, 136, 3039-45. 
NG, Z. X., CHUA, K. H., IQBAL, T. & KUPPUSAMY, U. R. 2013. Soluble Receptor for Advanced 
Glycation End-Product (sRAGE)/Pentosidine Ratio: A Potential Risk Factor Determinant for 
Type 2 Diabetic Retinopathy. International Journal of Molecular Sciences, 14, 7480-7491. 
NICHOLL, I. D. & BUCALA, R. 1998. Advanced glycation endproducts and cigarette smoking. Cell 
Mol Biol (Noisy-le-grand), 44, 1025-33. 
NICHOLL, I. D., STITT, A. W., MOORE, J. E., RITCHIE, A. J., ARCHER, D. B. & BUCALA, R. 1998. 
Increased levels of advanced glycation endproducts in the lenses and blood vessels of 
cigarette smokers. Mol Med, 4, 594-601. 
NICHOLSON, W., WANG, N. Y., BAPTISTE-ROBERTS, K., CHANG, Y. T. & POWE, N. R. 2013. 
Association between adiponectin and tumor necrosis factor-alpha levels at eight to 
fourteen weeks gestation and maternal glucose tolerance: the Parity, Inflammation, and 
Diabetes Study. J Womens Health (Larchmt), 22, 259-66. 
NIELSEN, S. E., FREESE, R., KLEEMOLA, P. & MUTANEN, M. 2002. Flavonoids in Human Urine as 
Biomarkers for Intake of Fruits and Vegetables. Cancer Epidemiology Biomarkers & 
Prevention, 11, 459-466. 
NIEMAN, D. C., GILLITT, N. D., KNAB, A. M., SHANELY, R. A., PAPPAN, K. L., JIN, F. & LILA, M. A. 
2013. Influence of a Polyphenol-Enriched Protein Powder on Exercise-Induced 
Inflammation and Oxidative Stress in Athletes: A Randomized Trial Using a Metabolomics 
Approach. Plos One, 8. 
NILSSON, P. M., LIND, L., POLLARE, T., BERNE, C. & LITHELL, H. O. 1995. Increased level of 
hemoglobin A1c, but not impaired insulin sensitivity, found in hypertensive and 
normotensive smokers. Metabolism, 44, 557-61. 
NISKANEN, L., LAAKSONEN, D. E., NYYSSÖNEN, K., PUNNONEN, K., VALKONEN, V.-P., FUENTES, R., 
TUOMAINEN, T.-P., SALONEN, R. & SALONEN, J. T. 2004. Inflammation, Abdominal 
Obesity, and Smoking as Predictors of Hypertension. Hypertension, 44, 859-865. 
O'BRIEN, T. E., RAY, J. G. & CHAN, W. S. 2003. Maternal body mass index and the risk of 
preeclampsia: A systematic overview. Epidemiology, 14, 368-374. 
O'HARTE, F. P., HOJRUP, P., BARNETT, C. R. & FLATT, P. R. 1996. Identification of the site of 
glycation of human insulin. Peptides, 17, 1323-30. 
OGAWA, S., MATSUMAE, T., KATAOKA, T., YAZAKI, Y. & YAMAGUCHI, H. 2013. Effect of acacia 
polyphenol on glucose homeostasis in subjects with impaired glucose tolerance: A 
randomized multicenter feeding trial. Exp Ther Med, 5, 1566-1572. 
OLIVEIRA, L. M., LAGES, A., GOMES, R. A., NEVES, H., FAMILIA, C., COELHO, A. V. & QUINTAS, A. 
2011. Insulin glycation by methylglyoxal results in native-like aggregation and inhibition of 
fibril formation. BMC Biochem, 12, 41. 
OLIVER, E. A., BUHIMSCHI, C. S., DULAY, A. T., BAUMBUSCH, M. A., ABDEL-RAZEQ, S. S., LEE, S. Y., 
ZHAO, G., JING, S., PETTKER, C. M. & BUHIMSCHI, I. A. 2011. Activation of the receptor for 
advanced glycation end products system in women with severe preeclampsia. J Clin 
Endocrinol Metab, 96, 689-98. 
126 
 
OLIVERAS-LOPEZ, M.-J., INNOCENTI, M., MARTIN BERMUDO, F., LOPEZ-GARCIA DE LA SERRANA, 
H. & MULINACCI, N. 2012. Effect of extra virgin olive oil on glycaemia in healthy young 
subjects. European Journal of Lipid Science and Technology, 114, 999-1006. 
OVASKAINEN, M.-L., TÖRRÖNEN, R., KOPONEN, J. M., SINKKO, H., HELLSTRÖM, J., REINIVUO, H. & 
MATTILA, P. 2008. Dietary Intake and Major Food Sources of Polyphenols in Finnish 
Adults. The Journal of Nutrition, 138, 562-566. 
OZA-FRANK, R. & KEIM, S. A. 2013. Should obese women gain less weight in pregnancy than 
recommended? Birth, 40, 107-14. 
PARK, S., BARRETTCONNOR, E., WINGARD, D. L., SHAN, J. & EDELSTEIN, S. 1996. GHb is a better 
predictor at cardiovascular disease than fasting or postchallenge plasma glucose in 
women without diabetes - The Rancho Bernardo Study. Diabetes Care, 19, 450-456. 
PEACOCK, T. P., SHIHABI, Z. K., BLEYER, A. J., DOLBARE, E. L., BYERS, J. R., KNOVICH, M. A., CALLES-
ESCANDON, J., RUSSELL, G. B. & FREEDMAN, B. I. 2008. Comparison of glycated albumin 
and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int, 73, 1062-8. 
PELUSO, M., MUNNIA, A., PIRO, S., JEDPIYAWONGSE, A., SANGRAJRANG, S., GIESE, R. W., CEPPI, 
M., BOFFETTA, P. & SRIVATANAKUL, P. 2012. Fruit and vegetable and fried food 
consumption and 3-(2-deoxy-beta-D-erythro-pentafuranosyl)pyrimido[1,2-alpha] purin-
10(3H)-one deoxyguanosine adduct formation. Free Radic Res, 46, 85-92. 
PENG, Y., YUAN, G., OVERHOLT, J. L., KUMAR, G. K. & PRABHAKAR, N. R. 2003. Systemic and 
cellular responses to intermittent hypoxia: evidence for oxidative stress and 
mitochondrial dysfunction. Adv Exp Med Biol, 536, 559-64. 
PENN, L., WHITE, M., LINDSTROM, J., DEN BOER, A. T., BLAAK, E., ERIKSSON, J. G., FESKENS, E., 
ILANNE-PARIKKA, P., KEINANEN-KIUKAANNIEMI, S. M., WALKER, M., MATHERS, J. C., 
UUSITUPA, M. & TUOMILEHTO, J. 2013. Importance of weight loss maintenance and risk 
prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention 
Study RCT. PLoS One, 8, e57143. 
PEREZ-JIMENEZ, J., HUBERT, J., HOOPER, L., CASSIDY, A., MANACH, C., WILLIAMSON, G. & 
SCALBERT, A. 2010. Urinary metabolites as biomarkers of polyphenol intake in humans: a 
systematic review. American Journal of Clinical Nutrition, 92, 801-809. 
PHAM-HUY, L. A., HE, H. & PHAM-HUY, C. 2008. Free radicals, antioxidants in disease and health. 
Int J Biomed Sci, 4, 89-96. 
PLUTZKY, J. 2011. Macrovascular effects and safety issues of therapies for type 2 diabetes. Am J 
Cardiol, 108, 25B-32B. 
POPPITT, S. D., SWANN, D., BLACK, A. E. & PRENTICE, A. M. 1998. Assessment of selective under-
reporting of food intake by both obese and non-obese women in a metabolic facility. Int J 
Obes Relat Metab Disord, 22, 303-11. 
PORTA, M., SJOELIE, A. K., CHATURVEDI, N., STEVENS, L., ROTTIERS, R., VEGLIO, M., FULLER, J. H. & 
GROUP, E. P. C. S. 2001. Risk factors for progression to proliferative diabetic retinopathy 
in the EURODIAB Prospective Complications Study. Diabetologia, 44, 2203-9. 
POSTON, L., BRILEY, A. L., BARR, S., BELL, R., CROKER, H., COXON, K., ESSEX, H. N., HUNT, C., 
HAYES, L., HOWARD, L. M., KHAZAEZADEH, N., KINNUNEN, T., NELSON, S. M., OTENG-
NTIM, E., ROBSON, S. C., SATTAR, N., SEED, P. T., WARDLE, J., SANDERS, T. A. & SANDALL, 
J. 2013. Developing a complex intervention for diet and activity behaviour change in 
obese pregnant women (the UPBEAT trial); assessment of behavioural change and 
process evaluation in a pilot randomised controlled trial. BMC Pregnancy Childbirth, 13, 
148. 
POU, K. M., MASSARO, J. M., HOFFMANN, U., VASAN, R. S., MAUROVICH-HORVAT, P., LARSON, M. 
G., KEANEY, J. F., MEIGS, J. B., LIPINSKA, I., KATHIRESAN, S., MURABITO, J. M., 
O’DONNELL, C. J., BENJAMIN, E. J. & FOX, C. S. 2007. Visceral and Subcutaneous Adipose 
Tissue Volumes Are Cross-Sectionally Related to Markers of Inflammation and Oxidative 
Stress: The Framingham Heart Study. Circulation, 116, 1234-1241. 
PRADHAN, A. D., RIFAI, N., BURING, J. E. & RIDKER, P. M. 2007. Hemoglobin a1c predicts diabetes 
but not cardiovascular disease in nondiabetic women. American Journal of Medicine, 120, 
720-727. 
127 
 
PUTT, S. N. H., SHAW, A. P. M., WOODS, A. J., TYLER, L. & JAMES, A. D. 1987. Veterinary 
epidemiology and economics in Africa. A manual for use in the design and appraisal of 
livestock health policy. 
QING, Z., LING-LING, E., DONG-SHENG, W. & HONG-CHEN, L. 2012. Relationship of advanced 
oxidative protein products in human saliva and plasma: age- and gender-related changes 
and stability during storage. Free Radical Research, 46, 1201-1206. 
RAIJMAKERS, M. T. M., DECHEND, R. & POSTON, L. 2004. Oxidative Stress and Preeclampsia: 
Rationale for Antioxidant Clinical Trials. Hypertension, 44, 374-380. 
RAMACHENDERAN, J., BRADFORD, J. & MCLEAN, M. 2008. Maternal obesity and pregnancy 
complications: A review. Australian and New Zealand Journal of Obstetrics and 
Gynaecology, 48, 228-235. 
RAMASAMY, R., VANNUCCI, S. J., YAN, S. S., HEROLD, K., YAN, S. F. & SCHMIDT, A. M. 2005. 
Advanced glycation end products and RAGE: a common thread in aging, diabetes, 
neurodegeneration, and inflammation. Glycobiology, 15, 16R-28R. 
RASMUSSEN, S., IRGENS, L. & ESPINOZA, J. 2014. Maternal obesity and excess of fetal growth in 
pre-eclampsia. Bjog. 
RAUCCI, A., CUGUSI, S., ANTONELLI, A., BARABINO, S., BIERHAUS, A., SAFTIG, P. & BIANCHI, M. E. 
2008. A soluble form of RAGE is produced by proteolytic cleavage of the membrane 
bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). Journal of 
Leukocyte Biology, 84, A10-A10. 
RAY, J. G., VERMEULEN, M. J., SHAPIRO, J. L. & KENSHOLE, A. B. 2001. Maternal and neonatal 
outcomes in pregestational and gestational diabetes mellitus, and the influence of 
maternal obesity and weight gain: the DEPOSIT study. QJM, 94, 347-356. 
REISER, K. M. 1994. Influence of Age and Long-Term Dietary Restriction on Enzymatically 
Mediated Crosslinks and Nonenzymatic Glycation of Collagen in Mice. Journal of 
Gerontology, 49, B71-B79. 
RIZZO, A. M., BERSELLI, P., ZAVA, S., MONTORFANO, G., NEGRONI, M., CORSETTO, P. & BERRA, B. 
2010. Endogenous antioxidants and radical scavengers. Adv Exp Med Biol, 698, 52-67. 
RODRIGO, R., MIRANDA, A. & VERGARA, L. 2011. Modulation of endogenous antioxidant system 
by wine polyphenols in human disease. Clinica Chimica Acta, 412, 410-424. 
ROMERO, R., GOTSCH, F., PINELES, B. & KUSANOVIC, J. P. 2007. Inflammation in pregnancy: its 
roles in reproductive physiology, obstetrical complications, and fetal injury. Nutr Rev, 65, 
S194-202. 
RONDEAU, P. & BOURDON, E. 2011. The glycation of albumin: structural and functional impacts. 
Biochimie, 93, 645-58. 
ROOHK, H. V. & ZAIDI, A. R. 2008. A review of glycated albumin as an intermediate glycation index 
for controlling diabetes. J Diabetes Sci Technol, 2, 1114-21. 
ROOS, N., KIELER, H., SAHLIN, L., EKMAN-ORDEBERG, G., FALCONER, H. & STEPHANSSON, O. 2011. 
Risk of adverse pregnancy outcomes in women with polycystic ovary syndrome: 
population based cohort study. Bmj, 343, d6309. 
ROTHWELL, J. A., URPI-SARDA, M., BOTO-ORDONEZ, M., KNOX, C., LLORACH, R., EISNER, R., CRUZ, 
J., NEVEU, V., WISHART, D., MANACH, C., ANDRES-LACUEVA, C. & SCALBERT, A. 2012. 
Phenol-Explorer 2.0: a major update of the Phenol-Explorer database integrating data on 
polyphenol metabolism and pharmacokinetics in humans and experimental animals. 
Database (Oxford), 2012, bas031. 
ROURA, E., ANDRÉS-LACUEVA, C., ESTRUCH, R. & LAMUELA-RAVENTÓS, R. M. 2006. Total 
Polyphenol Intake Estimated by a Modified Folin–Ciocalteu Assay of Urine. Clinical 
Chemistry, 52, 749-752. 
SABANAYAGAM, C., LIEW, G., TAI, E. S., SHANKAR, A., LIM, S. C., SUBRAMANIAM, T. & WONG, T. Y. 
2009. Relationship between glycated haemoglobin and microvascular complications: Is 
there a natural cut-off point for the diagnosis of diabetes? Diabetologia, 52, 1279-1289. 
SABATER, J., QUEREDA, C., HERRERA, I., PASCUAL, J., VILLAFRUELA, J. J. & ORTUNO, J. 1991. 
Nonenzymatic Glycosylation of Hemoglobin and Total Plasmatic Proteins in End-Stage 
Renal-Disease. American Journal of Nephrology, 11, 37-43. 
128 
 
SADO, T., NARUSE, K., NOGUCHI, T., HARUTA, S., YOSHIDA, S., TANASE, Y., KITANAKA, T., OI, H. & 
KOBAYASHI, H. 2011. Inflammatory pattern recognition receptors and their ligands: 
factors contributing to the pathogenesis of preeclampsia. Inflamm Res, 60, 509-20. 
SAHYOUN, N. R., ANDERSON, A. L., KANAYA, A. M., KOH-BANERJEE, P., KRITCHEVSKY, S. B., DE 
REKENEIRE, N., TYLAVSKY, F. A., SCHWARTZ, A. V., LEE, J. S. & HARRIS, T. B. 2005. Dietary 
glycemic index and load, measures of glucose metabolism, and body fat distribution in 
older adults. The American Journal of Clinical Nutrition, 82, 547-552. 
SAKURAI, M., SAITOH, S., MIURA, K., NAKAGAWA, H., OHNISHI, H., AKASAKA, H., KADOTA, A., 
KITA, Y., HAYAKAWA, T., OHKUBO, T., OKAYAMA, A., OKAMURA, T., UESHIMA, H. & 
GROUP, N. D. R. 2013. HbA1c and the risks for all-cause and cardiovascular mortality in 
the general Japanese population: NIPPON DATA90. Diabetes Care, 36, 3759-65. 
SAMAHA, F. F., IQBAL, N., SESHADRI, P., CHICANO, K. L., DAILY, D. A., MCGRORY, J., WILLIAMS, T., 
WILLIAMS, M., GRACELY, E. J. & STERN, L. 2003. A Low-Carbohydrate as Compared with a 
Low-Fat Diet in Severe Obesity. New England Journal of Medicine, 348, 2074-2081. 
SARGEANT, L. A., WAREHAM, N. J., BINGHAM, S., DAY, N. E., LUBEN, R. N., OAKES, S., WELCH, A. & 
KHAW, K. T. 2000. Vitamin C and hyperglycemia in the European Prospective Investigation 
into Cancer--Norfolk (EPIC-Norfolk) study: a population-based study. Diabetes Care, 23, 
726-732. 
SCALBERT, A., MORAND, C., MANACH, C. & RÉMÉSY, C. 2002. Absorption and metabolism of 
polyphenols in the gut and impact on health. Biomedicine & Pharmacotherapy, 56, 276-
282. 
SCALBERT, A. & WILLIAMSON, G. 2000. Dietary intake and bioavailability of polyphenols. Journal 
of Nutrition, 130, 2073s-2085s. 
SCHLEICHER, E. D., OLGEMÖLLER, B., WIEDENMANN, E. & GERBITZ, K. D. 1993. Specific glycation 
of albumin depends on its half-life. Clinical Chemistry, 39, 625-8. 
SCHMIDT, A. M., HORI, O., BRETT, J., YAN, S. D., WAUTIER, J. L. & STERN, D. 1994. Cellular 
receptors for advanced glycation end products. Implications for induction of oxidant 
stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler 
Thromb, 14, 1521-8. 
SCHMIDT, A. M., HORI, O., CHEN, J. X., LI, J. F., CRANDALL, J., ZHANG, J., CAO, R., YAN, S. D., 
BRETT, J. & STERN, D. 1995. Advanced glycation endproducts interacting with their 
endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in 
cultured human endothelial cells and in mice. A potential mechanism for the accelerated 
vasculopathy of diabetes. J Clin Invest, 96, 1395-403. 
SCHMIDT, A. M., VIANNA, M., GERLACH, M., BRETT, J., RYAN, J., KAO, J., ESPOSITO, C., HEGARTY, 
H., HURLEY, W., CLAUSS, M. & ET AL. 1992. Isolation and characterization of two binding 
proteins for advanced glycosylation end products from bovine lung which are present on 
the endothelial cell surface. J Biol Chem, 267, 14987-97. 
SCHMIDT, A. M., YAN, S. D., YAN, S. F. & STERN, D. M. 2000. The biology of the receptor for 
advanced glycation end products and its ligands. Biochim Biophys Acta, 1498, 99-111. 
SCHMIDT, A. M., YAN, S. D., YAN, S. F. & STERN, D. M. 2001. The multiligand receptor RAGE as a 
progression factor amplifying immune and inflammatory responses. The Journal of Clinical 
Investigation, 108, 949-955. 
SCHULTZE, H. E. & HEREMANS, J. F. 1966. Molecular biology of human proteins : with special 
reference to plasma proteins, Amsterdam ; London, Elsevier. 
SCHWARZE, P. E., OVREVIK, J., LAG, M., REFSNES, M., NAFSTAD, P., HETLAND, R. B. & DYBING, E. 
2006. Particulate matter properties and health effects: consistency of epidemiological and 
toxicological studies. Hum Exp Toxicol, 25, 559-79. 
SCOTTISH GOVERNMENT. 2013. Design and Content [Online]. Scottish Government, St. Andrew's 
House, Regent Road, Edinburgh EH1 3DG Tel:0131 556 8400 ceu@scotland.gsi.gov.uk. 
Available: http://www.scotland.gov.uk/Topics/Statistics/Browse/Health/scottish-health-
survey/SurveyDesignContent#samplesize. 
SCOTTISH GOVERNMENT. 2014. Scottish Health Survey [Online]. Scottish Government, St. 
Andrew's House, Regent Road, Edinburgh EH1 3DG Tel:0131 556 8400 
129 
 
ceu@scotland.gsi.gov.uk. Available: 
http://www.scotland.gov.uk/Topics/Statistics/Browse/Health/scottish-health-survey. 
SEBEKOVA, K., KRAJCOVIOVA-KUDLACKOVA, M., SCHINZEL, R., FAIST, V., KLVANOVA, J. & 
HEIDLAND, A. 2001. Plasma levels of advanced glycation end products in healthy, long-
term vegetarians and subjects on a western mixed diet. Eur J Nutr, 40, 275-81. 
ŠEBEKOVÁ, K. & SOMOZA, V. 2007. Dietary advanced glycation endproducts (AGEs) and their 
health effects – PRO. Molecular Nutrition & Food Research, 51, 1079-1084. 
SELL, D. R., LANE, M. A., OBRENOVICH, M. E., MATTISON, J. A., HANDY, A., INGRAM, D. K., CUTLER, 
R. G., ROTH, G. S. & MONNIER, V. M. 2003. The effect of caloric restriction on glycation 
and glycoxidation in skin collagen of nonhuman primates. J Gerontol A Biol Sci Med Sci, 
58, 508-16. 
SELL, D. R. & MONNIER, V. M. 1989a. Isolation, purification and partial characterization of novel 
fluorophores from aging human insoluble collagen-rich tissue. Connect Tissue Res, 19, 77-
92. 
SELL, D. R. & MONNIER, V. M. 1989b. Structure elucidation of a senescence cross-link from human 
extracellular matrix. Implication of pentoses in the aging process. J Biol Chem, 264, 21597-
602. 
SELVARAJ, N., BOBBY, Z., KONER, B. C. & DAS, A. K. 2005. Reassessing the increased glycation of 
hemoglobin in nondiabetic chronic renal failure patients: A hypothesis on the role of lipid 
peroxides. Clinica Chimica Acta, 360, 108-113. 
SELVARAJ, N., BOBBY, Z. & SRIDHAR, M. G. 2008. Oxidative stress: Does it play a role in the genesis 
of early glycated proteins? Medical Hypotheses, 70, 265-268. 
SELVIN, E., CORESH, J., SHAHAR, E., ZHANG, L., STEFFES, M. & SHARRETT, A. R. 2005. Glycaemia 
(haemoglobin A1c) and incident ischaemic stroke: the Atherosclerosis Risk in 
Communities (ARIC) Study. Lancet Neurol, 4, 821-6. 
SELVIN, E., HALUSHKA, M. K., RAWLINGS, A. M., HOOGEVEEN, R. C., BALLANTYNE, C. M., CORESH, 
J. & ASTOR, B. C. 2013. sRAGE and risk of diabetes, cardiovascular disease, and death. 
Diabetes, 62, 2116-21. 
SELVIN, E., RAWLINGS, A. M., GRAMS, M., KLEIN, R., SHARRETT, A. R., STEFFES, M. & CORESH, J. 
2014. Fructosamine and glycated albumin for risk stratification and prediction of incident 
diabetes and microvascular complications: a prospective cohort analysis of the 
Atherosclerosis Risk in Communities (ARIC) study. The Lancet Diabetes & Endocrinology. 
SELVIN, E., STEFFES, M. W., BALLANTYNE, C. M., HOOGEVEEN, R. C., CORESH, J. & BRANCATI, F. L. 
2011. Racial differences in glycemic markers: a cross-sectional analysis of community-
based data. Ann Intern Med, 154, 303-9. 
SELVIN, E., STEFFES, M. W., ZHU, H., MATSUSHITA, K., WAGENKNECHT, L., PANKOW, J., CORESH, J. 
& BRANCATI, F. L. 2010. Glycated hemoglobin, diabetes, and cardiovascular risk in 
nondiabetic adults. N Engl J Med, 362, 800-11. 
SENSI, M., TANZI, P., BRUNO, M. R., MANCUSO, M. & ANDREANI, D. 1986. Human Glomerular-
Basement-Membrane - Altered Binding Characteristics Following Invitro Nonenzymatic 
Glycosylation. Annals of the New York Academy of Sciences, 488, 549-552. 
SENSI, M., TANZI, P., BRUNO, M. R., POZZILLI, P., MANCUSO, M., GAMBARDELLA, S. & DI MARIO, 
U. 1989. Nonenzymic glycation of isolated human glomerular basement membrane 
changes its physicochemical characteristics and binding properties. Nephron, 52, 222-6. 
SERAFINI, M. & DEL RIO, D. 2004. Understanding the association between dietary antioxidants, 
redox status and disease: is the Total Antioxidant Capacity the right tool? Redox Rep, 9, 
145-52. 
SERAFINI, M., TESTA, M. F., VILLAÑO, D., PECORARI, M., VAN WIEREN, K., AZZINI, E., BRAMBILLA, 
A. & MAIANI, G. 2009. Antioxidant activity of blueberry fruit is impaired by association 
with milk. Free Radical Biology and Medicine, 46, 769-774. 
SEVERIN, F. F., FENIOUK, B. A. & SKULACHEV, V. P. 2013. Advanced glycation of cellular proteins as 
a possible basic component of the “master biological clock”. Biochemistry (Moscow), 78, 
1043-1047. 
130 
 
SHAKLAI, N., GARLICK, R. L. & BUNN, H. F. 1984. Nonenzymatic glycosylation of human serum 
albumin alters its conformation and function. J Biol Chem, 259, 3812-7. 
SHARMA, J. B., SHARMA, A., BAHADUR, A., VIMALA, N., SATYAM, A. & MITTAL, S. 2006. Oxidative 
stress markers and antioxidant levels in normal pregnancy and pre-eclampsia. 
International Journal of Gynecology & Obstetrics, 94, 23-27. 
SHIINA, Y., FUNABASHI, N., LEE, K., MURAYAMA, T., NAKAMURA, K., WAKATSUKI, Y., DAIMON, M. 
& KOMURO, I. 2009. Acute effect of oral flavonoid-rich dark chocolate intake on coronary 
circulation, as compared with non-flavonoid white chocolate, by transthoracic Doppler 
echocardiography in healthy adults. Int J Cardiol, 131, 424-9. 
SIES, H., STAHL, W. & SEVANIAN, A. 2005. Nutritional, Dietary and Postprandial Oxidative Stress. 
The Journal of Nutrition, 135, 969-972. 
SIMON, D., SENAN, C., GARNIER, P., SAINT-PAUL, M. & PAPOZ, L. 1989. Epidemiological features 
of glycated haemoglobin A1c-distribution in a healthy population. The Telecom Study. 
Diabetologia, 32, 864-9. 
SINCLAIR, D. A. 2005. Toward a unified theory of caloric restriction and longevity regulation. Mech 
Ageing Dev, 126, 987-1002. 
SINGLETON, V. L. & ROSSI, J. A. 1965. Colorimetry of Total Phenolics with Phosphomolybdic-
Phosphotungstic Acid Reagents. American Journal of Enology and Viticulture, 16, 144-158. 
SKYLER, J. S., BERGENSTAL, R., BONOW, R. O., BUSE, J., DEEDWANIA, P., GALE, E. A., HOWARD, B. 
V., KIRKMAN, M. S., KOSIBOROD, M., REAVEN, P., SHERWIN, R. S., AMERICAN DIABETES, 
A., AMERICAN COLLEGE OF CARDIOLOGY, F. & AMERICAN HEART, A. 2009. Intensive 
glycemic control and the prevention of cardiovascular events: implications of the 
ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American 
Diabetes Association and a Scientific Statement of the American College of Cardiology 
Foundation and the American Heart Association. J Am Coll Cardiol, 53, 298-304. 
SLAVIN, J. 2003. Why whole grains are protective: biological mechanisms. Proceedings of the 
Nutrition Society, 62, 129-134. 
SMITH, M. A., SAYRE, L. M., MONNIER, V. M. & PERRY, G. 1995. Radical AGEing in Alzheimer's 
disease. Trends Neurosci, 18, 172-6. 
SOMPONG, W., MEEPROM, A., CHENG, H. & ADISAKWATTANA, S. 2013. A Comparative Study of 
Ferulic Acid on Different Monosaccharide-Mediated Protein Glycation and Oxidative 
Damage in Bovine Serum Albumin. Molecules, 18, 13886-13903. 
SONG, Y., MANSON, J. E., BURING, J. E., SESSO, H. D. & LIU, S. 2005. Associations of dietary 
flavonoids with risk of type 2 diabetes, and markers of insulin resistance and systemic 
inflammation in women: a prospective study and cross-sectional analysis. J Am Coll Nutr, 
24, 376-84. 
SOULIMANE, S., SIMON, D., HERMAN, W., LANGE, C., LEE, C. Y., COLAGIURI, S., SHAW, J., ZIMMET, 
P., MAGLIANO, D., FERREIRA, S. G., DONG, Y., ZHANG, L., JORGENSEN, T., TUOMILEHTO, J., 
MOHAN, V., CHRISTENSEN, D., KADUKA, L., DEKKER, J., NIJPELS, G., STEHOUWER, C. A., 
LANTIERI, O., FUJIMOTO, W., LEONETTI, D., MCNEELY, M., BORCH-JOHNSEN, K., BOYKO, 
E., VISTISEN, D. & BALKAU, B. 2014. HbA1c, fasting and 2 h plasma glucose in current, ex- 
and never-smokers: a meta-analysis. Diabetologia, 57, 30-39. 
SOUSA, M. M., YAN, S. D., STERN, D. & SARAIVA, M. J. 2000. Interaction of the receptor for 
advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription 
factor kB (NF-kB) activation. Lab Invest, 80, 1101-10. 
SPANOS, G. A., WROLSTAD, R. E. & HEATHERBELL, D. A. 1990. Influence of Processing and Storage 
on the Phenolic Composition of Apple Juice. Journal of Agricultural and Food Chemistry, 
38, 1572-1579. 
SPENCER, J. P., ABD EL MOHSEN, M. M., MINIHANE, A. M. & MATHERS, J. C. 2008. Biomarkers of 
the intake of dietary polyphenols: strengths, limitations and application in nutrition 
research. Br J Nutr, 99, 12-22. 
SPIRO, R. G. 2002. Protein glycosylation: nature, distribution, enzymatic formation, and disease 
implications of glycopeptide bonds. Glycobiology, 12, 43R-56R. 
131 
 
SRIKANTH, V., MACZUREK, A., PHAN, T., STEELE, M., WESTCOTT, B., JUSKIW, D. & MUNCH, G. 
2011. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. 
Neurobiol Aging, 32, 763-77. 
STENSEN, M. H., TANBO, T., STORENG, R. & FEDORCSAK, P. 2014. Advanced glycation end 
products and their receptor contribute to ovarian ageing. Human Reproduction, 29, 125-
134. 
STEPHENS, N. G., PARSONS, A., SCHOFIELD, P. M., KELLY, F., CHEESEMAN, K. & MITCHINSON, M. J. 
1996. Randomised controlled trial of vitamin E in patients with coronary disease: 
Cambridge Heart Antioxidant Study (CHAOS). Lancet, 347, 781-6. 
STITT, A. W. 2001. Advanced glycation: an important pathological event in diabetic and age 
related ocular disease. British Journal of Ophthalmology, 85, 746-753. 
STOTE, K. S. & BAER, D. J. 2008. Tea consumption may improve biomarkers of insulin sensitivity 
and risk factors for diabetes. J Nutr, 138, 1584S-1588S. 
STRACKE, B. A., RUEFER, C. E., BUB, A., SEIFERT, S., WEIBEL, F. P., KUNZ, C. & WATZL, B. 2010. No 
effect of the farming system (organic/conventional) on the bioavailability of apple (Malus 
domestica Bork., cultivar Golden Delicious) polyphenols in healthy men: a comparative 
study. European Journal of Nutrition, 49, 301-310. 
STRATTON, I. M., ADLER, A. I., NEIL, H. A., MATTHEWS, D. R., MANLEY, S. E., CULL, C. A., HADDEN, 
D., TURNER, R. C. & HOLMAN, R. R. 2000. Association of glycaemia with macrovascular 
and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational 
study. BMJ, 321, 405-12. 
SWEET, M. 2011. Deaths from chronic disease fall in Australia but concerns rise for the future. 
BMJ, 342. 
SYDSJO, G., SYDSJO, A., BRYNHILDSEN, J. & JOSEFSSON, A. 2010. Trends in caesarean section and 
instrumental deliveries in relation to Body Mass Index: a clinical survey during 1978 - 
2001. Reprod Health, 7, 18. 
TAKAHASHI, S., UCHINO, H., SHIMIZU, T., KANAZAWA, A., TAMURA, Y., SAKAI, K., WATADA, H., 
HIROSE, T., KAWAMORI, R. & TANAKA, Y. 2007. Comparison of glycated albumin (GA) and 
glycated hemoglobin (HbA1c) in type 2 diabetic patients: Usefulness of GA for evaluation 
of short-term changes in glycemic control. Endocrine Journal, 54, 139-144. 
TAKEUCHI, M. & YAMAGISHI, S. 2008. Possible involvement of advanced glycation end-products 
(AGEs) in the pathogenesis of Alzheimer's disease. Curr Pharm Des, 14, 973-8. 
TANAKA, S., AVIGAD, G., BRODSKY, B. & EIKENBERRY, E. F. 1988. Glycation induces expansion of 
the molecular packing of collagen. J Mol Biol, 203, 495-505. 
TANJI, N., MARKOWITZ, G. S., FU, C. F., KISLINGER, T., TAGUCHI, A., PISCHETSRIEDER, M., STERN, 
D., SCHMIDT, A. M. & D'AGATI, V. D. 2000. Expression of advanced glycation end products 
and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. 
Journal of the American Society of Nephrology, 11, 1656-1666. 
TARWADI, K. & AGTE, V. 2011. Effect of Micronutrients on Methylglyoxal-Mediated In Vitro 
Glycation of Albumin. Biological Trace Element Research, 143, 717-725. 
TAYEH, N., RUNGASSAMY, T. & ALBANI, J. R. 2009. Fluorescence spectral resolution of tryptophan 
residues in bovine and human serum albumins. J Pharm Biomed Anal, 50, 107-16. 
TAYLOR, A., LIPMAN, R. D., JAHNGEN-HODGE, J., PALMER, V., SMITH, D., PADHYE, N., DALLAL, G. 
E., CYR, D. E., LAXMAN, E., SHEPARD, D. & ET AL. 1995. Dietary calorie restriction in the 
Emory mouse: effects on lifespan, eye lens cataract prevalence and progression, levels of 
ascorbate, glutathione, glucose, and glycohemoglobin, tail collagen breaktime, DNA and 
RNA oxidation, skin integrity, fecundity, and cancer. Mech Ageing Dev, 79, 33-57. 
TENENBAUM-GAVISH, K. & HOD, M. 2013. Impact of maternal obesity on fetal health. Fetal Diagn 
Ther, 34, 1-7. 
TERRY, T., RARAVIKAR, K., CHOKRUNGVARANON, N. & REAVEN, P. D. 2012. Does aggressive 
glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? 
Insights from ACCORD, ADVANCE, and VADT. Curr Cardiol Rep, 14, 79-88. 
THOME, J., MÜNCH, G., MÜLLER, R., SCHINZEL, R., KORNHUBER, J., BLUM-DEGEN, D., SITZMANN, 
L., RÖSLER, M., HEIDLAND, A. & RIEDERER, P. 1996. Advanced glycation endproducts — 
132 
 
associated parameters in the peripheral blood of patients with Alzheimer's disease. Life 
Sciences, 59, 679-685. 
THOMPSON F. E., S. A. F. 2008. Nutrition in the Prevention and Treatment of Disease. 
THORNALLEY, P., WOLFF, S., CRABBE, J. & STERN, A. 1984. The autoxidation of glyceraldehyde and 
other simple monosaccharides under physiological conditions catalysed by buffer ions. 
Biochim Biophys Acta, 797, 276-87. 
THORNALLEY, P. J. 2003a. The enzymatic defence against glycation in health, disease and 
therapeutics: a symposium to examine the concept. Biochem Soc Trans, 31, 1341-2. 
THORNALLEY, P. J. 2003b. Glyoxalase I--structure, function and a critical role in the enzymatic 
defence against glycation. Biochem Soc Trans, 31, 1343-8. 
THORNALLEY, P. J. 2003c. Use of aminoguanidine (Pimagedine) to prevent the formation of 
advanced glycation endproducts. Archives of Biochemistry and Biophysics, 419, 31-40. 
THORPE, S. R. & BAYNES, J. W. 2003. Maillard reaction products in tissue proteins: New products 
and new perspectives. Amino Acids, 25, 275-281. 
TOESCU, V., NUTTALL, S. L., MARTIN, U., KENDALL, M. J. & DUNNE, F. 2002. Oxidative stress and 
normal pregnancy. Clinical Endocrinology, 57, 609-613. 
TUCKER, K. L. 2007. Assessment of usual dietary intake in population studies of gene–diet 
interaction. Nutrition, Metabolism and Cardiovascular Diseases, 17, 74-81. 
TURK, Z., LJUBIC, S., TURK, N. & BENKO, B. 2001. Detection of autoantibodies against advanced 
glycation endproducts and AGE-immune complexes in serum of patients with diabetes 
mellitus. Clinica Chimica Acta, 303, 105-115. 
URIBARRI, J., CAI, W., SANDU, O., PEPPA, M., GOLDBERG, T. & VLASSARA, H. 2005. Diet-Derived 
Advanced Glycation End Products Are Major Contributors to the Body's AGE Pool and 
Induce Inflammation in Healthy Subjects. Annals of the New York Academy of Sciences, 
1043, 461-466. 
URIBARRI, J., WOODRUFF, S., GOODMAN, S., CAI, W., CHEN, X., PYZIK, R., YONG, A., STRIKER, G. E. 
& VLASSARA, H. 2010. Advanced Glycation End Products in Foods and a Practical Guide to 
Their Reduction in the Diet. Journal of the American Dietetic Association, 110, 911-
916.e12. 
URIOS, P., GRIGOROVA-BORSOS, A. M. & STERNBERG, M. 2007. Aspirin inhibits the formation of 
pentosidine, a cross-linking advanced glycation end product, in collagen. Diabetes Res Clin 
Pract, 77, 337-40. 
URPI-SARDA, M., MONAGAS, M., KHAN, N., LLORACH, R., MA LAMUELA-RAVENTOS, R., JAUREGUI, 
O., ESTRUCH, R., IZQUIERDO-PULIDO, M. & ANDRES-LACUEVA, C. 2009. Targeted 
metabolic profiling of phenolics in urine and plasma after regular consumption of cocoa 
by liquid chromatography-tandem mass spectrometry. Journal of Chromatography A, 
1216, 7258-7267. 
VAN'T RIET, E., RIJKELIJKHUIZEN, J. M., ALSSEMA, M., NIJPELS, G., STEHOUWER, C. D. A., HEINE, R. 
J. & DEKKER, J. M. 2012. HbA1c is an independent predictor of non-fatal cardiovascular 
disease in a Caucasian population without diabetes: a 10-year follow-up of the Hoorn 
Study. European Journal of Preventive Cardiology, 19, 23-31. 
VARGAS, H. O., NUNES, S. O. V., DE CASTRO, M. R. P., VARGAS, M. M., BARBOSA, D. S., 
BORTOLASCI, C. C., VENUGOPAL, K., DODD, S. & BERK, M. 2013. Oxidative stress and 
inflammatory markers are associated with depression and nicotine dependence. 
Neuroscience Letters, 544, 136-140. 
VARMA, S. D. & DEVAMANOHARAN, P. S. 1991. Hydrogen peroxide in human blood. Free Radic 
Res Commun, 14, 125-31. 
VAZZANA, N., SANTILLI, F., CUCCURULLO, C. & DAVÌ, G. 2009. Soluble forms of RAGE in internal 
medicine. Internal and Emergency Medicine, 4, 389-401. 
VEERANNA, V., RAMESH, K., ZALAWADIYA, S. K., NIRAJ, A., PRADHAN, J., JACOB, S. & AFONSO, L. 
2011. Glycosylated hemoglobin and prevalent metabolic syndrome in nondiabetic 
multiethnic U.S. adults. Metab Syndr Relat Disord, 9, 361-7. 
133 
 
VENKATRAMAN, J., AGGARWAL, K. & BALARAM, P. 2001. Helical peptide models for protein 
glycation: proximity effects in catalysis of the Amadori rearrangement. Chemistry & 
Biology, 8, 611-625. 
VERZELLONI, E., PELLACANI, C., TAGLIAZUCCHI, D., TAGLIAFERRI, S., CALANI, L., COSTA, L. G., 
BRIGHENTI, F., BORGES, G., CROZIER, A., CONTE, A. & DEL RIO, D. 2011a. Antiglycative and 
neuroprotective activity of colon-derived polyphenol catabolites. Mol Nutr Food Res, 55 
Suppl 1, S35-43. 
VERZELLONI, E., TAGLIAZUCCHI, D., DEL RIO, D., CALANI, L. & CONTE, A. 2011b. Antiglycative and 
antioxidative properties of coffee fractions. Food Chemistry, 124, 1430-1435. 
VINSON, J. A., DEMKOSKY, C. A., NAVARRE, D. A. & SMYDA, M. A. 2012. High-Antioxidant 
Potatoes: Acute in Vivo Antioxidant Source and Hypotensive Agent in Humans after 
Supplementation to Hypertensive Subjects. J Agric Food Chem. 
VINSON, J. A. & HOWARD, T. B. 1996. Inhibition of protein glycation and advanced glycation end 
products by ascorbic acid and other vitamins and nutrients. Journal of Nutritional 
Biochemistry, 7, 659-663. 
VIRTAMO, J., PIETINEN, P., HUTTUNEN, J. K., KORHONEN, P., MALILA, N., VIRTANEN, M. J., 
ALBANES, D., TAYLOR, P. R. & ALBERT, P. 2003. Incidence of cancer and mortality 
following alpha-tocopherol and beta-carotene supplementation: a postintervention 
follow-up. JAMA, 290, 476-85. 
VITAGLIONE, P., DONNARUMMA, G., NAPOLITANO, A., GALVANO, F., GALLO, A., SCALFI, L. & 
FOGLIANO, V. 2007. Protocatechuic Acid Is the Major Human Metabolite of Cyanidin-
Glucosides. The Journal of Nutrition, 137, 2043-2048. 
VITEK, M. P., BHATTACHARYA, K., GLENDENING, J. M., STOPA, E., VLASSARA, H., BUCALA, R., 
MANOGUE, K. & CERAMI, A. 1994. Advanced glycation end products contribute to 
amyloidosis in Alzheimer disease. Proc Natl Acad Sci U S A, 91, 4766-70. 
VLASSARA, H. 1996. Advanced glycation end-products and atherosclerosis. Ann Med, 28, 419-26. 
VLASSARA, H., LI, Y. M., IMANI, F., WOJCIECHOWICZ, D., YANG, Z., LIU, F. T. & CERAMI, A. 1995. 
Identification of galectin-3 as a high-affinity binding protein for advanced glycation end 
products (AGE): a new member of the AGE-receptor complex. Mol Med, 1, 634-46. 
VLASSARA, H. & PALACE, M. R. 2002. Diabetes and advanced glycation endproducts. J Intern Med, 
251, 87-101. 
VLASSOPOULOS, A., LEAN, M. & COMBET, E. 2013a. Influence of smoking and diet on glycated 
haemoglobin and 'pre-diabetes' categorisation: a cross-sectional analysis. BMC Public 
Health, 13, 1013. 
VLASSOPOULOS, A., LEAN, M. E. & COMBET, E. 2013b. Role of oxidative stress in physiological 
albumin glycation: a neglected interaction. Free Radic Biol Med, 60, 318-24. 
VOIGT, M., JORCH, G., BRIESE, V., KWOLL, G., BORCHARDT, U. & STRAUBE, S. 2011. The combined 
effect of maternal body mass index and smoking status on perinatal outcomes - an 
analysis of the german perinatal survey. Z Geburtshilfe Neonatol, 215, 23-8. 
VOS, P. A. J. M., DEGROOT, J., HUISMAN, A. M., OOSTVEEN, J. C. M., MARIJNISSEN, A. C. A., 
BIJLSMA, J. W. J., VAN EL, B., ZUURMOND, A. M. & LAFEBER, F. P. J. G. 2010. Skin and 
urine pentosidine weakly correlate with joint damage in a cohort of patients with early 
signs of osteoarthritis (CHECK). Osteoarthritis and Cartilage, 18, 1329-1336. 
VOZIYAN, P. A., KHALIFAH, R. G., THIBAUDEAU, C., YILDIZ, A., JACOB, J., SERIANNI, A. S. & 
HUDSON, B. G. 2003. Modification of proteins in vitro by physiological levels of glucose: 
pyridoxamine inhibits conversion of Amadori intermediate to advanced glycation end-
products through binding of redox metal ions. J Biol Chem, 278, 46616-24. 
WANG, H. Y., QIAN, H. & YAO, W. R. 2011. Melanoidins produced by the Mail lard reaction: 
Structure and biological activity. Food Chemistry, 128, 573-584. 
WAUTIER, J.-L. & SCHMIDT, A. M. 2004. Protein Glycation: A Firm Link to Endothelial Cell 
Dysfunction. Circulation Research, 95, 233-238. 
WEDICK, N. M., PAN, A., CASSIDY, A., RIMM, E. B., SAMPSON, L., ROSNER, B., WILLETT, W., HU, F. 
B., SUN, Q. & VAN DAM, R. M. 2012. Dietary flavonoid intakes and risk of type 2 diabetes 
in US men and women. Am J Clin Nutr, 95, 925-33. 
134 
 
WEISS, J. L., MALONE, F. D., EMIG, D., BALL, R. H., NYBERG, D. A., COMSTOCK, C. H., SAADE, G., 
EDDLEMAN, K., CARTER, S. M., CRAIGO, S. D., CARR, S. R. & D'ALTON, M. E. 2004. Obesity, 
obstetric complications and cesarean delivery rate–a population-based screening study. 
American Journal of Obstetrics and Gynecology, 190, 1091-1097. 
WEYKAMP, C. W., PENDERS, T. J., BAADENHUIJSEN, H., MUSKIET, F. A., MARTINA, W. & VAN DER 
SLIK, W. 1995. Vitamin C and glycohemoglobin. Clin Chem, 41, 713-6. 
WHO 2010. United Nations: World Population Prospects: The 2008 Revision, Volume 1: 
Comprehensive Tables and United Nations, World Population Prospects: The 2008 
Revision, Highlights. Population and Development Review, 36, 854-855. 
WHO 2011. Global status report on noncommunicable diseases 2010, Geneva, Switzerland, World 
Health Organization. 
WHO 2014. World Population Prospects, the 2012 Revision. 
WILDMAN, R. P., MUNTNER, P., REYNOLDS, K., MCGINN, A. P., RAJPATHAK, S., WYLIE-ROSETT, J. & 
SOWERS, M. R. 2008. The obese without cardiometabolic risk factor clustering and the 
normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 
phenotypes among the US population (NHANES 1999-2004). Arch Intern Med, 168, 1617-
24. 
WILLI, C., BODENMANN, P., GHALI, W. A., FARIS, P. D. & CORNUZ, J. 2007. Active smoking and the 
risk of type 2 diabetes: a systematic review and meta-analysis. JAMA, 298, 2654-64. 
WILLIAMSON, G. & MANACH, C. 2005. Bioavailability and bioefficacy of polyphenols in humans. II. 
Review of 93 intervention studies. American Journal of Clinical Nutrition, 81, 243s-255s. 
WING, R. R., LANG, W., WADDEN, T. A., SAFFORD, M., KNOWLER, W. C., BERTONI, A. G., HILL, J. O., 
BRANCATI, F. L., PETERS, A., WAGENKNECHT, L. & GROUP, T. L. A. R. 2011. Benefits of 
Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese 
Individuals With Type 2 Diabetes. Diabetes Care, 34, 1481-1486. 
WISEMAN, M. 2008. The second World Cancer Research Fund/American Institute for Cancer 
Research expert report. Food, nutrition, physical activity, and the prevention of cancer: a 
global perspective. Proc Nutr Soc, 67, 253-6. 
WITKOSARSAT, V., FRIEDLANDER, M., CAPEILLEREBLANDIN, C., NGUYENKHOA, T., NGUYEN, N. T., 
ZINGRAFF, J., JUNGERS, P. & DESCAMPSLATSCHA, B. 1996. Advanced oxidation protein 
products as a novel marker of oxidative stress in uremia. Kidney International, 49, 1304-
1313. 
WOLFF, M. S., COLLMAN, G. W., BARRETT, J. C. & HUFF, J. 1996. Breast cancer and environmental 
risk factors: epidemiological and experimental findings. Annu Rev Pharmacol Toxicol, 36, 
573-96. 
WOLFF, S. P. & DEAN, R. T. 1987. Glucose autoxidation and protein modification. The potential 
role of 'autoxidative glycosylation' in diabetes. Biochem J, 245, 243-50. 
WOLFF, S. P., JIANG, Z. Y. & HUNT, J. V. 1991. Protein glycation and oxidative stress in diabetes 
mellitus and ageing. Free Radic Biol Med, 10, 339-52. 
WOOD, I. S., DE HEREDIA, F. P., WANG, B. & TRAYHURN, P. 2009. Cellular hypoxia and adipose 
tissue dysfunction in obesity. Proceedings of the Nutrition Society, 68, 370-377. 
WU, C. H. & YEN, G. C. 2005. Inhibitory effect of naturally occurring flavonoids on the formation of 
advanced glycation endproducts. Journal of Agricultural and Food Chemistry, 53, 3167-
3173. 
WU, J. W., HSIEH, C. L., WANG, H. Y. & CHEN, H. Y. 2009. Inhibitory effects of guava (Psidium 
guajava L.) leaf extracts and its active compounds on the glycation process of protein. 
Food Chemistry, 113, 78-84. 
WYNDER, E. L., ROSE, D. P. & COHEN, L. A. 1994. Nutrition and prostate cancer: a proposal for 
dietary intervention. Nutr Cancer, 22, 1-10. 
XI, M., HAI, C., TANG, H., CHEN, M., FANG, K. & LIANG, X. 2008. Antioxidant and antiglycation 
properties of total saponins extracted from traditional Chinese medicine used to treat 
diabetes mellitus. Phytother Res, 22, 228-37. 
135 
 
XIAO, J. B. & KAI, G. Y. 2012. A Review of Dietary Polyphenol-Plasma Protein Interactions: 
Characterization, Influence on the Bioactivity, and Structure-Affinity Relationship. Critical 
Reviews in Food Science and Nutrition, 52, 85-101. 
XIE, Y. & CHEN, X. 2013. Structures required of polyphenols for inhibiting advanced glycation end 
products formation. Curr Drug Metab, 14, 414-31. 
YAN, S. F., RAMASAMY, R., NAKA, Y. & SCHMIDT, A. M. 2003. Glycation, inflammation, and RAGE - 
A scaffold for the macrovascular complications of diabetes and beyond. Circulation 
Research, 93, 1159-1169. 
YAN, S. F., RAMASAMY, R. & SCHMIDT, A. M. 2010. The RAGE axis: a fundamental mechanism 
signaling danger to the vulnerable vasculature. Circ Res, 106, 842-53. 
YU, Y., HANSSEN, K. F., KALYANARAMAN, V., CHIRINDEL, A., JENKINS, A. J., NANKERVIS, A. J., 
TORJESEN, P. A., SCHOLZ, H., HENRIKSEN, T., LORENTZEN, B., GARG, S. K., MENARD, M. K., 
HAMMAD, S. M., SCARDO, J. A., STANLEY, J. R., WU, M., BASU, A., ASTON, C. E. & LYONS, 
T. J. 2012. Reduced soluble receptor for advanced glycation end-products (sRAGE) 
scavenger capacity precedes pre-eclampsia in Type 1 diabetes. BJOG, 119, 1512-20. 
YUDKIN, J. S., STEHOUWER, C. D. A., EMEIS, J. J. & COPPACK, S. W. 1999. C-Reactive Protein in 
Healthy Subjects: Associations With Obesity, Insulin Resistance, and Endothelial 
Dysfunction: A Potential Role for Cytokines Originating From Adipose Tissue? 
Arteriosclerosis, Thrombosis, and Vascular Biology, 19, 972-978. 
YUN, T. K. 2003. Experimental and epidemiological evidence on non-organ specific cancer 
preventive effect of Korean ginseng and identification of active compounds. Mutat Res, 
523-524, 63-74. 
ZHANG, Q. B., AMES, J. M., SMITH, R. D., BAYNES, J. W. & METZ, T. O. 2009. A Perspective on the 
Maillard Reaction and the Analysis of Protein Glycation by Mass Spectrometry: Probing 
the Pathogenesis of Chronic Disease. Journal of Proteome Research, 8, 754-769. 
ZHANG, X., CHEN, F. & WANG, M. 2014. Antioxidant and Antiglycation Activity of Selected Dietary 
Polyphenols in a Cookie Model. Journal of Agricultural and Food Chemistry, 62, 1643-
1648. 
ZIEMAN, S. J., MELENOVSKY, V., CLATTENBURG, L., CORRETTI, M. C., CAPRIOTTI, A., 
GERSTENBLITH, G. & KASS, D. A. 2007. Advanced glycation endproduct crosslink breaker 
(alagebrium) improves endothelial function in patients with isolated systolic 
hypertension. J Hypertens, 25, 577-83. 
 
  
136 
 
 
 
 
 
 
 
Appendix 
 
